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effectiveness of magnesium sulphate compared with
sotalol, and to assess the clinical effectiveness of
magnesium sulphate compared with placebo in the
prevention of atrial fibrillation (AF) in patients who
have had a coronary artery bypass graft (CABG).
Data sources: Major electronic databases were
searched from December 2003 to May 2007. 
Review methods: Selected studies were assessed,
subjected to data extraction using a standard template
and quality assessment using published criteria. 
A simple short-term economic model was developed,
informed by a systematic review of economic
evaluations and populated with data from a review of
costing/resource-use studies and other published
studies. The cost-effectiveness of magnesium sulphate
as prophylaxis was estimated for a set of base-case
assumptions and the robustness of these results was
assessed using deterministic and probabilistic sensitivity
analysis.
Results: Twenty-two papers met the inclusion criteria
reporting 15 trials which all compared magnesium
sulphate with placebo or control. They ranged in size
from 15 to 176 patients randomised, and were
conducted in Europe, the USA and Canada. The
standard of reporting was generally poor, with details
of key methodological attributes difficult to elucidate.
No trials were identified that specifically aimed to
compare magnesium sulphate with sotalol. Of 1070
patients in the pooled magnesium group, 230 (21%)
developed postoperative AF, compared with 307 of
1031 (30%) patients in the placebo or (control) group.
Meta-analysis using a fixed-effects model generated a
pooled odds ratio (OR) that was significantly less than
1.0 [OR = 0.65, 95% confidence interval (CI) 0.53 to
0.79, test for overall effect p < 0.0001], but with
statistically significant heterogeneity (I2 = 63.4%, 
p = 0.0005). Two randomised controlled trials (RCTs)
were notable as they had relatively lower ORs in 
favour of magnesium sulphate. When these were
removed from the analyses the pooled OR remained
statistically significant, but heterogeneity no longer
remained significant. These two studies tended to
impart a highly significant reduction in the odds of AF
to whichever subgroup they were analysed in. When
studies were ordered by total duration of prophylaxis,
an apparent relationship between duration and odds of
AF was evident, with decreasing odds of AF as duration
of prophylaxis increased. This was confirmed by linear
regression analysis (R2 = 0.743, p < 0.001). When the
data were grouped into three classes according to
duration, a statistically significant intervention effect
was only present for the longest duration (OR = 0.12,
95% CI 0.06 to 0.23, p = 0.00001). Statistically
significant intervention effects were associated with the
initiation of prophylaxis 12 hours or more before
surgery (OR 0.26; 95% CI 0.16 to 0.44, test for overall
effect p = 0.00001, fixed-effects model) and less than
12 hours before surgery or during the surgery itself 
(OR = 0.73, 95% CI 0.56 to 0.97, test for overall
effect p = 0.03, fixed-effects model), but not when
prophylaxis was initiated at the end of surgery or
postsurgery (OR = 0.85, 95% CI 0.59, 1.22, p = 0.37,
fixed-effects model). When studies were ordered by
total dose of intravenous magnesium sulphate (<25 g),
the odds of AF were independent of the dose. 
A notable exception was that for a total dose of 9 g
magnesium sulphate; here the odds of AF were
significantly reduced relative to the control group,
although this may be explained by the fact that these
studies had excluded patients who were on
antiarrhythmic drugs and so may have been at higher
risk of AF. Sixty-three potentially relevant references
about cost-effectiveness were identified, but no
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Intravenous magnesium sulphate and sotalol for prevention 
of atrial fibrillation after coronary artery bypass surgery: 
a systematic review and economic evaluation 
J Shepherd,* J Jones, GK Frampton, L ´
Tanajewski,† D Turner and A Price
Southampton Health Technology Assessments Centre (SHTAC), University of Southampton, UK
* Corresponding author
† Present address: Department of Health Technology Assessment, The Agency for Health Technology Assessment
in Poland (AHTAPol), Polandeconomic evaluations of intravenous magnesium alone
as prophylaxis against AF following CABG, compared
with sotalol as prophylaxis or no prophylaxis, were
identified. Studies reporting resource use by patients
with AF following CABG suggest that while AF
significantly increased inpatient stays, by up to 2.3 days
in the intensive care unit (ICU) and 3.4 days on the
ward, differences in length of stay and costs between
patients receiving prophylaxis and those not receiving
prophylaxis were not statistically significant. In the
base-case analysis, magnesium sulphate prophylaxis
resulted in 0.081 fewer cases of AF at an incremental
cost of £2.55. The incremental cost-effectiveness ratio
(ICER) was £32 per AF case avoided. The estimated
difference in average length of stay between the
prophylaxis and no-prophylaxis strategies was only 0.24
days, despite a large assumed difference of 3 days for
patients experiencing AF in each group (1 extra day in
the ICU and 2 extra days on the ward). In a
deterministic sensitivity analysis the greatest variation in
ICERs was observed for input parameters relating to
the baseline risk of AF following CABG and the
effectiveness of prophylaxis, cost of prophylaxis and the
resource consequences of postoperative AF. The
largest ICER (£2092) in the sensitivity analysis was
associated with increasing the length of patients’
preoperative stay. In the base case it was assumed that
admission routines would be identical under both
strategies. However, patients receiving prophylaxis by
intravenous infusion may have longer preoperative
stays. In a probabilistic analysis the majority of the
simulations were associated with improved outcomes
(in this case fewer cases of AF), but also higher costs.
Prophylaxis was the dominant strategy (better outcome
at lower cost) in about 41% of the simulations using
the base-case assumptions. Under an alternative
scenario where patients receiving prophylaxis are
admitted for longer before their operation, to receive
their initial infusion, the proportion of simulations
where prophylaxis dominates fell to around 5%. The
probability of being cost-effective was 99% at a
willingness to pay (WTP) threshold of £2000 per AF
case avoided and 100% at a WTP threshold of £5000
per AF case avoided under the base-case assumptions.
Under the alternative scenario of longer preoperative
stays the probability of being cost-effective at these
two threshold values fell to 48% and 93%,
respectively. It is unclear what the appropriate decision
threshold should be, given that this model used
intermediate rather than final outcomes.
Conclusions: No RCTs were identified that specifically
aimed to compare intravenous magnesium with sotalol
as prophylaxis for AF in patients undergoing CABG.
Intravenous magnesium, compared with placebo or
control, is effective in preventing postoperative AF, as
confirmed by a statistically significant intervention effect
based on pooled analysis of 15 RCTs. It was also found
that AF was less likely to occur when a longer duration
of prophylaxis was used, and the earlier that
prophylaxis is started; however, this finding was
associated with two RCTs that had more favourable
results than the other trials. No clear relationship
between dose and AF was observed, although a lower
constant dose rate was associated with the lowest odds
of AF. Further research should investigate the
relationship between dose, dose rate, duration of
prophylaxis, timing of initiation of therapy and patient
characteristics, such as degree of risk for AF. This will
provide stronger evidence for the optimum delivery of
intravenous magnesium in patients undergoing CABG.
In the base-case analysis in the economic model,
magnesium sulphate prophylaxis reduced the number
of postoperative AF cases at a modest increase in cost.
The results of the economic analysis are highly sensitive
to variation in certain key parameters. Prophylaxis is
less likely to be a cost-effective option if it requires
changes in admission routines that result in longer
preoperative stays than would be the case without
prophylaxis.
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ivHealth Technology Assessment 2008; Vol. 12: No. 28
v
Glossary and list of abbreviations ............. vii
Executive summary .................................... ix
1 Aim of the review ...................................... 1
2 Background ................................................ 3
Description of the underlying health 
problem ...................................................... 3
Current service provision ........................... 3
Description of the intervention  ................. 4
3 Methods of assessing clinical 
effectiveness ............................................... 5
Inclusion and exclusion criteria ................. 5
Search strategy  ........................................... 5
Study inclusion ........................................... 5
Data extraction ........................................... 6
Quality assessment ..................................... 6
Data synthesis ............................................. 6
4 Clinical effectiveness results ...................... 9
Quantity and quality of research available  9
Systematic reviews ...................................... 9
Characteristics of the included RCTs ......... 10
Assessment of effectiveness ........................ 10
5 Economic analysis ...................................... 23
Methods for economic analysis .................. 23
Results of the systematic review of 
economic evaluations ................................. 23
SHTAC economic model methods  ............ 26
Results of the economic model .................. 33
6 Discussion ................................................... 39
Clinical effectiveness .................................. 39
Cost-effectiveness ....................................... 40
7 Conclusions ................................................ 43
Acknowledgements .................................... 45
References .................................................. 47
Appendix 1 Search strategy for RCTs and
systematic reviews ....................................... 51
Appendix 2 Decision tree for screening
abstracts and full papers ............................ 55
Appendix 3 Data extraction templates for 
the 15 RCTs included in this review .......... 57
Appendix 4 Studies screened and included 
in the current review .................................. 85
Appendix 5 Detection and definitions of 
atrial fibrillation given in the included 
RCTs ........................................................... 87
Appendix 6 Exclusion criteria reported 
for the selection of patients in RCTs  ......... 89
Appendix 7 Search strategy for economic
evaluations .................................................. 91
Appendix 8 Inclusion criteria for 
economic review ......................................... 95
Health Technology Assessment reports
published to date ....................................... 97
Health Technology Assessment 
Programme ................................................ 115
ContentsGlossary
Atrial arrhythmia Altered atrial rhythm
(includes atrial fibrillation, atrial flutter and
atrial tachycardia).
Atrial fibrillation Uncoordinated atrial
pulsation.
Atrial flutter Increased but coordinated atrial
pulsation.
Atrial tachycardia Increased atrial beat rate.
F waves (ECG) Regular, rapid atrial waves
indicative of atrial flutter.
Left ventricular ejection fraction The
fraction of blood pumped out of a ventricle
with each heart beat; one of the most
important predictors of prognosis.
P wave (ECG) The wave of depolarisation
that spreads from the sinoatrial node
throughout the atria.
PQ interval (ECG) The time between the
beginning of atrial depolarisation and the
beginning of ventricular depolarisation.
QRS complex (ECG) Deflections in the
tracing comprising the Q, R and S waves
indicating currents generated when the
ventricles depolarise before their contraction.
QT interval The time between the start of
the Q wave and the end of the T wave in the
heart’s electrical cycle.
Supraventricular arrhythmia A rhythmic
abnormality of the heart caused by impulses
originating above the ventricles, e.g. in the
atrioventricular (sinoatrial) node; may be
synonymous with atrial arrhythmia.
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Glossary and list of abbreviations
Technical terms and abbreviations are used throughout this report. The meaning is usually clear from
the context, but a glossary is provided for the non-specialist reader. In some cases, usage differs in the
literature, but the term has a constant meaning throughout this review.List of abbreviations
ACE angiotensin-converting enzyme 
AF atrial fibrillation
BMI body mass index
BNF British National Formulary
BP blood pressure
bpm beats per minute
BSA body surface area
CABG coronary artery bypass graft
CDSR Cochrane Database of Systematic
Reviews
CEAC  cost-effectiveness acceptable curve
CI confidence interval
COPD chronic obstructive pulmonary
disease
CPB cardiopulmonary bypass
CRD Centre for Reviews and
Dissemination
D5W 5% dextrose water solution
df degrees of freedom
ECV electrical cardioversion
FEV1 forced expiratory volume in
1 second
HRG Healthcare Resource Group
ICER incremental cost-effectiveness ratio
ICU intensive care unit
ITT intention-to-treat
i.v. intravenous
LVEF left ventricular ejection fraction
MI myocardial infarction
NA not applicable
NICE National Institute for Health and
Clinical Excellence
NR not reported
ns not significant
NYHA New York Heart Association
OR odds ratio
PCV pharmacological cardioversion 
POAT postoperative atrial tachycardia
PSA probabilistic sensitivity analysis
PVD peripheral vascular disease
QALY quality-adjusted life-year
RCT randomised controlled trial
SD standard deviation
SDU step-down unit
SHTAC Southampton Health Technology
Assessments Centre
SR systematic review
SVA supraventricular arrhythmia
SVT supraventricular tachycardia
WTP willingness to pay
Glossary and list of abbreviations
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Background
Atrial fibrillation (AF) is a supraventricular
arrhythmia characterised by abnormal heart
rhythm, with symptoms such as palpitations and
nausea. It is one of the most common
complications after coronary artery bypass graft
(CABG) and 20–40% of patients experience AF
following cardiac or thoracic surgery. AF increases
the risk of mortality and morbidity from stroke,
heart failure, myocardial infarction and
thromboembolism. This can result in prolonged
hospitalisation, hospital readmission, excess
utilisation of hospital resources and increased
health service costs. Risk factors include advanced
age (particularly over the age of 50), previous
history of AF, male gender, hypertension, diabetes,
smoking, myocardial infarction and valvular heart
disease.
Clinical guidelines recommend that  -blockers are
used routinely as first choice for the prophylaxis of
AF in all patients undergoing cardiac surgery. It is
also recommended that sotalol hydrochloride, a 
 -blocker with class III antiarrhythmic activity, is
used. Magnesium may also be given to patients
undergoing cardiothoracic surgery to reduce
hypomagnesaemia, a common occurrence
following this kind of surgery. However, it is not a
first line choice for prophylaxis and it is not
known to what extent it is used in current practice.
Objective
The aim of this research is to conduct a systematic
review and economic evaluation of the clinical and
cost-effectiveness of magnesium sulphate
compared with sotalol, and to assess the clinical
effectiveness of magnesium sulphate compared
with placebo in the prevention of atrial fibrillation
in patients who have had a CABG. 
Methods
Methods for assessing clinical
effectiveness
A systematic review was conducted to compare
intravenous magnesium sulphate with placebo (or
control), and intravenous magnesium sulphate
with sotalol given as prophylaxis before the onset
of AF, in patients over 18 years, undergoing
elective isolated CABG. Studies of other
magnesium compounds (e.g. chloride, hydroxide
or unspecified) were excluded. The primary
outcome was incidence of postoperative AF.
Supraventricular arrhythmias other than AF (e.g.
tachycardias and atrial flutter) and all other non-
atrial arrhythmias were excluded. Patient length of
postoperative stay and the total length of hospital
stay were additional outcomes. 
A comprehensive search strategy was developed to
identify relevant randomised controlled trials
(RCTs) and systematic reviews. As this systematic
review updates a previous published systematic
review the searches were limited to studies
published after the cut-off date for literature
searching in that review (December 2003). The
strategy was applied to ten general and specialist
health and biomedical databases. Titles and
abstracts were screened systematically against the
inclusion criteria and full papers were ordered for
further investigation. All included trials were
subjected to data extraction using a standard
template and quality assessment using published
criteria. Data were analysed by narrative synthesis
and quantitative meta-analysis, with sensitivity
analyses where necessary. A priori defined
subgroup analyses were performed to assess the
effects of different delivery strategies for
intravenous magnesium, including different total
doses, timing of the initiation of prophylaxis and
total duration of prophylaxis. 
Methods for assessing cost-effectiveness
A systematic literature search was undertaken to
identify economic evaluations of intravenous
magnesium sulphate alone as prophylaxis against
AF following CABG compared with sotalol as
prophylaxis or no prophylaxis. A secondary aim 
of this review was to identify economic evaluations
of other agents used for prophylaxis against
postoperative AF or studies that reported
cost/resource-use differences for patients
undergoing CABG who developed AF. The purpose
of reviewing these studies was to identify the scope
and methods adopted in previous economic
evaluations of prophylaxis against postoperative
Executive summaryx
AF and to identify the impact of postoperative AF
on patients’ resource use, which would inform the
development of an economic model.
A comprehensive search strategy was developed to
identify relevant economic evaluations and costing
studies. The strategy was applied to a number of
general and specialist health and biomedical
databases. Titles and abstracts were screened
against the inclusion criteria and full papers were
ordered for further investigation. Included studies
were discussed in a narrative review.
A simple short-term economic model was
developed, informed by the systematic review of
economic evaluations and populated with data
from the review of costing/resource-use studies and
other published studies. The cost-effectiveness of
magnesium sulphate as prophylaxis was estimated
for a set of base-case assumptions and the
robustness of these results was assessed using
deterministic and probabilistic sensitivity analysis.
Results of the assessment of
clinical effectiveness
The review identified 206 potentially relevant
references. Of these, 22 papers met the inclusion
criteria, comprising 17 papers that reported
parallel-group RCTs (15 RCTs altogether) and five
systematic reviews. 
Of the 15 trials included, all compared magnesium
sulphate with placebo or control. No trials were
identified that specifically aimed to compare
magnesium sulphate with sotalol. The 15 trials
ranged in size from 15 to 176 patients randomised,
and were conducted in Europe, the USA and
Canada. The standard of reporting was generally
poor, with details of key methodological attributes
(e.g. method of randomisation and concealment of
allocation) difficult to elucidate.
Of 1070 patients in the pooled magnesium group,
230 (21%) developed postoperative AF, compared
with 307 of 1031 (30%) patients in the placebo or
(control) group. Meta-analysis using a fixed-effects
model generated a pooled odds ratio (OR) that
was significantly less than 1.0 [OR = 0.65, 95%
confidence interval (CI) 0.53 to 0.79, test for
overall effect p < 0.0001], but with statistically
significant heterogeneity (I2 = 63.4%, p = 0.0005).
Two RCTs were notable as they had relatively
lower ORs in favour of magnesium sulphate.
When these were removed from the analyses the
pooled OR remained statistically significant, but
heterogeneity no longer remained significant.
These two studies tended to impart a highly
significant reduction in the odds of AF to
whichever subgroup they were analysed in.
When studies were ordered by total duration of
prophylaxis, an apparent relationship between
duration and odds of AF was evident, with
decreasing odds of AF as duration of prophylaxis
increased. This was confirmed by linear regression
analysis (R2 = 0.743, p < 0.001). When the data
were grouped into three classes according to
whether duration of prophylaxis was 1 day or less,
2–4 days, or 5 days or greater, a statistically
significant intervention effect was only present for
the longest duration group (OR = 0.12, 95% CI
0.06 to 0.23, p = 0.00001).
Statistically significant intervention effects were
associated with the initiation of prophylaxis 
12 hours or more before surgery (OR 0.26; 
95% CI 0.16 to 0.44, test for overall effect
p = 0.00001, fixed-effects model) and less than 
12 hours before surgery or during the surgery
itself (OR = 0.73, 95% CI 0.56 to 0.97, test for
overall effect p = 0.03, fixed-effects model), but
not when prophylaxis was initiated at the end of
surgery or postsurgery (OR = 0.85, 95% CI 0.59,
1.22, p = 0.37, fixed-effects model). 
When studies were ordered by total dose of
intravenous magnesium sulphate (<25 g), the
odds of AF were independent of the dose. A
notable exception was that for a total dose of 9 g
magnesium sulphate, the odds of AF were
significantly reduced relative to the control group,
based on three studies that used this dose,
including the two RCTs mentioned above that
appeared to contribute to heterogeneity. This may
be explained by the fact that each had excluded
patients who were on antiarrhythmic drugs. They
may have been at higher risk of AF compared with
patients in other studies and, if so, might have
benefited more from prophylactic magnesium.
Within the subgroup of eight studies that
maintained a constant dose rate there appears to
be a relationship between the dose rate of
magnesium sulphate and the odds of AF, with the
largest prophylactic effects being seen at the
lowest dose rates. 
Results of the assessment of 
cost-effectiveness
Sixty-three potentially relevant references were
found. No economic evaluations of intravenous
Executive summarymagnesium alone as prophylaxis against AF
following CABG, compared with sotalol as
prophylaxis or no prophylaxis, were identified.
Four studies were included in the secondary
review. One of the included studies was a report of
an economic evaluation of oral amiodarone for
prophylaxis against AF following CABG. The
evaluation suggested that the principal
determinant of the cost-effectiveness of
prophylaxis against AF is likely to be the length of
stay in the intensive care unit (ICU) and on
hospital wards. A simple economic model, using a
decision tree, was constructed. A flow diagram
developed from this decision tree was assessed for
its relevance to UK clinical practice and
applicability to modelling the cost-effectiveness of
magnesium sulphate prophylaxis. The diagram
was taken to be a reasonable representation of
current practice for patients developing AF
following CABG, subject to modifications that
would make it more consistent with current UK
and European clinical guidelines. 
Studies reporting resource use by patients with AF
following CABG suggest that, while AF
significantly increased inpatient stays, by up to
2.3 days in the ICU and 3.4 days on the ward,
differences in length of stay and costs between
patients receiving prophylaxis and those not
receiving prophylaxis were not statistically
significant. The lack of significant findings, with
respect to differences in length of stay or cost, may
reflect clinical trials being powered to detect
differences in clinical outcome and not differences
in resource use. However, the lack of significant
differences may also reflect the fact that, since
postoperative AF affects a minority of patients
(albeit a large minority), the difference in resource
use between patients with and without AF may be
diluted when looking at mean values across a
cohort of patients.
A simple economic model was developed to
estimate the cost-effectiveness of magnesium
sulphate prophylaxis against AF following CABG.
This was populated with data on the baseline risk
of AF following CABG and the relative risk of AF
with magnesium sulphate prophylaxis from the
meta-analysis, along with cost and resource-use
data from published sources. In the base-case
analysis, magnesium sulphate prophylaxis resulted
in 0.081 fewer cases of AF at an incremental cost
of £2.55. That is, the cost of prophylaxis was
slightly higher than the expected savings due to
reduced ICU and ward stays resulting from the
reduction in AF cases. The incremental cost-
effectiveness ratio (ICER) was £32 per AF case
avoided. The estimated difference in average
length of stay between the prophylaxis and no-
prophylaxis strategies was only 0.24 days, despite
a large assumed difference of 3 days for patients
experiencing AF in each group (1 extra day in the
ICU and 2 extra days on the ward). In the
deterministic sensitivity analysis the greatest
variation in ICERs was observed for input
parameters relating to the baseline risk of AF
following CABG and the effectiveness of
prophylaxis, the cost of prophylaxis and the
resource consequences of postoperative AF. The
largest ICER (£2092) in the sensitivity analysis was
associated with increasing the length of patients’
preoperative stay. In the base case it was assumed
that admission routines would be identical under
both strategies. However, patients receiving
prophylaxis by intravenous infusion may have
longer preoperative stays.
In the probabilistic analysis the majority of the
simulations were associated with improved
outcomes (in this case fewer cases of AF), but also
higher costs. Prophylaxis was the dominant
strategy (better outcome at lower cost) in about
41% of the simulations using the base-case
assumptions. Under an alternative scenario where
patients receiving prophylaxis are admitted for
longer before their operation, to receive their
initial infusion, the proportion of simulations
where prophylaxis dominates falls to around 5%.
Analysis using an acceptability curve showed that
the probability of magnesium sulphate prophylaxis
being cost-effective, compared with surgery with
no prophylaxis, increases with willingness to pay
(WTP) for a unit of outcome. The probability of
being cost-effective was 99% at a WTP threshold of
£2000 per AF case avoided and 100% at a WTP
threshold of £5000 per AF case avoided under the
base-case assumptions. Under the alternative
scenario of longer preoperative stays the
probability of being cost-effective at these two
threshold values fell to 48% and 93%, respectively.
It is unclear what the appropriate decision
threshold should be, given that this model used
intermediate rather than final outcomes.
Conclusions
No RCTs were identified that specifically aimed to
compare intravenous magnesium with sotalol as
prophylaxis for AF in patients undergoing CABG.
Such a comparison does not appear to be clinically
meaningful. Intravenous magnesium, compared
with placebo or control, is effective in preventing
postoperative AF, as confirmed by a statistically
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analysis of 15 RCTs. It was also found that AF was
less likely to occur when a longer duration of
prophylaxis was used, and the earlier that
prophylaxis is started; however, this finding was
associated with two RCTs that had more
favourable results than the other trials, but with no
clear explanation as to why. No clear relationship
between dose and AF was observed, although a
lower constant dose rate was associated with the
lowest odds of AF. 
In the base-case analysis in the economic model,
magnesium sulphate prophylaxis reduced the
number of postoperative AF cases at a modest
increase in cost. The results of the economic
analysis are highly sensitive to variation in certain
key parameters. Prophylaxis is less likely to be a
cost-effective option if it requires changes in
admission routines that result in longer
preoperative stays than would be the case without
prophylaxis.
Recommendations for further
research
Further research should investigate the
relationship between dose, dose rate, duration of
prophylaxis, timing of initiation of therapy and
patient characteristics, such as degree of risk for
AF. This will provide stronger evidence for the
optimum delivery of intravenous magnesium in
patients undergoing CABG. 
Executive summary
xiiT
he aim of this research is to conduct a
systematic review and economic evaluation of
the clinical effectiveness and cost-effectiveness of
magnesium sulphate compared with sotalol, and
to assess the clinical effectiveness of magnesium
sulphate compared with placebo in the prevention
of atrial fibrillation (AF) in patients who have had
a coronary artery bypass graft (CABG).
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Chapter 1
Aim of the reviewDescription of the underlying
health problem
AF is a supraventricular arrhythmia characterised
by uncoordinated atrial activation with consequent
deterioration of atrial mechanical function, and is
one of the most common complications after
CABG. Between 20 and 40% of patients
experience AF following cardiac or thoracic
surgery.1 AF usually occurs early in the
postoperative period, with 70% of events
developing within 4 days. However, AF sometimes
occurs after discharge.2
During an episode of AF patients can experience
symptoms such as palpitations, nausea and
malaise. The management of AF aims to restore
sinus rhythm through pharmacological or
electrical cardioversion, and to reduce the risk of
thromboembolism with the use of antithrombotic
drugs (e.g. warfarin or aspirin). Rate control is
another management goal, with the use of drugs
such as digoxin (for non-acute episodes), 
 -blockers and rate-limiting calcium antagonists.
Rate control has been shown to be as effective as
rhythm control.3
AF increases the risk of mortality and morbidity
from stroke, heart failure, myocardial infarction,
thromboembolism and bleeding from
anticoagulation.1 This results in prolonged
hospitalisation, hospital readmission, excess
utilisation of hospital resources and increased
health service costs.2 Consequently, primary
prevention of AF after CABG is of great
importance. 
The exact cause of AF after CABG is thought to be
multifactorial. Risk factors include advanced age
(particularly over the age of 50), previous history
of AF, male gender, hypertension, diabetes,
smoking, myocardial infarction and valvular heart
disease.3 Magnesium is essential to the functioning
of the cardiovascular system and patients with
cardiac problems often exhibit abnormal
magnesium metabolism. Cardiac surgical
procedures may also cause rapid and acute
changes in magnesium status.
Approximately 23,000 CABG operations are
performed annually in England.4 For adults
undergoing elective CABG the procedure may be
on- or off-pump (i.e. the patient’s circulation is, or
is not, diverted through a pump oxygenator
machine). During surgery the heart is beating
when a patient is off-pump and can be either be
beating or artificially stopped when the patient is
on-pump.
AF is detected in an ECG by the presence of 
rapid oscillations or fibrillatory waves that vary in
size, shape and timing. A distinction is made
between AF and atrial flutter, the latter being a
more organised arrhythmia characterised by a
sawtooth pattern of regular atrial flutter waves in
the ECG. 
Current service provision
European clinical guidelines recommend that 
 -blockers are used routinely as first choice for the
prophylaxis of AF in all patients undergoing
cardiac surgery.1  -blockers act as antiarrhythmic
drugs principally by attenuating the effects of the
sympathetic system on automaticity and
conductivity within the heart.5 Commonly used 
 -blockers include metoprolol, bisoprolol and
atenolol. Amiodarone, a class III antiarrhythmic
drug, is recommended for all patients undergoing
cardiac surgery in whom  -blocker therapy is not
possible. 
In 2006 the National Institute for Health and
Clinical Excellence (NICE) issued a clinical
guideline on the management of AF.6 In terms of
prophylaxis of postoperative AF it recommends
that one of the following drugs be used:
amiodarone, a  -blocker, sotalol (class III 
 -blocker), or a rate-limiting calcium antagonist
(e.g. verapamil or diltiazem). In addition, patients
undergoing cardiac surgery on pre-existing 
 -blocker therapy should continue with this unless
contraindications develop (e.g. bradycardia or
hypotension). However, the role of magnesium was
not assessed and therefore it is not covered by
their recommendations. 
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Chapter 2
BackgroundDescription of the intervention
Magnesium may be given to patients undergoing
cardiothoracic surgery to reduce
hypomagnesaemia, a common occurrence
following this kind of surgery. Magnesium may
exhibit antiarrhythmic activity through a number
of mechanisms including inhibiting L-type
calcium channels, which reduces sinus node rate
firing.7 However, the mechanisms are not fully
understood.8 Magnesium is not a first line choice
for prophylaxis of AF and there appear to be few
data on the extent to which it is used in current
practice. 
Magnesium may be used in combination with
other drugs such as  -blockers (e.g. bisoprolol or
sotalol).9 The drug is usually administered
intravenously at a dose of 1–4 g in 10–20%
solution at a rate not exceeding 1.5 ml of 10%
solution, or equivalent per minute, or intravenous
infusion of 4 g in 250 ml of 5% dextrose at a rate
not exceeding 3 ml per minute. It may also be
given as an intravenous bolus, intramuscularly or
orally in the form of magnesium
glycerophosphate. Prophylaxis with magnesium
can begin before, during or after cardiothoracic
surgery. The duration of prophylaxis varies from a
matter of hours to several days. 
Magnesium is well tolerated by patients and is
unlikely to cause drug reactions such as plaques
associated with antiarrhythmic agent use and the
side-effects of drowsiness and lethargy from using
 -blockers. However, it has wide effects on basic
biological mechanisms and is unlikely to be
particularly targeted in action. 
Sotalol hydrochloride (Beta-cardone®, Celltech;
Sotacor®; Bristol-Myers Squibb; non-proprietary)
is a non-selective  -blocker with class III
antiarrhythmic activity, used in the prophylaxis of
paroxysmal supraventricular arrhythmias. By
blocking the potassium channels, sotalol prolongs
repolarisation, therefore lengthening the QT
interval and decreasing automaticity.
Sotalol has an appreciable class III action only at
high doses (240–480 mg per day). At low doses
commonly prescribed in the UK (80–160 mg per
day) the main antiarrhythmic effect is its class II
(i.e.  -blocker) action. Side-effects may include
ventricular proarrhythmias.2 It is available orally
for prophylaxis at a dose of 80 mg daily in one or
two divided doses, increased gradually at intervals
of 2–3 days to a usual dose of 160–320 mg daily in
two divided doses.5 Sotalol via injection is not
recommended routinely for prophylaxis. No
estimates of the extent to which it is currently used
were available, but expert opinion suggests that
most clinicians use  -blockers other than sotalol. 
Background
4A
systematic review was conducted according to 
the scope and methods outlined in the
protocol issued in March 2007 (based on the HTA
commissioning brief). 
Inclusion and exclusion criteria
Populations
For studies to be included, patients had to be
aged over 18 years, undergoing elective isolated
CABG (either on-pump or off-pump, with any
number of grafts or any conduit type). Studies
were excluded if patients received other
concomitant surgical procedures (e.g. valvular
operations), unless the proportion of patients
undergoing isolated CABG was also clearly
documented. Studies in which methods of
detecting AF were not specified, in which patients
had a history of AF or history of AF was not
reported, and/or studies in which length of 
follow-up was not reported were included in this
review if they met the other inclusion criteria.
Interventions
Studies using intravenously administered
magnesium sulphate alone, as either a bolus or a
continuous infusion of clearly specified dosage
and duration, given as prophylaxis before the
onset of AF, were included. Studies of other
magnesium compounds (e.g. chloride, hydroxide
or unspecified) were excluded. Studies in which
patients received other drugs (e.g.  -blockers)
were included in this review only if the drugs were
administered as usual patient care and did not
differ between the randomised study groups. 
Comparators
The study compared:
● intravenous magnesium sulphate versus
different administration strategies of
intravenous magnesium sulphate
● intravenous magnesium sulphate versus
placebo/control
● intravenous magnesium sulphate versus sotalol.
Outcomes
The primary outcome was incidence of AF after
CABG. Supraventricular arrhythmias other than
AF (e.g. tachycardias and atrial flutter) and all
other non-atrial arrhythmias were excluded.
Study types
Randomised controlled trials (RCTs) were
included. Systematic reviews were identified for
context, but their results were not extracted and
their methodological quality was not appraised. 
Search strategy
A comprehensive search strategy was developed to
identify RCTs and systematic reviews that have
investigated the effects of prophylactic intravenous
magnesium sulphate on AF after CABG. The
search strategy (Appendix 1) aimed to identify
systematically all relevant studies that met the
inclusion criteria reported above. As the current
review provides an update to a previous systematic
review by Alghamdi and colleagues10 (as requested
in the HTA commissioning brief), the searches for
intravenous magnesium versus placebo/control
were limited to studies published after 2003 (the
cut-off date for literature searching in Alghamdi’s
systematic review being December 2003). No date
restriction was applied to searches for sotalol
studies.
The search strategy was applied to the following
general and specialist health and biomedical
databases (Appendix 1): Cochrane Library (2007
Issue 2), Ovid MEDLINE® (1950 to May 2007
week 1), Ovid MEDLINE® In-process and Other
Non-indexed Citations, EMBASE (1980 to 2007
week 19), Database of Abstracts of Reviews of
Effectiveness (DARE), Health Technology
Assessment (HTA) Database, Centre for Reviews
and Dissemination (CRD) database, National
Research Register (NRR), Current Controlled
Trials, including the Medical Research Council
(MRC) Trials Database (controlled-trials.com) and
Clinical Trials (clinicaltrials.gov). Each database
was searched once, during 14–17 May 2007. 
Study inclusion
All references identified by the literature searches
were imported into a Reference Manager
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Chapter 3
Methods of assessing clinical effectivenessbibliographic database. After duplicate references
had been deleted from the database, the title and
(where available) abstract of each reference were
screened systematically against the inclusion
criteria reported above, to assess the relevance of
the study for inclusion in the review. This initial
screening step was carried out by a reviewer using
a standard decision tree (Appendix 2). Cases of
uncertainty were resolved by discussion with a
second reviewer. For those references that did not
fulfil the inclusion criteria (owing to inappropriate
population, study design, intervention or
outcome) the reason for exclusion was recorded.
Full papers for those references that appeared
relevant on the basis of title and (where available)
abstract were retrieved. Full papers were checked
for their relevance using the same decision tree
independently by two independent reviewers. Any
disagreements between the reviewers were resolved
by discussion and, if necessary, consultation with a
third reviewer. Reasons for excluding papers at
this stage were also recorded. Reference lists of
relevant systematic reviews that were identified
using the search strategy were checked for
additional relevant literature not identified in the
systematic searches.
Data extraction
Data were extracted from the included studies
using a predesigned and piloted data extraction
template to report the study design, patient
populations, interventions, outcomes, analyses and
any study limitations (Appendix 3). Data were
extracted for incidence of AF and other relevant
AF outcomes (e.g. time to onset of AF). If
available, data on the patients’ length of stay in
the intensive care unit (ICU), postoperative stay
and total hospital stay were also extracted. Data
from each study were extracted by one reviewer
and checked by a second reviewer. Any
disagreements were resolved by consensus, if
necessary involving a third reviewer.
Quality assessment
The methodological quality of each of the
included studies was assessed systematically
according to guidelines provided by the NHS
CRD.11 Study quality was assessed independently
by two reviewers and reported in Table 2 for each
of seven criteria [randomisation, treatment
allocation concealment, homogeneity of patient
populations, blinding of outcome assessors,
presentation of outcome data, intention-to-treat
analysis (ITT), and description of withdrawals and
dropouts]. Any disagreements in quality
classification were resolved by consensus, if
necessary involving a third reviewer.
Data synthesis
Two forms of synthesis were conducted, a narrative
synthesis and quantitative meta-analysis. Both
forms of analysis were conducted according to
standard principles, and using accepted
methods.11,12 The key characteristics of the
included studies (e.g. details of the study
populations, intervention characteristics and
outcomes measured) and the results (e.g.
incidence of AF, length of hospital stay and
adverse events) were summarised narratively and
tabulated.
The feasibility and appropriateness of meta-
analysis were considered once narrative synthesis
had been completed. Meta-analysis to quantify the
effects of prophylaxis on incidence of AF was
performed using Cochrane Review Manager
Software (RevMan, version 4.2). A similar
approach to meta-analysis used by Alghamdi and
colleagues was followed here.10 The proportion of
patients experiencing AF in the intervention and
comparator groups and the total number of
patients in each study group were entered into
RevMan. Data for the ITT population were
entered where available; however, in the majority
of studies it was not clear whether a true ITT
analysis had been performed owing to poor
reporting. Study authors were not routinely
contacted to supply missing data or to clarify their
analysis (with the exception of Nurözler and
colleagues,25 see section ‘Subgroup analyses: dose’,
p. 19).
A fixed-effects analysis was performed, with
random-effects analysis reserved for cases where
statistical heterogeneity could not be explained.
Heterogeneity was defined by a statistically
significant  2 test (p > 0.10) and quantified by the
I2 statistic, where a figure greater than 50%
indicates substantial heterogeneity.12
Sensitivity analyses were performed in cases of
statistical heterogeneity (e.g. based on study
methodological quality). Subgroup analyses were
performed to assess the effects of different
delivery strategies for intravenous magnesium,
including different total doses, timing of the
initiation of prophylaxis and total duration of
prophylaxis. These subgroups were defined a priori
Methods of assessing clinical effectiveness
6in the research protocol, based on the HTA
commissioning brief for this assessment which
requested analysis of optimal delivery strategies.
For each subgroup, trials were assigned to
mutually exclusive categories for analysis. (The
categories themselves were not defined in the
protocol, but were devised by the authors during
the course of the systematic review.) For the total
duration of infusion the categories were: 1 day or
less, 2–4 days, and 5 days or more. The studies
were also ordered by duration, from shortest to
longest. For timing of the initiation of prophylaxis
the categories were: 12 hours or more presurgery,
less than 12 hours presurgery or during surgery,
and termination of surgery or immediately
postsurgery. The total dose of magnesium was not
split into separate subgroups as it was considered
that defining subgroups on the basis of dose
thresholds would be an arbitrary process. Expert
clinical opinion suggested that there is no
consensus over high or low dose thresholds.
Alternatively, all doses were displayed graphically
in a forest plot from lowest to highest to permit
examination of the relationship between dose and
odds of AF. A fourth delivery strategy specified in
the research protocol, bolus versus intravenous
infusion, was not assessed as only two trials were
included that reported administering magnesium
via bolus. 
Effect measures were expressed as the odds ratio
(OR) with 95% confidence intervals (CIs).
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available
The search strategy (Appendix 1), together with
the previous systematic review by Alghamdi and
colleagues,10 yielded 204 potentially relevant
references. Two additional relevant references13,14
were identified during checking of the reference
lists of the retrieved systematic reviews. Of these
initial 206 papers, 158 were excluded on screening
of titles and abstracts and a further 26 were
subsequently excluded on screening of the full
papers (Appendix 4). The remaining 22 papers
that met the inclusion criteria for this review
comprised 17 that reported parallel-group RCTs
(15 trials altogether)13–29 and five systematic
reviews.7–10,30
Systematic reviews
As mentioned earlier, the current systematic review
updates a systematic review published by
Alghamdi and colleagues (2005).10 The inclusion
criteria for the current review were based on those
used by Alghamdi and colleagues.10 Seven of the
eight studies included in that systematic review are
included here. (NB. The additional study31
appears to have been erroneously included by
Alghamdi and colleagues; it evaluated magnesium
chloride, yet their inclusion criteria specified only
magnesium sulphate, hence it is not included in
the current report.) Note that of the additional
eight studies included here, three were new
studies16,22,29 published since Alghamdi and
colleagues’ review, and five were studies published
before 2003, of which two were not found by
Alghamdi and colleagues but identified by the
present authors’ search of reference lists of other
systematic reviews13,14 and three were studies that
Alghamdi and colleagues excluded.15,24,26 Of these
three exclusions, two were rejected because the
primary outcome measure was a broader measure
of arrhythmia including other forms of arrhythmia
as well as AF (e.g. atrial flutter or atrial
tachycardia).15,24 However, these studies are
included in the current report as it was discernible
from the published papers that the proportion of
arrhythmic events that were AF was relatively high
(e.g. greater than 90%). The third study26 was
excluded by Alghamdi and colleagues because
their inclusion criteria prohibited studies in which
patients had a prior history of AF. However, it is
included in the current review as that particular
study excluded patients with chronic AF, and the
proportion of patients in the trial with previous
non-chronic AF was relatively low (less than 10%).
It should be pointed out that some of the studies
included here and in the review by Alghamdi and
colleagues10 did not report whether or not
patients had experienced previous AF, and
consequently it cannot be guaranteed that all
patients in these trials were being treated for first
occurrence of AF. 
Four other relevant published systematic reviews
were identified from the literature search.7–9,30
The systematic reviews varied slightly in terms of
inclusion criteria and when they were conducted,
meaning that each contained a different set of
studies. The systematic reviews with the highest
degree of overlap with the current systematic
review were by Burgess and colleagues (2006),30
Miller and colleagues (2005)7 and Shiga and
colleagues (2004),8 which included up to 11 of the
15 studies included here. These reviews included
other studies that are excluded from the current
review, reflecting differences in inclusion criteria.
For example, some of the reviews included studies
of magnesium chloride.
One of the key differences between the current
review and the five published systematic reviews is
that none of those reviews specifically aimed to
assess the role of delivery characteristics in the
effectiveness of magnesium prophylaxis, with the
exceptions of Henyan and colleagues9 and Miller
and colleagues,7 who performed subgroup
analyses based on dose and timing of the initiation
of therapy. Another key difference is that none of
the five published systematic reviews aimed to
assess the effectiveness of magnesium sulphate
compared with sotalol. The systematic review by
Burgess and colleagues30 also included a set of
studies comparing sotalol to placebo, and a
Cochrane systematic review has also compared
sotalol with placebo;32 however, such a comparison
is outside the scope of the current review.
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Chapter 4
Clinical effectiveness resultsIn summary, this systematic review updates and
expands a previous review by Alghamdi and
colleagues,10 adding in three newly published
RCTs and a further five older RCTs that were not
previously included. There is some degree of
overlap with other published systematic reviews,
but none specifically aimed to assess the role of
intravenous magnesium delivery or to compare
intravenous magnesium with sotalol.
Characteristics of the included
RCTs
Most of the trials included in the current report
were conducted in Turkey (five trials14,17,18,23,25,27)
and the USA (four trials15,16,19,22), with single trials
also in Canada,24 Finland,26 Israel13 and
Switzerland28 The number of patients randomised
to each intervention ranged from 15 to 176
(Table 1). In nine trials the comparator was
explicitly reported as a placebo group, whereas in
six trials it was referred to as a control group. One
of the trials, by Forlani and colleagues,20,21
compared magnesium and sotalol in combination
with a control group, and against magnesium
alone and sotalol alone (Table 1). According to the
authors the study was not designed to compare
magnesium against sotalol directly, and no
statistical tests were reported for the comparison
of the two drugs.
The standard of reporting in these trials was
generally poor. In the majority of studies the
adequacy of randomisation, concealment of
treatment allocation, blinding of assessors and
analysis of missing data could not be elucidated
(Table 2). Although most of the studies reported
baseline characteristics of their patient
populations, the quantity of information given and
whether differences between groups were tested
statistically were highly variable among the
studies. None of the studies reported the ethnic or
socio-demographic status of their recruited
patients. Reporting of the methods of detecting
AF and the definitions of AF used in the studies
were variable (Appendix 5).
Assessment of effectiveness
Incidence of AF
As mentioned earlier, only one RCT included both
a sotalol and an intravenous magnesium arm.20,21
However, the trial was designed to compare the
clinical efficacy of combined sotalol and
Clinical effectiveness results
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TABLE 1 Characteristics of 15 RCTs that met the criteria for inclusion in this review
Study Population Intervention N Comparator N Outcomes
AF Length of stay
ICU Postop. Hospital
Bert et al., 200115 CABG + V Mg  63 Control 60 (✓) ✓
Bhudia et al., 200616 CABG + V Mg  174 Placebo  176 ✓✓ ✓ ✓
Caspi et al., 199513 CABGa Mg 50 Placebo 48 ✓
Dagdelen et al., 2002,17 CABG Mg 93 Control 55 ✓
200318
Fanning et al., 199119 CABG Mg 49 Placebo 50 (✓)
Forlani et al., 2002,20 CABG Mg 54 Control 50 ✓✓
200321 Sotalol 51
Mg + sotalol 52
Hazelrigg et al., 200422 CABG Mg 105 Control 97 ✓✓ ✓
Kaplan et al., 200323 CABG Mg 100 Placebo  100 ✓✓ ✓
Karmy-Jones et al., 199524 CABG + V Mg  46 Placebo 54 (✓) ✓✓
Nurözler et al., 199625 CABG Mgb 25 Placebo 25 ✓
Parikka et al., 199326 CABG Mg 69 Placebo 71 ✓
Toraman et al., 200127 CABG Mg 100 Control 100 ✓✓ ✓
Treggiari-Venzi et al., 200028 CABG Mg 49 Placebo 53 ✓✓
Yilmaz et al., 200014 CABGa Mgc 15 Control 15 ✓
Zangrillo et al., 200529 CABG Mg 80 Placebo 80 ✓✓ ✓
Unless stated otherwise, CABG was isolated (anot reported whether CABG was isolated). 
Hospital, total hospital time; ICU, time in intensive care unit; Mg, magnesium sulphate given by intravenous delivery
(bunclear whether all magnesium administered was given as sulphate; cnot reported whether delivery was intravenous);
Postop, total postoperative time; V, valvular surgery; ✓, directly reported; (✓), inferred indirectly. intravenous magnesium against the two agents
separately, and against a control. No statistical
tests were performed for the comparison between
sotalol and intravenous magnesium. In the study
postoperative AF occurred in 12% of patients
receiving sotalol and in 15% of patients receiving
magnesium. 
No RCTs were identified that compared different
delivery strategies of intravenous magnesium. The
remainder of this section therefore focuses on the
results of the RCTs that compared intravenous
magnesium with placebo or control.
Of 1070 patients in the pooled magnesium group,
230 (21%) developed postoperative AF, compared
with 307 of 1031 (30%) patients in the control (or
placebo) group. Figure 1 shows the forest plot of
the meta-analysis of all 15 RCTs on the incidence
of AF. Initial analysis using a fixed-effect model
gave a pooled OR significantly less than 1.0 
(OR = 0.65, 95% CI 0.53 to 0.79, test for overall
effect p < 0001), but with statistically significant
heterogeneity (I2 = 63.4%, p = 0.0005).
All individual studies with an OR that was
significantly different from 1.0, and those with an
OR bordering on significance (whose CI only just
included 1.0) were in favour of magnesium
sulphate. The overall effect favouring magnesium
was driven by a relatively small proportion of the
studies, with the majority (nine out of 15)
exhibiting ORs very close to 1.0. Two RCTs, by
Dagdelen and colleagues (2002)17 and Toraman
and colleagues (2001),27 are notable as they had
lower ORs in favour of magnesium sulphate than
all the other studies.
Sensitivity analyses
Sensitivity analyses were performed to explore the
likely reasons for heterogeneity. When the analysis
was restricted to the two RCTs that were judged to
have adequately concealed random allocation16,28
(Table 2), the intervention effect was no longer
statistically significant (OR = 0.84, 95% CI 0.57 to
1.26, test for overall effect p = 0.40), although
heterogeneity was absent (I2 = 0%) and no longer
significant (p = 0.92). A similar pattern was
evident when analyses were restricted to the three
RCTs whose randomisation procedures were
judged to be adequate15,20,21,29 (Table 2) or the five
RCTs whose blinding was considered
adequate13,15,17,18,24,27 (forest plots not shown).
Given that the number of studies meeting the
criteria of methodological adequacy for these
attributes was comparatively low, these results
should be interpreted with caution. 
In a meta-analysis of eight RCTs, which included
seven of the RCTs included in the current report,
Alghamdi and colleagues10 also identified a
statistically significant intervention effect and
statistically significant heterogeneity. When their
analysis was restricted to the six highest quality
studies scored using the Van Tulder methodological
quality assessment scale, their intervention effect
remained statistically significant, but heterogeneity
was reduced and no longer statistically significant.
The two studies that were excluded were Dagdelen
(2002)17 and Toraman (2001).27 These two trials
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TABLE 2 Quality of the RCTs assessed systematically according to the criteria of the NHS CRD
Study Randomi- Conceal- Baseline Blinding  of  Primary  ITT  Missing 
sation ment of  charac- assessors outcome  analysis  values
allocation teristics data
Bert et al., 200115 Adequate Unknown Reported Adequate Adequate Inadequate Partial
Bhudia et al., 200616 Unknown Adequate Reported Unknown Adequate Inadequate Unknown
Caspi et al., 199513 Unknown Unknown Reported Adequate Partial Inadequate Unknown
Dagdelen et al., 2002,17 Unknown Unknown Reported Adequate Adequate Inadequate Unknown
200318
Fanning et al., 199119 Unknown Unknown Reported Unknown Adequate Inadequate Unknown
Forlani et al., 2002,20 200321 Adequate Unknown Reported Unknown Adequate Inadequate Inadequate
Hazelrigg et al., 200422 Inadequate Inadequate Reported Inadequate Partial Inadequate Inadequate
Kaplan et al., 200323 Inadequate Inadequate Reported Inadequate Adequate Inadequate Inadequate
Karmy-Jones et al., 199524 Unknown Unknown Reported Adequate Partial Inadequate Unknown
Nurözler et al., 199625 Unknown Unknown Reported Unknown Adequate Inadequate Unknown
Parikka et al., 199326 Unknown Unknown Reported Unknown Adequate Inadequate Adequate
Toraman et al., 200127 Inadequate Inadequate Reported Adequate Adequate Inadequate Inadequate
Treggiari-Venzi et al., 200028 Partial Adequate Reported Unknown Adequate Inadequate Inadequate
Yilmaz et al., 200014 Unknown Unknown Unknown Unknown Adequate Inadequate Unknown
Zangrillo et al., 200529 Adequate Unknown Reported Inadequate Adequate Adequate Adequate
Overall (modal class) Unknown Unknown Reported Unknown Adequate Inadequate UnknownClinical effectiveness results
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TABLE 3 Dosage and duration of magnesium sulphate administration in the intervention group (indicated only where this differed from
the control or placebo comparator group)
Study Method of  Time  MgSO4 dose or  Carrier Duration
delivery concentration
Bert et al., 200115 i.v. infusion 1. After termination  2 g 50 ml normal  30 minutes
of CPB saline
2. On arrival in ICU 2 g 50 ml normal  30 minutes
saline
3. Each morning for  2 g × 4 50 ml normal  30 minutes 
first 4 days  saline × 4 × 4
postsurgery
Overall total 12 g 300 ml normal  3 h in 5 days
saline
Bhudia et al., 200616 CPB circuit 1. During CPB 3.6 to 4.8 mg dl–1 ––
i.v. 2. During anaesthesia  0.78 g (32 mmol)  100 ml normal  15 minutes
induction saline
3. After anaesthesia 3.16 g (130 mmol) 100 ml normal  24 h
induction saline
Overall total  3.94 g (162 mmol)  200 ml normal  24.25 h
+ CPB conc. saline + 
CPB prime
Caspi et al., 199513 i.v. via  1. During interval  16 mmol 20 ml saline –
syringe pump between induction 
of anaesthesia and 
aortic cross-clamp
i.v. 2. After release of  32 mmol 20 ml saline 24 h
cross-clamp
Overall total 48 mmol 40 ml saline ~24 h
Dagdelen et al., 2002,17 i.v. infusion 1. 1 day presurgery 1.5 g 100 ml 0.9 NaCl  1 day
200318 solution 
(25 ml h–1)
2. Just after surgery 1.5 g  100 ml 0.9 NaCl  1 day
solution 
(25 ml h–1)
3. Once daily for  1.5 g × 4 100 ml 0.9 NaCl  4 days
4 days postsurgery solution 
(25 ml h–1) × 4
Overall total 9 g 600 ml 0.9 NaCl  6 days
solution
Fanning et al., 199119 i.v. infusion 1. First 24 h postsurgery 40 mEq l–1 at  5% dextrose in  1 day
100 ml h–1 water + 20 mEq 
(total 96 mEq at  potassium 
4 mEq h–1) chloride l–1 at 
100 ml h–1
2. Next 72 h postsurgery 40 mEq l–1 at  5% dextrose in  3 days
(25–96 h) 25 ml h–1 water + 20 mEq 
(total 72 mEq at  potassium 
1 mEq h–1) chloride L–1 at 
25 mL h–1
Overall total 168 mEq 5% dextrose in  4 days
water + 80 mEq 
potassium chloride
continuedHealth Technology Assessment 2008; Vol. 12: No. 28
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TABLE 3 Dosage and duration of magnesium sulphate administration in the intervention group (indicated only where this differed from
the control or placebo comparator group) (cont’d)
Study Method of  Time  MgSO4 dose or  Carrier Duration
delivery concentration
Forlani et al., 2002,20 i.v. From just before CPB  1.5 g (12 mEq)  NR 6 days
200321 until 5 days postsurgery day–1 × 6
Magnesium group
Overall total 9 g (72 mEq) – 6 days
Forlani et al., 2002,20 i.v.  From just before CPB  As above plus  NR 6 days
200321 magnesium +  until 5 days postsurgery sotalol 80 mg orally 
Magnesium + sotalol  oral sotalol twice daily
group
Overall total 9 g (72 mEq)  – 6 daysa
MgSO4 + 960 mg 
sotalol
Hazelrigg et al., 200422 Bolus (no  1. 30 minutes before  80 mg kg–1 (ideal  100 ml of D5W 30  minutes
other details) CPB body weight)
i.v. drip  2. Subsequent 48 h 8 mg kg–1 (ideal  100 ml of D5W 48 h
infusion body weight) h–1
Overall total 464 mg kg–1 200 mL of D5W 48.5 h
(ideal body weight)
Kaplan et al., 200323 i.v. infusion 1. 12 h presurgery  3 g (24.34 mEq) at  100 ml saline at  2 h
50 ml h–1 50 ml h–1
2. After termination of  3 g (24.34 mEq) at  100 ml saline at  2 h
CPB or anastomosis  50 ml h–1 50 ml h–1
of last graft
3. First postsurgery  3 g (24.34 mEq) at  100 ml saline at  2 h
dose in ICU 50 ml h–1 50 ml h–1
4. 1–3 days postsurgery  3 g (24.34 mEq) at  100 ml saline at  2 h × 3
50 ml h–1 daily × 3 50 ml h–1
Overall total 18 g (146.04 mEq) 600 ml saline 12 h in 
4.5 days
Karmy-Jones et al.,  i.v. 1. At termination of CPB 2.4 g (19.2 mEq)  50 mL of D5W 20 minutes
199524
2. Every 4 h for a  2.4 g (19.2 mEq)  50 ml of D5W 100 minutes
further five doses × 5
Overall total 14.4 g (115 mEq) 100 mL of D5W 2 h in 20.3 h
Nurözler et al., 199625 i.v. infusion 1. In cardioplegiab 16 mmol l–1b NR NR
2. First postoperative day 100 mEq  1000 ml of  1 day
D5W day
3. Postoperative  25 mEq day–1 × 4 1000 ml of  4 days
days 2–5 D5W day–1 × 4
Overall total 200 mEq 5 litres of D5W 5 days
Parikka et al., 199326 i.v. infusion 1. First 24 h after  40 mmol 1 litre of 5%  1 day
surgery (started  glucose solution 
within 2 h of 
operation)
2. Next 24 h after  30 mmol 500 ml of 5%  1 day
surgery glucose solution
Overall total 70 mmol 1.5 l of 5% glucose 2 days
solution
continuedwere conducted by the same team of investigators
and appear to be similar in many intervention and
study design characteristics. 
In the current meta-analysis quality scores were
not assigned to studies as this is not recommended
practice.33 Critical appraisal of the various aspects
of the methodological quality of these two RCTs
(Table 2) concluded that, in terms of key
methodological attributes such as method of
randomisation or concealment of allocation, either
they were inadequate or details were not reported
clearly enough to allow an informed judgement to
be made (although it should be noted that these
two studies are not atypical, as standards of
reporting were generally poor in most trials).
From visual inspection of Figure 1 these two studies
appeared to contribute to the statistical
heterogeneity, with relatively small ORs. Removing
them from the analysis meant that heterogeneity
was no longer statistically significant (p = 0.35,
I2 = 9.4%), but increased the pooled OR to 0.78
and widened the CIs (95% CI 0.63 to 0.97),
although a statistically significant intervention
effect remained (p = 0.02). The analyses presented
in the next section illustrate that these two trials
appear to be different from the other trials in all
subgroup analyses.
Subgroup analyses: total duration of prophylaxis 
The total duration of magnesium sulphate
prophylaxis ranged from 30 minutes to 6 days (0.5
to 144 hours) (Table 3). When studies were ordered
by duration of prophylaxis, an apparent
relationship between duration of prophylaxis and
odds of AF was evident, with decreasing odds of
AF as duration of prophylaxis is increased
Clinical effectiveness results
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TABLE 3 Dosage and duration of magnesium sulphate administration in the intervention group (indicated only where this differed from
the control or placebo comparator group) (cont’d)
Study Method of  Time  MgSO4 dose or  Carrier Duration
delivery concentration
Toraman et al., 200127 i.v. infusion 1. One day presurgery 6 mmol 100 ml 0.9%  1 day
NaCl (25 ml h–1)
2. Just after CPB 6 mmol 100 ml 0.9%  1 day
NaCl (25 ml h–1)
3. Once daily for 4 days  6 mmol × 4 100 ml 0.9%  4 days
postsurgery NaCl (25 ml h–1) 
× 4
Overall total 36 mmol 600 ml 0.9% NaCl 6 days
Treggiari-Venzi et al.,  i.v. infusion For 72 h, starting  4 g (16 mmol)  NRc 3 days
200028 within 1 h of arrival  (32 mEq) day–1
in ICU × 3
Overall total 12 g (48 mmol)  – 3 days
(96 mEq)
Yilmaz et al., 200014 Bolus (no  At initiation of CPBd 0.4 mmol kg–1 NR NR
other details) (15%)e
Overall total 0.4 mmol kg–1 ––
(15%)e
Zangrillo et al., 200529 Infusion For 30 minutes  2.5 g (20 mEq)f 100 ml of  30 minutes
immediately after  normal saline
central venous 
cannulation
Overall total 2.5 g (20 mEq) 100 ml of normal  30 minutes
saline
CPB, cardiopulmonary bypass; D5W, 5 % dextrose water solution; NR, not reported.
a Sotalol was subsequently continued at 40 mg orally twice daily for a further 4 weeks.
b Magnesium compound and volume (litres) administered in cardioplegia not reported.
c Noted that placebo was 0.9% NaCl.
d Magnesium sulphate was also administered to both groups in the cardioplegia solution.
e Parameter not stated (may refer to body weight or ideal body weight?).
f 2.5 g magnesium sulphate was also administered to both groups in the ICU within the first 24 h postsurgery.(Figure 2). Note that the forest plot displaying this
relationship includes all studies except for one by
Yilmaz and colleagues14 (for which the duration of
prophylaxis was not reported), and consequently
the heterogeneity and overall effect are similar to
those reported above in Figure 1. As noted above,
two studies, by Dagdelen17,18 and Toraman27
warrant careful consideration because they appear
to influence strongly the overall pattern in the
forest plot. Both these studies excluded patients
on  -blockers and might therefore have analysed
populations who were at relatively high risk of AF,
who might have been more likely to respond to
prophylaxis for AF. A third study that warrants
consideration is by Nurözler and colleagues.25 In
their study, the full dose and duration of
magnesium sulphate administration are uncertain;
as well as giving magnesium intravenously it
appears to have been applied in the cardioplegia
solution used during surgery, with unspecified
details of dose (Table 3). Omitting these three
studies from the meta-analysis subgroup would
result in a forest plot that still appears to support
the relationship between duration of prophylaxis
and odds of AF (Figure 3). Excluding these studies
also considerably reduces the heterogeneity of the
overall effect (I2 = 5.8%, p = 0.39, fixed-effects
model). 
The relationship between the duration of
prophylaxis and the odds of AF appears
approximately linear, irrespective of whether the
OR is plotted on an arithmetic (Figure 4) or a
logarithmic scale. A linear metaregression with ln
OR as the dependent variable (random-effects
least-squares model in which studies are weighted
according to the inter-trial and intra-trial
variances) based on 14 studies (omitting only the
study by Yilmaz,14 which did not report duration)
would confirm the linear relationship (R2 = 0.743,
p < 0.001). The linear relationship would still be
supported by this model if a further three studies
by Dagdelen,17,18 Nurözler25 and Toraman27
(discussed above) were excluded (R2 = 0.704,
p = 0.001). 
It is difficult to determine how (or indeed
whether) the studies should be grouped for
analysing effects of prophylaxis duration on odds
of AF. If the data are grouped into three classes
Health Technology Assessment 2008; Vol. 12: No. 28
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Review:  Intravenous magnesium compared wth sotalol for prevention of atrial fibrillation after coronary artery bypass surgery
Comparison:  Intravenous magnesium sulphate versus placebo
Outcome: Incidence  of  AF
 Fanning  et al., 199119
 Parikka  et al., 199326
 Caspi  et al., 199513
 Karmy-Jones  et al., 199524
 Nurözler  et al., 199625
 Treggiari-Venzi  et al., 200028
 Yilmaz  et al., 2000  14
 Bert  et al., 200115
 Toraman  et al., 200127
 Dagdelen  et al., 2002,17 200318
 Forlani  et al., 2002,20 200321
 Kaplan  et al., 200323
 Hazelrigg,  et al. 200422
 Zangrillo  et al., 200529
 Bhudia  et al., 200616
Total (95% CI)
Total events: 230 (magnesium), 307 (placebo)
Test for heterogeneity:  2 = 38.22, df = 14 (p = 0.0005), I2 = 63.4%
Test for overall effect: z = 4.26 (p < 0.0001)
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FIGURE 1 Meta-analysis of incidence of AF (fixed-effects model)Clinical effectiveness results
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Review:  Intravenous magnesium compared wth sotalol for prevention of atrial fibrillation after coronary artery bypass surgery
Comparison:  Intravenous magnesium sulphate versus placebo
Outcome:  Incidence of AF (ranked by total duration)
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FIGURE 2 Studies ordered by duration of magnesium sulphate intervention (random-effects model). The data column ‘Order’ shows
the duration of intervention (hours, rounded to the nearest 1 hour). 
Review:  Intravenous magnesium compared wth sotalol for prevention of atrial fibrillation after coronary artery bypass surgery
Comparison:  Intravenous magnesium sulphate versus placebo
Outcome:  Incidence of AF (ranked by total duration)
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Test for heterogeneity:  2 = 10.61, df = 10 (p = 0.39), I2 = 5.8%
Test for overall effect: z = 1.95 (p = 0.05)
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FIGURE 3 Studies ordered by duration of magnesium sulphate intervention, excluding studies by Dagdelen et al.,17,18 Nurözler et al.25
and Toraman et al.27 (fixed-effects model; other details as in Figure 2)according to whether duration of prophylaxis was
1 day or less, 2–4 days, or 5 days or greater, a
statistically significant intervention effect is only
present for the longest duration group (OR =
0.12, 95% CI 0.06 to 0.23, test for overall effect
p = 0.00001) (forest plot not shown). In this
subgroup heterogeneity is not statistically
significant (p = 0.12), although the I2 value (48%),
is just below the suggested threshold of substantial
heterogeneity (50%).12 The effect for a duration of
5 days or greater would remain statistically
significant after excluding the trials by Toraman27
and Dagdelen17,18 (data not shown).
Subgroup analyses: timing of initiation of
prophylaxis
Most of the studies did not report the exact 
timing of the start of magnesium prophylaxis, but
the studies can be grouped according to whether
prophylaxis commenced 12 hours or more
presurgery (Figure 5), within 12 hours of surgery
(including during surgery itself) (Figure 6) or at 
the termination of surgery or immediately
postsurgery (Figure 7). For the first two subgroups
there was a statistically significant intervention
effect, while in the third there was no significant
effect. 
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FIGURE 4 Relationship between the duration of magnesium sulphate prophylaxis and the odds of AF. Studies by Dagdelen,17,18
Nurözler25 and Toraman27 are encircled; a study by Yilmaz14 is omitted (see text). 
Review:  Intravenous magnesium compared wth sotalol for prevention of atrial fibrillation after coronary artery bypass surgery
Comparison:  Intravenous magnesium sulphate versus placebo
Outcome:  Incidence of AF: timing – initiation of therapy  12 hours presurgery
 Toraman  et al., 200127
 Dagdelen  et al., 2002,17 200318
 Kaplan  et al., 200323
Total (95% CI)
Total events: 19 (magnesium), 57 (placebo)
Test for heterogeneity:  2 = 19.43, df = 2 (p < 0.0001), I2 = 89.7%
Test for overall effect: z = 4.96 (p < 0.00001)
35.02
41.85
23.14
100.00
21/100
20/55
16/100
     255
  2/100
  2/93
15/100
     293
0.08 (0.02 to 0.34)
0.04 (0.01 to 0.17)
0.93 (0.43 to 1.99)
0.26 (0.15 to 0.44)
OR (fixed)
(95% CI)
OR (fixed)
(95% CI)
Weight
(%)
Placebo
n/N
Magnesium
n/N
Study
or subcategory
0.001 0.01 0.1 1 10 100
Favours treatment Favours control
1000
FIGURE 5 Subgroup analysis: timing of initiation of prophylaxis (greater than or equal to 12 hours presurgery) (fixed-effects model)For the subgroup of studies that initiated
prophylaxis 12 hours or more before surgery the
OR was 0.26 (95% CI 0.15 to 0.44, test for overall
effect p = 0.00001, fixed-effects model) (Figure 5).
However, there was statistically significant
heterogeneity (I2 = 89.7%, p < 0.0001). This is
likely to be due to the different effects in the
Toraman27 and Dagdelen17,18 trials, compared
with the trial by Kaplan and colleagues.23 When 
a random-effects model was used the OR was
reduced to 0.15, but the CIs included 1.0 (95% CI
0.02 to 1.38, test for overall effect=0.09) and the
effect was therefore no longer statistically
significant. 
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Review:  Intravenous magnesium compared wth sotalol for prevention of atrial fibrillation after coronary artery bypass surgery
Comparison:  Intravenous magnesium sulphate versus placebo
Outcome:  Incidence of AF: timing – initiation of therapy <12 hours presurgery/during surgery
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Total (95% CI)
Total events: 136 (magnesium), 163 (placebo)
Test for heterogeneity:  2 = 7.56, df = 5 (p = 0.18), I2 = 33.8%
Test for overall effect: z = 2.19 (p = 0.03)
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FIGURE 6 Subgroup analysis: timing of initiation of prophylaxis (less than 12 hours presurgery or during surgery) (fixed-effects model)
Review:  Intravenous magnesium compared wth sotalol for prevention of atrial fibrillation after coronary artery bypass surgery
Comparison:  Intravenous magnesium sulphate versus placebo
Outcome:  Incidence of AF: timing – initiation of therapy during termination of surgery/immediately postsurgery
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 Parikka  et al., 199326
 Karmy-Jones  et al., 199524
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Total (95% CI)
Total events: 75 (magnesium), 87 (placebo)
Test for heterogeneity:  2 = 5.08, df = 15 (p = 0.41), I2 = 1.6%
Test for overall effect: z = 0.89 (p = 0.37)
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FIGURE 7 Subgroup analysis: timing of initiation of prophylaxis (at termination of surgery or immediately postsurgery) (fixed-effects
model)For studies that initiated prophylaxis less than
12 hours before surgery or during the surgery
itself, there was a significant intervention effect
(OR = 0.73, 95% CI 0.56 to 0.97, p = 0.03, fixed-
effects model) without statistically significant
heterogeneity (I2 = 33.8%, p = 0.18) (Figure 6).
The subgroup of studies that initiated prophylaxis
at the end of surgery or postsurgery was not
associated with a significant intervention effect
(OR = 0.85, 95% CI 0.59 to 1.22, p = 0.37, fixed-
effects model); heterogeneity was also not
statistically significant in this subgroup (I2 = 1.6%,
p = 0.41) (Figure 7).
Subgroup analyses: dose
In eight of the 15 trials the dose of magnesium
sulphate was reported in grams. In five trials the
dose in grams was converted by the reviewers from
millimoles or milliequivalents, by assuming 
1 g ≡ 4 mmol ≡ 8 mEq of magnesium sulphate
(based on a conversion formula provided by Shiga
and colleagues8). The total dose of magnesium
sulphate administered in 13 of the trials ranged
from 2.5 to 25 g (Table 3). In the remaining two
trials, total doses of magnesium sulphate were
given per kilogram of unspecified ideal body
weight22 or per an unspecified parameter,14
precluding them from meta-analysis. 
The dose–response relationship has not previously
been characterised for effects of magnesium
sulphate on AF. Meta-analysis (Figure 8) shows that
for total doses of magnesium sulphate less than
21 g, the odds of AF were independent of the
dose. A notable exception is that for a total dose of
9 g magnesium sulphate the odds of AF were
significantly reduced relative to the control group
(OR = 0.12, test for overall effect p < 0.00001,
heterogeneity p = 0.06). Previous studies have
identified serum magnesium concentration as a
predictor of AF, but it is unclear why a profound
prophylactic effect of magnesium sulphate would
be found only at a total dose of 9 g. It is notable
that the three studies that administered
magnesium sulphate at the total dose of 9 g
(Dagdelen,17.18 Forlani20,21 and Toraman27) had
each excluded patients who were on antiarrhythmic
drugs (Appendix 6). As mentioned previously, the
patients included in these studies might have been
at higher risk of AF compared with patients in
other studies and, if so, might have benefited
more from prophylactic magnesium. The studies
by Dagdelen17,18 and Toraman27 in particular tend
to impart a highly significant reduction in the
odds of AF to whichever subgroup these studies
are analysed in (see above).
If the study by Nurözler and colleagues25 is
included in the meta-analysis, the forest plot
(Figure 8) would suggest a possible dose–response
relationship, as the highest doses tested (21 and
25 g) are associated with a reduction in the odds
of AF, although for these individual doses the CIs
of the OR include 1 (p > 0.05). Repeating the
meta-analysis with the two highest doses grouped
together (n = 2) would yield a significant OR for
this high-dose ( 21 g) group (OR = 0.35, 95% CI
0.14 to 0.88, test for overall effect p = 0.02,
heterogeneity p = 0.45; forest plot not shown).
The Nurözler and colleagues study is problematic,
however, because in addition to the total of 200
mEq magnesium sulphate that they administered
intravenously, they gave an unspecified dose of an
unspecified magnesium compound only to the
intervention group, during cardioplegia. This
effectively confounds their intravenous magnesium
sulphate dose with an unknown variable.
Excluding the Nurözler and colleagues data from
the forest plot is therefore advisable unless the
details of how magnesium was administered in
cardioplegia can be clarified. (The authors were
contacted during preparation of the current
review, but no response was received at the time of
submission of this report.) Excluding the Nurözler
and colleagues study would weaken the support
for a dose–response relationship. 
A potential limitation of comparing studies in
terms of the total magnesium sulphate dose
administered is that total dosage does not take
into account the dose rate, which may have 
clinical relevance. An analysis of whether the dose
rate of magnesium sulphate affects the incidence
of AF was possible for eight trials in which the
dose rate was kept constant (Table 4). In the
remaining seven trials either the dose rates were
varied during the course of a study, or they were
unclear13,14,16,19,22,25,26 (Table 3). 
Within the subgroup of eight studies that
maintained a constant dose rate there appears to
be a relationship between the dose rate of
magnesium sulphate and the odds of AF, with the
largest prophylactic effects being at the lowest
dose rates (Figure 9). In the forest plot the dose
rates (mg hour–1) are ordered from lowest
(62.5 mg hour–1) to highest (7200 mg hour–1). The
forest plot illustrates a large and statistically
significant degree of heterogeneity (I2 = 76.6%,
p = 0.0001, random-effects model). It is notable
that two studies that appear influential in this
relationship (by Dagdelen17,18 and Toraman27)
have been highlighted previously in terms of their
low ORs and possibly atypical patient populations
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Review:  Intravenous magnesium compared wth sotalol for prevention of atrial fibrillation after coronary artery bypass surgery
Comparison:  Intravenous magnesium sulphate versus placebo
Outcome:  Incidence of AF (in dosage subgroups)
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FIGURE 8 Subgroup analysis: total magnesium dose (fixed-effects model). NA, not applicable. (see above). Excluding these two trials from the
sub-group reduces the heterogeneity to a non-
significant level (I2 = 11.6%, p = 0.34, fixed-
effects model), but also weakens the evidence for
an effect of dose rate, with only one out of the
remaining six studies exhibiting an OR that is
clearly and significantly different from 1.0 
(Figure 10). 
Adverse events
Studies varied in whether they reported adverse
events, and how such events were reported; for
example, in some cases, AF was reported as an
adverse event. Ten of the 15 studies mentioned
whether mortality differed between the
magnesium sulphate and control (or placebo)
groups (Table 5). Overall, numbers of deaths were
too low for differences to attain statistical
significance.
Potentially adverse events that were reported
included a wide range of electrocardiological
conditions (e.g. ventricular tachycardia, ischaemia,
other arrhythmias), haemodynamic changes (e.g.
altered blood pressure) and biochemical events
(e.g. changes in serum electrolytes and creatinine
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TABLE 4 Studies in which the dose rate of magnesium sulphate was kept constant
Dose rate reported Dose rate  Total time  Total dose  i.v. carrier
(mg h–1) (h) (g)
Bert et al., 200115 2 g in 30 minutes 4000 3 12 50 ml saline
Dagdelen et al., 2002,17 1.5 g day–1 62.5  144 (= 6 days)  9 100 ml saline
200318
Forlani et al., 2002,20 1.5 g day–1 62.5 144 (= 6 days) 9 NR
200321
Kaplan et al., 200323 3 g in 2 h 1500 12 18 100 ml saline
Karmy-Jones et al., 199524 2.4 g in 20 minutes 7200 2 14.4 50 ml dextrose water
Toraman et al., 200127 6 mmol (≡ 1.5 g) day–1 62.5 144 (= 6 days) 9 100 ml saline
Treggiari-Venzi et al.,  4 g day–1 167 72 (= 3 days) 12 NR
200028
Zangrillo et al., 200529 2.5 g in 30 minutes 5000 0.5 2.5 100 ml saline
Review:  Intravenous magnesium compared wth sotalol for prevention of atrial fibrillation after coronary artery bypass surgery
Comparison:  Intravenous magnesium sulphate versus placebo
Outcome:  Incidence of AF (dose rate in mg per hour)
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FIGURE 9 Subgroup analysis: all studies that maintained a constant dose rate (random-effects model). Studies are ordered from
lowest dose rate (top) to highest (bottom). Order: dose rate in mg h –1.kinase concentrations). One study, by Hazelrigg
and colleagues,22 reported a statistically
significant, but not clinically significant, lower
arterial pressure in magnesium-treated patients
immediately after surgery (no p-value reported).
They also reported a significantly greater
excretion (p < 0.001) of magnesium and calcium
over a 24-hour period in the magnesium sulphate-
treated patients, but the timing relative to surgery
was unclear. In all other studies where adverse
events differed significantly between the groups, it
was the magnesium sulphate group that had the
more favourable incidence (or concentration).
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TABLE 5 Summary of mortality reported in patients receiving magnesium sulphate compared with control (or placebo) patients
Study Postoperative in-study mortality (n) Mortality reported after discharge 
or main follow-up (n)
Bert et al., 200115 0 Mg, 0 control NR
Bhudia et al., 200616 1 Mg, 1 placebo 1 Mg, 4 placebo (p = 0.2)
Caspi et al., 199513 1 Mg, 0 placebo NR
Dagdelen et al., 2002,17 200318 NR NR
Fanning et al., 199119 0 Mg, 1 placebo NR
Forlani et al., 2002,20 200321 1 Mg, 0 control NR
Hazelrigg et al., 200422 1 Mg, 2 control NR
Kaplan et al., 200323 1 Mg, 1 placebo NR
Karmy-Jones et al., 199524 0 Mg, 2 placebo NR
Nurözler et al., 199625 NR NR
Parikka et al., 199326 NR 1 (group not specified)
Toraman et al., 200127 NR NR
Treggiari-Venzi et al., 200028 0 Mg, 0 placebo (inferred) 0 Mg, 1 placebo
Yilmaz et al., 200014 NR NR
Zangrillo et al., 200529 0 Mg, 0 placebo NR
Review:  Intravenous magnesium compared wth sotalol for prevention of atrial fibrillation after coronary artery bypass surgery
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Outcome:  Incidence of AF (dose rate in mg per hour)
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FIGURE 10 Subgroup analysis: studies that maintained a constant dose rate, excluding those by Dagdelen et al.17,18 and Toraman 
et al.27 (fixed-effects model). Studies are ordered from lowest dose rate (top) to highest (bottom). Order: dose rate in mg h –1.T
he aim of this section is to assess the cost-
effectiveness of intravenous magnesium
sulphate alone as prophylaxis against AF following
CABG compared with no prophylaxis. The
economic analysis comprises:
● a systematic review of the literature on the cost-
effectiveness of intravenous magnesium
sulphate alone as prophylaxis against AF
following CABG
● identification of appropriate methods to model
the cost-effectiveness of prophylaxis against AF
following CABG
● identification of key resource-use differences
between post-CABG patients with and without
AF
● presentation of the economic model and cost-
effectiveness evaluation.
Methods for economic analysis
A systematic literature search was undertaken to
identify economic evaluations comparing
intravenous magnesium sulphate as prophylaxis
against AF following CABG compared with sotalol
or no prophylaxis. The details of the search
strategy are documented in Appendix 7. 
Titles and abstracts of studies identified by the
search strategy were assessed for potential
eligibility by three health economists
independently. The inclusion criteria for the
review are documented in Appendix 8. Economic
evaluations were eligible for inclusion if they
reported the cost-effectiveness of intravenous
magnesium sulphate alone as prophylaxis against
AF following CABG compared with sotalol as
prophylaxis or compared with no prophylaxis.
Studies reporting the economic evaluation of
other agents for prophylaxis against AF following
CABG, and studies reporting costs or resource use
associated with postoperative AF and its
management were included in a secondary review.
The purpose of the secondary review was to
identify appropriate methods for modelling the
cost-effectiveness of prophylaxis against AF
following CABG, and key resource-use 
differences between post-CABG patients with and
without AF.
On the basis of the secondary review a short-term
economic model was developed to assess the cost-
effectiveness of magnesium sulphate prophylaxis
against AF following CABG. The model needed to
take account of any additional resource use by
patients with AF, including the costs of managing
postoperative AF during the patient’s admission.
The outcome used in the economic analysis was
cases of AF avoided. Long-term modelling to
estimate gains in life expectancy or quality-
adjusted life expectancy was not attempted.
Results of the systematic review
of economic evaluations
Tailored searches, using the terms reported in
Appendix 7, were applied to specialist health,
biomedical and health economic databases: Ovid
MEDLINE® (1950 to May week 1 2007), EMBASE
(1980 to 2007 week 19), Ovid MEDLINE In-
Process and Other Non-Indexed Citations (14
May, 2007), and NHS EED and Econlit. A total of
63 references was downloaded into a Reference
Manager bibliographic database. References were
coded according to whether they were identified
by drug-specific filters (eight magnesium studies
and 55 sotalol studies were coded). None of these
studies met the prespecified criteria for inclusion
in the primary review of economic evaluations of
intravenous magnesium sulphate alone as
prophylaxis against AF following CABG compared
with sotalol as prophylaxis or no prophylaxis.
On initial assessment of title and abstract, 49
references were excluded from the review, while
two references were included in the secondary
review. The remaining 12 references were
classified as unclear on screening of title and
abstract. 
The 12 references classified as unclear on
screening of title and abstract were reassessed once
the full papers were retrieved. Of these, two were
included in the secondary review (one was an
economic evaluation of another agent for
prophylaxis against AF following CABG, and the
other was a meta-analysis reporting resource-use
differences) and all other references were
excluded.
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Chapter 5
Economic analysisSummary
● Sixty-three references were identified by the
literature search. No studies met the inclusion
criteria for the primary review of economic
evaluations of intravenous magnesium sulphate
as prophylaxis against AF following CABG
compared with sotalol as prophylaxis or no
prophylaxis.
● Four of the 63 references were included in a
secondary review of economic evaluation of
other agents for prophylaxis against AF
following CABG, and studies reporting costs or
resource use associated with postoperative AF
and its management.
Secondary review of economic
evaluations
Since no studies met the inclusion criteria for the
primary review, a review was conducted of papers
that reported economic evaluations of other
agents used for prophylaxis against postoperative
AF, or papers that reported cost/resource-use
differences for patients undergoing CABG who
developed AF. Of the four included studies, one is
an economic evaluation of oral amiodarone for
prophylaxis,34 two are reviews of clinical trials35,36
that also reported economic outcomes (including
trials of amiodarone and sotalol) and one is a
clinical trial report28 (including amiodarone,
magnesium sulphate and placebo) that reported
resource use for patients receiving prophylaxis and
for patients with or without AF. The review is
broken down into a discussion of:
● the scope of analysis and methods adopted in
previous economic evaluation of prophylaxis
against postoperative AF
● resource-use differences for patients with 
and without AF reported in the included
studies.
Scope and methodology of economic evaluations
Reddy and colleagues34 developed a simple
decision-tree model to assess the cost-effectiveness
of amiodarone as prophylaxis against AF for
patients undergoing CABG. The proportions of
patients developing AF with or without
prophylaxis (31.2% and 25.5%, respectively) 
were taken from a controlled trial.37 Other data
used to populate the model were taken from
published literature and a clinical database at the
Hartford Hospital Cardiology Department. The
time-frame for the model was the initial
hospitalisation for cardiac surgery, and outcomes
were expressed as costs to discharge and 
AF events occurring during hospital stay following
CABG.
Patients who did not develop AF simply accrued
costs associated with oral amiodarone prophylaxis
(if in the intervention group) and hospital stay, in
the ICU and the cardiac step-down unit (SDU).
Costs of hospitalisation were based on length of
stay in the ICU and SDU, estimated from the
literature (the paper contains no information on
how these length of stay estimates were derived,
other than giving reference to source papers), and
unit costs (cost per day) estimated from the local
hospital cost database. Cost per day was 32%
higher for ICU than for SDU. The same unit costs
were applied for patients with and without AF.
However, ICU costs were 43% higher and SDU
costs 54% higher for patients developing AF,
owing to the longer lengths of stay (4.32 versus
3.02 days in the ICU and 5.7 versus 3.7 days in
SDU).
It was assumed that AF developed on the second
day after surgery; therefore, this was the date on
which treatment for AF would start. All patients
with AF were assumed to be treated with digoxin,
with an initial loading dose and subsequent daily
maintenance doses. Patients with AF of greater
than 48 hours’ duration were also treated with
anticoagulants, receiving 2 days of heparin and
8 days of warfarin. Patients received two activated
partial thromboplastin (aPTT) tests per day while
on heparin and one international normalised ratio
(INR) per day while on warfarin. The proportion
of patients with AF lasting for more than 48 hours
was taken from the hospital cardiology
department’s clinical database and was estimated
at 16.7%.
In addition to costs of hospitalisation and drug
treatments for AF, patients may require rhythm
control (using electrical or pharmacological
cardioversion) or rate control (using drugs such as
digoxin). The proportion of patients with AF
following CABG who spontaneously convert to
normal sinus rhythm (33%) and the proportion
requiring electrical cardioversion (13%) were taken
from the literature.38 The proportion receiving
rate control, which was assumed to continue until
discharge from hospital, was the complement of
these two proportions (i.e. 54%). The proportion
of patients having successful electrical
cardioversion or successful pharmacological
cardioversion, which was assumed to follow
unsuccessful electrical cardioversion, was also
taken from the literature.
The flow of patients implied by the model
adopted by Reddy and colleagues34 appears to be
a reasonable representation of current practice for
Economic analysis
24patients developing AF following CABG, subject to
modifications that would make it more consistent
with current clinical guidelines related to England
and Wales6 and Europe.1
The model appears to have been evaluated using
Monte Carlo simulation. It is difficult to assess the
validity of this approach as only the central
estimates (with minima and maxima) for
parameter values adopted in the model are
reported, with no information on how values were
selected in any given simulation or whether
distributions were assigned to parameters. The
base-case results are presented as average cost per
AF case avoided for each strategy rather than an
incremental analysis for the prophylaxis strategy
compared with no prophylaxis. However, the
analysis shows that the most influential variables
were the cost of hospitalisations and the frequency
of AF. The dominant effect of hospital costs is not
surprising given the unit costs of US$1080 and
$1420 for step-down care and ICU bed days,
compared with $64 for prophylaxis with oral
amiodarone or $152 for electrical cardioversion.
Resource-use differences, with and without AF
Treggiari-Venzi and colleagues28 suggest that
prophylaxis with either amiodarone or magnesium
sulphate will not be cost-effective since the
proportion of patients developing AF with
prophylaxis is not significantly different, at the 5%
level, from placebo [placebo 27% versus
magnesium sulphate 23% (p = 0.82) and
amiodarone 14% (p = 0.14)]. They support their
argument with a brief analysis which suggests that
length of stay in ICU will be longer with
amiodarone prophylaxis than without. This is
based on the observation that, while patients in
the trial who developed postoperative AF had a
median length of ICU stay 2 days longer than
those without AF (median 5 versus 3 days),
patients receiving amiodarone had a median
length of ICU stay 1 day longer than placebo
patients (median 4 versus 3 days). With an
avoidable risk of AF with amiodarone prophylaxis
calculated as 13% (27–14%) they estimate that
routine amiodarone prophylaxis for all patients
undergoing CABG would be associated with an
extra 740 days in the ICU for every 1000 patients
compared with no prophylaxis (Table 6).
In effect, Treggiari-Venzi and colleagues28 argue,
on the basis of the comparison of oral amiodarone
prophylaxis against placebo, that prophylaxis
against postoperative AF is dominated by the 
no-prophylaxis option (with symptomatic
management of AF) and therefore no
consideration of the cost of prophylaxis was
required. They reinforced this conclusion by
stating that the oral amiodarone group
experienced a higher adverse event rate than did
placebo patients, which “may be attributable to the
study drug”. The same does not apply for
magnesium sulphate prophylaxis which, while not
having a statistically significant effect on the
occurrence of postoperative AF, could save 80 days
of ICU stay using a similar analysis as reported for
oral amiodarone (Table 6), which was not reported
by Treggiari-Venzi and colleagues.28 Treggiari-
Venzi and colleagues28 did not report length of
stay on ward following discharge from ICU or total
hospital stay, whereas other studies have suggested
that AF may increase ward stay as well as ICU stay.
Reddy and colleagues35 reviewed six trials of
amiodarone (either oral or intravenous) and one
trial of sotalol as prophylaxis against AF following
CABG. The main economic outcomes reported
were length of stay (reported for all trials and
given as total hospital stay or broken down by ICU
and ward stay) and hospital costs (reported in five
of the amiodarone trials). Trials included in the
review typically reported length of stay for each
arm of the trial (prophylaxis versus placebo) and
do not indicate the difference in length of stay for
patients with and without AF. Reddy and
colleagues35 reviews additional studies that
reported length of stay for patients with AF,
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TABLE 6 Days in ICU with and without prophylaxis (from Treggiari-Venzi and colleagues28)
Days in ICU for cohort of 1000 patients
Prophylaxis type With AFa Without AFb Total
Oral amiodarone  840 3440 4280
None 1350 2190 3540
Magnesium sulphate  1150 2310 3460
a Length of stay × probability of AF × 1000.
b Length of stay × (1 – probability of AF) × 1000.suggesting that AF may increase total stay by
between 3.239 and 640 days. Breaking this down by
ICU and ward stay, one study showed that AF
increased ICU stay by 2.3 days (5.7 versus 3.4 days)
and ward stay by 3.4 days (10.9 versus 7.5 days).41
In the clinical trials of prophylaxis against
postoperative AF, while all studies reported a lower
average length of stay for patients receiving
prophylaxis (and five of the studies showing a
significant decrease in the proportion of patients
with AF), only one study reported a statistically
significant reduction in length of stay.38 This may
be a reflection of the trials being underpowered to
show significant differences in resource use, since
they will typically be powered only to detect
differences in clinical outcome. The lack of
significant differences may also reflect the fact that,
while it may substantially increase length of stay in
the ICU or on the ward for some patients,
postoperative AF only affects a minority of
patients, so the effect of this difference is diluted
when looking at mean length of stay across a
cohort of patients. Among those studies that
reported costs, only one study reported a
statistically significant difference38 (with lower costs
for patients receiving prophylaxis). The results with
respect to cost were less consistent, with two studies
reporting lower costs for placebo patients.
Zimmer and colleagues36 included similar studies
to those reviewed by Reddy and colleagues35 in
their meta-analysis. This included meta-analysis of
the effect of amiodarone or sotalol prophylaxis on
length of hospital stay and on hospital costs.
Summary
A simple decision tree can be used to estimate the
short-term cost-effectiveness of magnesium
sulphate prophylaxis against AF following CABG.
The form of the analysis in this report will be cost-
effectiveness analysis with AF events avoided as
the outcome measure.
The principal determinant of the cost-effectiveness
of prophylaxis against AF following CABG is likely
to be length of stay in the ICU and on hospital
wards.
The structure presented by Reddy and
colleagues34 is reasonable, but requires some
modification to make it consistent with current
clinical guidelines relevant to the NHS.
The economic analysis will need to examine
potential resource differences that may be
associated with statistically non-significant
differences in outcome, particularly in terms of
length of stay.
A comparison of the cost-effectiveness of
prophylaxis with intravenous magnesium sulphate
compared with sotalol will not be performed. No
RCTs or economic evaluations of this comparison
were identified in the present systematic review,
and expert clinical opinion suggests that it is not a
clinically meaningful comparison.
SHTAC economic model methods
Estimation of net benefits (taking
account of disbenefits)
The outcome of interest in the economic model in
this report is the proportion of patients
experiencing AF following CABG, with or without
prophylaxis with magnesium sulphate; or,
alternatively, the number of patients experiencing
AF in a given patient cohort, for example 
1000 patients. The pooled risk ratio derived 
in the meta-analysis (estimated as a relative 
risk, rather than OR as presented in ‘Incidence 
of AF’, p. 10) will be applied to the estimated
baseline proportion of patients experiencing 
AF following CABG with prophylaxis. This will
provide an estimate of the proportion of AF 
cases averted by prophylaxis with magnesium
sulphate.
As reported in ‘Description of the underlying
health problem’ (p. 3), the typical range reported
for AF following CABG, without prophylaxis, is
between 20 and 40% of patients. For the economic
model a point estimate of 30%, which is the
average across the placebo arms from trials
included in the meta-analysis, will be used. Table 7
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TABLE 7 Baseline risk of AF following CABG and relative risk with magnesium sulphate prophylaxis: inputs to economic model
Point estimate Lower confidence  Upper confidence
Limit/maximum Limit/minimum
Relative risk of AF with magnesium sulphate prophylaxis 0.73 0.63a 0.84a
Baseline risk of AF following CABG 0.30 0.20 0.40
a 95% confidence interval.summarises the point estimates and confidence
limits/ranges used in the analysis.
Applying 27% risk reduction to the baseline
estimate of risk of AF following CABG produces
an estimate of the proportion of patients receiving
prophylaxis who experience AF of 21.9%. In terms
of the estimated 23,000 operations performed
annually in England (see ‘Description of
underlying health problem’, p. 3) this would
translate to 1863 fewer patients experiencing AF
following CABG, if all patients were assumed to be
eligible for prophylaxis. In resource terms,
assuming that patients with AF stay in the ICU
1 day longer than those without AF, this could
result in the avoidance of 1836 ICU days
attributable to AF following CABG.
There would be additional resource savings in
terms of avoided drug treatments for AF, reduced
requirements for anticoagulation and associated
tests, and averted cardioversions as the number of
patients with AF is reduced. Treatments for AF are
not without complications, so a reduced risk of AF
following CABG may not only reduce the potential
morbidity burden in terms of AF and consequent
risk of stroke and other conditions (discussed in
‘Description of underlying health problem’, p. 3),
but also avoid morbidity of adverse events
associated with AF treatment (not quantified in the
model).
As discussed earlier, a short-term model was
adopted that only estimates the reduction in the
proportion of patients experiencing AF and
resource use up to hospital discharge. 
Estimation of net costs
The net costs of consumables for providing
magnesium sulphate prophylaxis are calculated as
£9.84 per infusion. These are based on unit costs
of £2.91 for a 2-ml ampoule of magnesium
sulphate (which corresponds to 4 mmol of
magnesium sulphate) and £2.01 for a 50-ml
ampoule of sodium chloride intravenous infusion
solution (0.9% NaCl). Unit costs are taken from
the British National Formulary (BNF), No. 53
(March 2007).5 A range of concentrations has been
adopted in clinical trials: the European
Association of Cardiothoracic Surgeons guidelines
recommend a 6-mmol infusion in 100 ml 0.9%
NaCl solution at a rate of 25 ml per hour.1 The
recommended regimen is to provide one infusion
on the day before surgery, one just after bypass and
an infusion once daily for 4 days postoperatively.
If the typical length of stay in the ICU following
surgery is 1–2 days, it can be assumed that three of
the infusions occur alongside usual care and would
not require any additional set-up time or
monitoring. However, the preoperative and two of
the postoperative infusions would take place on
the wards and would have additional staff costs for
set-up and monitoring.
To estimate the staff costs associated with
providing magnesium sulphate prophylaxis by
intravenous infusion, it was assumed that 10
minutes of doctor time would be required to
initiate and terminate the infusion. In addition,
10 minutes of nurse time would be required each
hour of the infusion for patient monitoring. If the
infusion occurs at a rate of 25 ml per hour, this
implies that each infusion takes 4 hours. Using
hourly costs for a specialist registrar and for nurse
staff on a 24-hour ward (Unit Costs of Health and
Social Care, 200642) gives a cost of £11.33 for
medical staff and £14.67 for nursing staff per
infusion (Table 8). Following the recommended
regimen of six infusions and assuming that three
of these occur in settings where additional costs
for initiating and monitoring infusions would be
minimal, the total net cost of providing
magnesium sulphate prophylaxis by intravenous
infusion was estimated at £137.04.
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TABLE 8 Unit costs applied in the economic model (£)
Point estimate Lower limit Upper limit
Magnesium sulphate (per infusion) 9.84
Medical staff cost (per infusion) 11.33 5.67 17.00
Nurse staff cost (per infusion) 14.67 7.33 22.00
CABG (excluding critical care costs)a 8172
Coronary intensive care (per day)b 925 693 1196
CABG – excess bed daysa 334 231 369
Lower and upper limit are based on variation of ± 50% unless otherwise stated.
a HRG – E04: coronary bypass; elective inpatient. (NHS Reference Costs 2005/0643).
b HRG – CC6L2: cardiac intensive care unit – level 2 care (NHS Reference Costs 2005/0643).
For NHS reference costs the lower and upper limits are the lower and upper quartiles.Unit costs for the coronary artery bypass
admission, cost per bed day in coronary intensive
care and costs for additional bed days associated
with postoperative AF were taken from NHS
Reference Costs (2005/06).43 The elective inpatient
cost for Healthcare Resonance Group (HRG) E04
(coronary bypass) was taken as the unit cost for the
coronary artery bypass admission; this excludes
costs associated with critical care. The cost for
postoperative intensive care was taken as level 2
care in the cardiac intensive care unit (HRG
CC6L2). The Intensive Care Society defines level 2
care as being for “patients requiring more detailed
observation or intervention, single failing organ
system or postoperative care, and higher levels of
care.”44 The excess bed-day cost for HRG E04 was
taken as the unit cost for additional bed days
associated with postoperative AF. Reference costs,
along with the lower and upper quartiles, are
reported in Table 8.
To estimate the cost of a typical CABG admission,
using NHS Reference Costs, an estimate of ICU
use must be added. The Bristol Royal Infirmary
Cardiac services, adult cardiac surgery audit report45
reported a mean cardiac ICU stay between 1.7 and
2.3 days, with a median of 1 day. This analysis
assumes a normal postoperative ICU stay of 1 day.
Since this estimate is common to all patients in the
model (as is the cost of CABG), it has no impact
on the cost-effectiveness estimates, only on total
cost. Using these assumptions an uncomplicated
CABG admission may be expected to cost £9097
using the unit costs adopted for this analysis.
The greatest anticipated savings from the use of
prophylaxis against AF following CABG are likely
to be a reduction in the proportion of patients
having longer stays in the ICU and a reduction in
the proportion of patients having longer overall
stays. Using the 27% risk reduction discussed in
the previous section would suggest eight fewer
patients experiencing AF per 100 operations. To
estimate the additional inpatient resource use
associated with postoperative AF, studies reporting
additional ICU and ward stays associated with
postoperative AF were briefly reviewed. These
studies were selected from the list of references
identified by the search for economic evaluations
and costing studies of magnesium sulphate and
sotalol as prophylaxis against AF following CABG
reported in the section ‘Results of the systematic
review of economic evaluations’ (p. 23). Additional
studies were identified from the reference lists of
included papers.
Where studies have reported length of stay in ICU
following CABG and postoperative length of stay
for patients with and without postoperative AF, they
have consistently shown longer stays for patients
with postoperative AF (Table 9), although the
difference is not always shown to be statistically
significant at the 5% level. The range for extra time
spent in the ICU is between 8 hours and 2.3 days
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TABLE 9 Estimated increase in length of stay, by location of care, associated with patients with AF after CABG
Length of stay
Study ICU (days) Ward (days) Overall (days)
Creswell et al., 199341 2.3 3.4
Mendes et al., 199546 1.7
Mathew et al.,199647 0.54 2
Aranki et al.,199640 4.9a
Kowey et al., 199748 3b
Almassi et al., 199749 1.6b 3b
Zaman et al., 199750 1.1
Borzak et al.,199851 1 2.9a
Tamis and Steinberg, 200039 3.2
Treggiari-Venzi et al., 200028 2b
Zaman et al., 200052 1.9
Kim et al., 200153 1.2a
Hravnak et al., 200254 1.4
Thompson et al., 200255 5.5
Tamis-Holland et al., 200656 1.1a
Hosokawa et al., 200757 0.33 3
a Adjusted for confounding factors.
b Median (mean not reported).and for extra days spent on the ward range the
range is 1.1–3.4 days. The range for overall
postoperative stay is 1.1–5.5 days. These values are
similar to those adopted by Reddy and colleagues34
in their economic evaluation of amiodarone
prophylaxis, where the base-case estimates were 
1.3 additional days in the ICU (range 1.3–1.85) 
and 2 additional days on the ward (range 0–5.95)
associated with postoperative AF.
Postoperative AF is associated with patient factors
(such as age) that may also be associated with
longer inpatient stays. For example, the Society
for Cardiothoracic Surgery’s National Adult
Surgical Database Report (2000/01)58 reported
average postoperative stays between 6 and 10 days,
with older patients having the longer average
length of stay. Therefore, the unadjusted lengths
of stay reported in Table 9 may overestimate the
effect of AF on postoperative length of stay. Those
studies that have sought to control for
confounding factors40,51,53,56 have typically shown
that the effect of AF alone is reduced, but that
differences between patients with and without AF
remain significant. Variables that were found to be
significant confounders, and included in the
adjustments, are patient sex,40,51,53 age,40,51,53,56
postoperative complications,40,56 preoperative
unstable angina53 and digoxin use before
surgery.56 On the basis of these studies it was
assumed that postoperative AF results in 1
additional day in the ICU (range 0–2) and 2
additional days on the ward (range 0–4) (Table 10).
The additional cost per 100 patients undergoing
CABG, with a 30% baseline risk of postoperative
AF and using the unit costs in Table 8, would be
£47,785 if overall stay were increased by 3 days for
patients experiencing AF following CABG (1 extra
day in the ICU and 2 extra days on the ward). If
prophylaxis with magnesium sulphate is associated
with a relative risk of postoperative AF of 0.73, the
reduction in costs associated with extra bed days
due to AF could be £12,902 per 100 patients.
Costs of drugs used for pharmacological
cardioversion (PCV) are based on an assumed
body weight of 84 kg for a male patient
undergoing CABG. This was derived from the
distribution of body surface area (BSA) reported in
the Society for Cardiothoracic Surgery’s National
Adult Surgical Database Report (2003),59 which
has a mean of approximately 2.00 m2. Using the
equation reported to derive BSA [see equation (1)]
and an assumed average height of 175 cm (5 10 ),
the patient weight associated with a BSA of 2.00
can be estimated. A range for body weight was
calculated using heights of 170 and 180 cm, giving
a weight range of 80–89 kg.
BSA = 7.184 × 10–3 × m0.425 × h0.725 (1)
where m is weight (kg) and h is height (cm).
Using a dosing protocol for amiodarone of a
loading dose of 5 mg/kg–1 for 30 minutes as
intravenous infusion, followed by 25 mg per hour
for 24 hours and continuing treatment for 24
hours after cardioversion, gives a consumables cost
of £40.88 for the loading dose and 48 hours of
treatment (assuming that cardioversion occurs with
24 hours) (Table 11). This excludes staff costs for
initiation of the intravenous infusions and for
patient monitoring, as it was assumed that the
majority of PCV will be initiated in the ICU. The
reported effectiveness of amiodarone, for
cardioversion, ranges from 77 to 93% of patients
with postoperative AF converting to sinus rhythm
at 24 hours.1
An alternative strategy for PCV was costed, using
sotalol with a loading dose of 1 mg kg–1, followed
by 0.2 mg kg–1 for 12 hours as an intravenous
infusion. If cardioversion occurs patients receive a
maintenance dose of 160 mg oral sotalol, taken
twice daily, for 2 weeks. The estimated
consumables cost of this strategy was £20.11 for
intravenous infusions and £3.55 for oral drugs,
giving a total cost of £23.66 (Table 11). The
reported effectiveness of sotalol, for cardioversion,
ranges from 85 to 100% of patients with
postoperative AF converting to sinus rhythm at
24 hours,1 although these values were derived
from small studies.
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TABLE 10 Lengths of stay with and without postoperative AF used in the model
Point estimate Lower limit Upper limit
CABG, excluding ICU, without AF 7
ICU stay, without AF 1
Additional ICU days with AF 1 0 2
Additional ward days with AF 2 0 4Costs for electrical cardioversion (ECV) were taken
from Buxton and colleagues.60 This gave a cost of
£100 at 2001 prices, which was updated to
2005/06 prices using the Hospital and Community
Health Services Pay and Prices Index.42 Similarly,
costs of anticoagulation were taken from Reddy
and colleagues.34 Costs for warfarin and heparin
reported in 1998 US dollars were converted 
to UK pounds using 1998 purchasing power
parities61 and then updated to 2005/06 prices
using the Hospital and Community Health
Services Pay and Prices Index.42 Patients who did
not convert to sinus rhythm within 48 hours
received 2 days of intravenous heparin and 8 days
of warfarin.
Rate control was costed using digoxin with a
loading dose of 0.5 mg followed by 0.25 mg per
2 hours up to a maximum of 1.5 mg. This was
followed by an oral maintenance dose of 0.25 mg
daily. The estimated consumables cost of the
intravenous loading dose was £13.74 and oral
maintenance dosing was costed at £0.08 per day
(based on a unit cost of £2.35 per packet of 
28 × 250- g tablets).5
Estimation of cost-effectiveness
Model structure
Figure 11 illustrates the model developed to
estimate the cost-effectiveness of intravenous
magnesium as prophylaxis against AF following
CABG. The rounded rectangles (CABG and
Discharge) indicate the “start” and “end” states.
The non-rounded rectangles are “outcomes”:
● presence or absence of postoperative AF
● success or failure of rhythm or rate control.
The diamonds indicate “decisions”:
● whether patients spontaneously revert to sinus
rhythm (effectively a decision not to initiate
treatment for AF, and observe)
● choice of rhythm or rate control (and choice of
electrical or pharmacological rhythm control).
The flowchart allows for patients with AF, who fail
to convert spontaneously to sinus rhythm, to
receive pharmacological rate control rather than
electrical or pharmacological rhythm control. It
also allows for patients who fail PCV to move
directly to rate control rather than ECV. The flow
chart was converted to a decision tree (Figure 12)
to perform the cost-effectiveness analysis.
Model inputs
Table 7 lists the point estimates (with lower and
upper limits) for key parameters related to the
baseline risk of AF following CABG and the
relative risk of AF with magnesium sulphate
prophylaxis used in the base-case analysis and in
the deterministic sensitivity analyses. Tables 8 and
11 report the point estimates (with lower and
upper limits) for unit costs used in the model,
while Table 10 reports the point estimates (with
lower and upper limits) for length of stay, with
and without postoperative AF, used in the base-
case analysis and in the deterministic sensitivity
analyses.
Table 12 reports all parameter inputs to the model,
with their point estimates along with the
distribution types (and distribution parameters)
applied in the probabilistic sensitivity analysis (PSA).
Methods
The decision tree can be used to estimate the cost-
effectiveness, in terms of incremental cost per AF
case avoided with magnesium sulphate prophylaxis
compared with no prophylaxis. In addition to
reporting the incremental costs and incremental
effectiveness, the average length of stay for the
prophylaxis and no-prophylaxis options is
reported, as well as the average additional ICU
and ward days under each option. Key areas of
uncertainty in the model are examined using
deterministic and probabilistic sensitivity analyses.
Deterministic sensitivity analysis is used to address
particular areas of uncertainty in the model
related to:
Economic analysis
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TABLE 11 Costs for treating AF: cardioversion or rate control (£)
Point estimate Lower limit Upper limit
Amiodarone – PCV 40.88 20.44 61.32
Sotalol –PCV 23.66 11.83 35.49
Direct current cardioversion 117 58.50 175.50
Digoxin – rate control 14.41 7.21 21.62
Anticoagulation 22.84 21.62 34.26
Lower and upper limit are based on variation of ±50% unless otherwise stated.● model structure
● methodological assumptions
● parameters around which there is considerable
uncertainty or that may be expected, a priori, to
have disproportionate impact on study results.
The purpose of this analysis is to identify clearly
the impact of this uncertainty and to test the
robustness of the cost-effectiveness results to
variation in structural assumptions and parameter
inputs.
Parameter uncertainty is addressed using PSA.
Probability distributions are assigned to the point
estimates used in the base-case analysis, using 
the point estimates and ranges listed in Tables 7, 
8, 10 and 11. Table 12 reports the variables
included in the PSA, the form of distribution 
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CABG
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FIGURE 11 Flowchart for drug prophylaxis for, and management of, AF following CABGEconomic analysis
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.used for sampling and the parameters of the
distribution.
Results of the economic model
Base-case results
The base-case results of the analysis are reported
in Table 13. Costs under the strategy of providing
magnesium sulphate as prophylaxis against
postoperative AF are slightly higher than with no
prophylaxis (£2.55). Prophylaxis is associated with
a reduction in the proportion of patients
experiencing AF following CABG (0.081), giving
an incremental cost-effectiveness ratio (ICER) of
£32 per AF case avoided.
To identify which factors have contributed most to
these results, Table 14 reports the average total
inpatient stay estimated for each strategy and the
average number of additional ICU and ward days
associated with AF for each strategy.
As with the studies investigating the effect of
prophylaxis on hospital stay (reviewed in the
section ‘Secondary review of economic
evaluations’, p. 24), there was only a small
difference in length of stay (in the ICU or on the
ward) between the prophylaxis and no-prophylaxis
strategies (8.66 and 8.90, respectively), despite
large assumed differences in length of stay for
patients with and without postoperative AF
(average of 11 versus 8 days, respectively). This
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TABLE 12 Parameter input values in the economic model
Parameter Point Distribution
estimate (parameters of distribution)
Probabilities
Baseline risk of AF following CABG 0.30 Beta
  = 59.8621;   =139.6782
Relative risk of AF with magnesium sulphate prophylaxis 0.73 Normal
  = ln(0.73);   = 0.0734
Probability of spontaneous conversion to sinus rhythm34,38 0.35 Beta
n = 40; r = 14
Probability of cardioversion34,38 0.60 Beta
n = 40; r = 24
Probability of successful PCV62,63 0.736 Beta
n = 72; r = 53
Probability of successful ECV following unsuccessful PCV62,63 0.842 Beta
n = 19; r = 16
Additional resource use associated with AF
Additional days in ICU due to postoperative AF 1 Gamma
  =6.1117;   = 0.1636
Additional days on ward due to postoperative AF 2 Gamma
  = 9.5495;   = 0.2094
Costs
Magnesium sulphate prophylaxis 137.04
Rate control – digoxin  14.41
PCV with amiodarone 40.88
PCV with sotalol 23.66
Anticoagulation – heparin and warfarin 22.84
Cost of ECV 117
Cost of CABG admission 8172
Coronary intensive care (per bed day) 925 Gamma
  = 88.7514;   = 3.7613
Hospital ward (cost per excess bed day) 344 Gamma
  = 52.1459;   = 17.7421analysis assumes that admission routines would be
identical for patients under both the no-
prophylaxis and prophylaxis strategies.
Deterministic sensitivity analysis
A sensitivity analysis was conducted to consider
the effect of uncertainty around model structure
and variation in model parameters. The method
adopted was univariate sensitivity analysis; that is,
varying one parameter at a time, leaving all other
variables unchanged. This is to highlight the
impact, if any, of each selected parameter alone on
the cost-effectiveness results.
Table 15 reports the results of the sensitivity
analysis. The table is divided to distinguish
between analyses undertaken due to uncertainties
over parameters related to:
● the risk of postoperative AF and effectiveness of
magnesium sulphate prophylaxis
● the cost of prophylaxis
● resource consequences of postoperative AF
● resources used in the management of
postoperative AF.
Table 15 shows large variations in cost-effectiveness
estimates relating to uncertainty over both the
baseline risk and relative risk of postoperative AF
with magnesium sulphate prophylaxis. At the
upper limit of baseline risk of AF (40%) the
prophylaxis option dominates, providing better
outcome at lower cost. At the lower limit
incremental cost is positive, the prophylaxis option
costs more than no prophylaxis and the
incremental effectiveness is reduced, leading to a
substantial increase in ICER. This is further
illustrated in Figure 13.
Variation in the relative risk of AF with
prophylaxis shows a similar pattern, with the
prophylaxis dominating at the lower limit (larger
treatment effect). At the upper limit the
prophylaxis option has positive incremental cost
and reduced incremental effect, leading to a large
increase in ICER. This is further illustrated in
Figure 14.
The cost-effectiveness estimates also seem to be
highly sensitive to the overall cost of prophylaxis,
and to variation in components of the cost of
prophylaxis. Varying the total cost of prophylaxis
by plus or minus 50% shows wide variation, from a
situation where prophylaxis dominates (at lower
cost of prophylaxis) to an increase in ICER
equivalent to that for the lower limit in baseline
risk of AF. Varying assumptions over staff inputs to
initiate intravenous infusions and patient
monitoring show large variations in ICER. A
strategy where nurses initiate and terminate
intravenous infusions (labelled “no medical input”
in Table 15) reduces the cost for the prophylaxis
option below the cost for no prophylaxis, using all
other base-case assumptions, causing prophylaxis
to be dominant. 
It is possible that the prophylaxis option may
increase preoperative length of stay, since one
recommended regimen for magnesium sulphate
includes an infusion on the day before surgery. If
patients having prophylaxis stay on average half a
day longer than those without prophylaxis the
incremental cost increases by almost £167 and the
ICER increases to £2092 per AF case avoided.
This is the largest ICER for any option included in
the one-way sensitivity analyses.
Considering the resource consequences of AF, the
ICERs are highly sensitive to assumptions over 
the number of additional ICU days due to 
AF, and to a lesser extent the number of
additional ward days. The range of ICERs was
Economic analysis
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TABLE 13 Base-case results of economic analysis
Strategy Cost (£) Incremental  AF cases AF cases  Incremental cost per 
cost (£) avoided AF case avoided (£)
No prophylaxis 9595 0.300
Prophylaxis 9598 2.55 0.219 0.081 31.51
TABLE 14 Estimated total stays for CABG patients and additional days due to AF
Strategy Total stay (days) Additional ICU days Additional ward days Costs of inpatient days (£)
No prophylaxis 8.90 0.30 0.60 9581
Prophylaxis 8.66 0.22 0.44 9450lower for variation in the cost of ICU bed days or
of excess ward days.
Tamis-Holland and colleagues56 suggest that
patients with postoperative AF who spontaneously
convert to sinus rhythm do not experience longer
stays than do patients without AF. Setting the
additional bed days to zero for patients with
postoperative AF who spontaneously convert
increases the incremental cost of the prophylaxis
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TABLE 15 Univariate sensitivity analysis
Variable (base case) Lower limit Incremental  Incremental  ICER (£/AF  Range
Upper limit cost (£) effectiveness case averted)
Risk of AF and effectiveness of prophylaxis
Probability of AF (0.30) 0.20 47.38 0.054 877.44  1268.89
0.40 –42.28 0.108 Dominant
Relative risk of AF (0.73) 0.63 –42.28 0.108 Dominant 1620.40
0.84 57.34 0.048 1194.66
Cost of prophylaxis
Prophylaxis cost (137.04) 68.52 –65.97 0.081 Dominant 1691.85
205.56 71.07 0.081 877.44
Minutes of doctor time for prophylaxis (20) 10 –14.45  0.081 Dominant 419.75
30 19.55 0.081 241.39
Minutes of nurse time for prophylaxis (40) 20 –19.45 0.081 Dominant 543.21
60 24.55 0.081 303.12 
Nurse initiates infusion and monitors  30 –42.45  0.081 Dominant 814.81
patient: no medical input 60 –9.45  0.081 Dominant
90 23.55 0.081 290.77
Number of prophylaxis infusions with  6 80.55 0.081 994.47 NA
additional staff costs (3)
Additional preoperative days (0) 0.50 169.46  0.081 2092.13 NA
Resource consequences of postoperative AF
Additional ICU days (1) 0.00 77.48  0.081 956.59  1850.40 
2.00 –72.40 0.081 Dominant
Additional ward days (2) 0.00 56.63  0.081 699.08  1335.37 
4.00 –51.54 0.081 Dominant
Additional bed days for spontaneous  0 47.70  0.081 588.92 NA
converters (3)
Cost of ICU bed day (925) 693.00 21.36  0.081 263.66  502.94
1196.00 –19.38 0.081 Dominant
Cost of excess bed day (344) 231.00 19.21  0.081 237.12 275.95
369.00 –3.15 0.081 Dominant
Resources used in managing postoperative AF
PCV/ECV attempted (0.6) 0.30 4.76  0.081 58.79 54.57
0.90 0.34 0.081 4.23
Spontaneous conversion (0.35) 0.175 1.16  0.081 14.30  34.43 
0.525 3.95 0.081 48.72 
Cost of ECV (117) 58.50 4.40 0.081 54.33 45.63
175.50 0.70 0.081 8.70
Cost of amiodarone PCV (40.88) 20.44 2.72  0.081 33.61  4.21 
61.32 2.38 0.081 29.41 
Use sotalol for PCV 23.66 2.70 0.081 33.28 NA
Cost of sotalol PCV (23.66) 11.83 2.79 0.081 34.50 2.44 
35.49 2.60 0.081 32.07Economic analysis
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FIGURE 14 Sensitivity analysis on relative risk of AF following CABG with magnesium sulphate prophylaxisstrategy and increases the ICER to almost £600
per AF case avoided.
Table 15 shows that the ICERs are largely
insensitive to variation in values of parameters
related to management of postoperative AF.
Probabilistic sensitivity analysis
In a PSA of magnesium sulphate prophylaxis,
where probabilities of postoperative AF, relative
risk of AF with magnesium sulphate prophylaxis
and additional bed days (ward or ICU) associated
with AF were sampled across the distributions
described in Table 12, just over half of the
simulations are associated with better outcomes
(fewer cases of AF), but also increased costs
(Figure 15). Many of the simulations (41%) have
negative incremental costs. In this area
magnesium sulphate prophylaxis is the dominant
strategy, achieving better outcome at lower costs.
Simulations where costs for prophylaxis are lower
are most likely to be associated with high estimates
of additional stay on the ward or in the ICU
associated with AF.
In this analysis magnesium sulphate prophylaxis
had a probability of being cost-effective (compared
with surgery without prophylaxis) of 99% at a
willingness-to-pay (WTP) threshold of £2000 per
AF case avoided and 100% at a WTP threshold of
£5000 per AF case avoided (Figure 16, (CEAC:
base-case assumptions).
The base-case analysis assumes identical admission
routines for patients under the no-prophylaxis and
prophylaxis strategies. An alternative scenario,
where patients receiving magnesium sulphate
prophylaxis by intravenous infusion are admitted
early to receive their initial infusion, was included
in the PSA (mean additional stay = 0.5 days, using
a uniform distribution with minimum = 0 and
maximum = 1). The effect of including this
assumption in the PSA is to shift the scatter of
points on the cost-effectiveness plane (Figure 15)
upwards to a mean incremental cost of
approximately £170, so that only around 5% of
simulations have negative incremental costs. This
increase in mean incremental costs also changes
the location of the cost-effectiveness acceptability
Health Technology Assessment 2008; Vol. 12: No. 28
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FIGURE 15 Cost-effectiveness plane: incremental cost and AF cases avoided for magnesium sulphate prophylaxis against
postoperative AFcurve (CEAC) (Figure 16) and the probability of
prophylaxis being cost-effective at each threshold
of WTP. Now the probability of magnesium
sulphate prophylaxis being cost-effective
(compared with surgery without prophylaxis) is
48% at a WTP threshold of £2000 per AF case
avoided and 93% at a WTP threshold of £5000 per
AF case avoided.
In reporting this probabilistic analysis, much lower
thresholds were used than would commonly be
applied in models reporting outcomes in terms of
quality-adjusted life-years (QALYs). It is not clear
in this model how the avoidance of postoperative
AF would translate to final outcomes, such as gains
in life expectancy or quality-adjusted life
expectancy. The European Association of
Cardiothoracic Surgeons guideline1 suggests that
AF following cardiac surgery doubles the risk of
stroke, with a baseline risk of between 1.4%41 and
2.5%49 for patients in sinus rhythm in the studies
reviewed. At these levels of risk it is unlikely 
that the reduction in risk, modelled in this
analysis, would translate to substantial gains in 
life expectancy or quality-adjusted life 
expectancy.
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FIGURE 16 CEAC: magnesium sulphate prophylaxis PSA resultClinical effectiveness
This systematic review did not identify any RCTs
that aimed to compare intravenous magnesium
with sotalol. Expert clinical advice suggests that in
practice this would not be a meaningful
comparison, as the decision would be more likely
to be whether or not to use these (and other)
drugs in combination, as opposed to choosing
between them. The clinical effectiveness of
magnesium sulphate and sotalol combination
therapy has been evaluated in RCTs, although it is
outside the scope of the current review.20,21,64 This
would be a worthwhile topic for future evidence
synthesis.
This systematic review has updated and expanded
the review published by Alghamdi and colleagues
in 2005,10 adding in a further eight RCTs. In that
systematic review it was found that intravenous
magnesium administered perioperatively to
patients undergoing CABG was effective, with a
statistically significant intervention effect. The
current review comes to a similar conclusion, that
intravenous magnesium is associated with a
statistically significant reduction in the odds of a
postoperative AF. 
Effects of total dose, dose rate and
duration of magnesium sulphate
intervention
If the studies by Dagdelen and colleagues17,18 and
Toraman and colleagues27 are excluded, the
current review would suggest that the total
magnesium sulphate dose up to 21 g is probably
not a useful predictor of effects on AF. It should
be noted, however, that a robust analysis of total
dose should, ideally, include co-variables, but this
was not possible owing to the heterogeneity of
reporting in the primary studies. The possibility of
effects at higher total doses (>21 g) is unclear
owing to ambiguity within the study by Nurözler
and colleagues25 (25 g total dose), in which
confounding of variables might have occurred.
Analyses of the duration of prophylaxis and the
dose rate suggest that these may be better
predictors of effects on AF, but the dose rate and
duration of prophylaxis were not generally
independent and their relative importance cannot
be ascertained from the available trials [only one
total dose (12 g) was administered at more than
one dose rate]. An hypothesis arising from these
findings that may warrant further investigation is
that continuous low-dose administration of
magnesium sulphate would be more effective for
prophylaxis of AF than a similar total dose
administered over a shorter period.
Two of the five systematic reviews identified in the
searches assessed the influence of total dose of
magnesium sulphate on AF.7,9 Henyan and
colleagues9 divided the studies according to
whether they administered magnesium sulphate in
low doses (<10 g) or moderate to high doses
( 10 g), whereas Miller and colleagues7 divided
the studies according to whether they
administered low doses (<35 mmol), medium
doses (35–50 mmol) or high doses (>50 mmol).
These dose subgroups appear to have been
defined on an arbitrary basis, and it is unclear
whether they have clinical or biochemical
relevance. Only one of the subgroups in each
review exhibited a significant intervention effect
(the low-dose group of Henyan and colleagues9
and the medium-dose group of Miller and
colleagues7) and it is notable that the studies by
Dagdelen and colleagues17,18 and Toraman and
colleagues27 were in these sub-groups. Given that
the studies by Dagdelen17,18 and Toraman27
differed in other respects besides their dose of
magnesium sulphate, the findings that low-dose9 or
medium-dose7 magnesium sulphate significantly
reduced the incidence of AF appear questionable
and are not supported in the current review. 
Possible influence of -blocker therapy
and other factors on effects of
magnesium sulphate
As noted above, the studies by Dagdelen17,18 and
Toraman27 impart a significant intervention effect
to almost any subgroup in which the studies are
analysed. It is difficult to determine which aspects
of these studies drive the significant intervention
effect, as the studies differed in several respects
from the other studies included in this review. For
example, they were the only studies that explicitly
excluded patients who were on  -blockers, and
they started prophylactic therapy earlier than most
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Discussionother studies, continued prophylaxis over a longer
duration and used a lower dose rate than other
studies. It is possible that an interaction between
these (and possibly other) factors was responsible
for the uniquely low ORs reported in these two
studies.  -Blockers prevent the loss of intracellular
magnesium and it has been suggested that
prophylactic magnesium sulphate may be more
effective in patients who are not offered
preoperative  -blockers.22 The relative importance
of  -blockers, the time of initiation and the
duration of prophylaxis appear to warrant further
investigation, given the overall positive results of
these studies for prophylaxis of AF. 
Heterogeneity of exclusion criteria in
the primary studies
The criteria used to exclude patients from the
trials were reported in variable detail, with up to
15 main criteria listed in one study, whereas three
of the studies did not report any exclusion criteria
(Appendix 6). The selection of exclusion criteria
could have an important bearing on the risk
classification of the recruited populations. As
discussed above, excluding patients who are on
antiarrhythmic drugs might have led to the
included patients being at higher risk of AF.
Conversely, excluding high-risk patients (e.g. those
with ventricular dysfunction or history of AF)
might have led to the included patients being at
lower risk of AF. Ideally, meta-analysis should be
stratified by patient risk to account for such
interpopulation differences. This was not possible,
however, as in most cases the exclusion criteria
were weakly defined or undefined (e.g. unclear
whether supraventricular arrhythmia included
AF), and because it is difficult to weigh up
objectively the relative importance of individual
exclusion criteria in the risk of AF (Appendix 6). 
Cost-effectiveness
The systematic review of economic evaluations did
not identify any studies comparing magnesium
sulphate prophylaxis with sotalol or with no
prophylaxis. It is unlikely that economic
evaluations of intravenous magnesium sulphate
compared with sotalol have been performed, given
the lack of RCT evidence for this comparison. The
secondary review of economic evaluations of other
agents as prophylaxis for AF found one study of
oral amiodarone conducted using a short-term
model. Short-term models such as this only follow
up patients to discharge from hospital and use
intermediate outcomes. It is unclear from the
current evidence base how a reduction in
postoperative AF cases relates to changes in final
outcomes.
The secondary review suggests that postoperative
AF leads to increases in resource use, particularly
increased stay in the ICU and on hospital wards.
Estimates of the additional resource use associated
with postoperative AF were developed using the
results of the literature search. However, the data
were not suitable for a quantitative synthesis. The
applicability of all the included studies to current
UK clinical practice may be questioned as the
publication dates of the studies ranged over 14
years. Moreover, the included studies were
conducted in a number of countries, which may
have significantly different criteria for admission
or discharge from the ICU and patterns of
postoperative management. Existing UK cardiac
surgical databases, such as the Society of
Cardiothoracic Surgeons’ National Adult Cardiac
Surgical Database, could be investigated for
suitable data to refine the inputs to the economic
model. Such databases could also be used to
define current patterns of practice in management
of surgical patients and of postsurgical patients
with AF.
The analysis presented here suggests that
prophylaxis may achieve a reduction in AF cases at
a modest additional cost and that this result is not
sensitive to assumptions made regarding the
management of postoperative AF, but is sensitive
to assumptions over the length of stay for patients
with AF. The results were also sensitive to the
baseline risk of AF and to the effectiveness of
prophylaxis, as would be expected. The PSA
suggests that prophylaxis is most likely to be
associated with increased treatment costs, although
these may be modest. If intensive care facilities are
in short supply it may be reasonable to accept a
slight increase in treatment costs to release scarce
resources. However, if prophylaxis requires earlier
admission of patients than would be the case
under the no-prophylaxis option, a more careful
evaluation of the relative benefits of increasing
ward stays compared with freeing up some
intensive care facilities is required.
A key question that is beyond the scope of this
report is the extent to which avoiding
postoperative AF cases translates to changes in life
expectancy or quality-adjusted life expectancy for
patients undergoing coronary artery bypass
surgery. Evidence reviewed in the European
Association of Cardiothoracic Surgeons guideline1
suggests that postoperative AF is associated with
an approximate doubling in the risk of stroke
Discussion
40following CABG (from 1.4–2.5% for patients in
sinus rhythm to 3.3–5.2% for patients who
experience postoperative AF). Patients
experiencing postoperative AF tend to have
higher preoperative risks of stroke, such as older
age and hypertension,49 although a retrospective
study by Stamou and colleagues65 demonstrated
an independent effect for postoperative AF on risk
of stroke in multivariate analysis (OR = 1.7, 95%
CI 1.4 to 2.2). While the epidemiological evidence
is currently insufficient to support the construction
of a robust, long-term model of outcomes for
patients experiencing postoperative AF, these data
suggest that for every 1000 patients undergoing
CABG between one and two strokes could be
avoided through the use of magnesium sulphate
prophylaxis (by averting 81 cases of postoperative
AF). In addition to quality of life impacts resulting
from the mortality and morbidity associated with
strokes, costs of strokes have been estimated to be
between £16,000 and £91,000 (2004 prices)
depending on severity of stroke and time-horizon;
the lower figure is for a mild stroke over 5 years,
the higher figure is a lifetime cost for a major
ischaemic stroke.66 (Costs were reported in US
dollars. These have been converted to UK sterling
by the authors of this report, using purchasing
power parities in the original article66.)
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o RCTs were identified that specifically aimed
to compare intravenous magnesium with
sotalol as prophylaxis for AF in patients
undergoing CABG. Intravenous magnesium, when
compared with placebo or control, is effective in
preventing postoperative AF, as confirmed by a
statistically significant intervention effect based on
pooled analysis of 15 RCTs. It was also found that
AF was less likely to occur with a longer duration
of prophylaxis and when prophylaxis was started
earlier, although there were uncertainties
associated with the trials in these subgroups. No
clear relationship between dose and AF was
observed, although a lower constant dose rate was
associated with the lowest odds of AF. Further
primary research should investigate the
relationship between dose, dose rate, duration of
prophylaxis, timing of initiation of therapy and
patient characteristics, such as degree of risk for
AF. This will provide stronger evidence for the
optimum delivery of intravenous magnesium in
patients undergoing CABG.
In terms of cost-effectiveness, magnesium sulphate
prophylaxis can lead to reductions in the number
of postoperative AF cases at low or no additional
costs, owing to offsetting the additional costs of
prophylaxis with reductions in ICU and ward 
stays as well as avoided costs of managing
postoperative AF.
The results of the cost-effectiveness analysis are
sensitive to plausible changes in certain
assumptions. In particular, the results were
sensitive to variation in the baseline risk of AF, the
relative risk of postoperative AF with magnesium
sulphate prophylaxis, the cost of prophylaxis (in
particular the possibility of a longer preoperative
stay to allow for the first infusion to occur on the
day before surgery) and the number of additional
ICU or ward days associated with AF.
The probabilistic analysis showed that the
proportion of simulations where magnesium
sulphate prophylaxis was dominant depended on
assumptions over the admission routines for
patients receiving prophylaxis. If these were the
same for both strategies then the proportion of
simulations where prophylaxis was dominant was
41%. This reduced to 5% if it was assumed that
patients receiving prophylaxis are admitted, on
average, half a day early. The majority of
simulations in both scenarios were associated with
increased costs. All simulations had positive
incremental effectiveness (i.e. magnesium
prophylaxis was always effective in reducing the
number of AF cases).
The CEAC shows that the probability of
prophylaxis being cost-effective increases with
increasing WTP for a unit of outcome. It is unclear
what the appropriate decision threshold (threshold
WTP) should be, with outcome in the model being
expressed as AF cases averted.
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Searched 14 May 2007
#1 MeSH descriptor Coronary Artery Bypass
explode all trees
#2 (CABG or coronary artery bypass graft*):ti,ab
#3 (coronary artery bypass NEAR/3
surgery):ti,ab
#4 coronary revascular*:ti,ab
#5 (#1 OR #2 OR #3 OR #4)
#6 MeSH descriptor Magnesium Sulfate
explode all trees
#7 magnesium (sulphate* or sulfate*):ti,ab
#8 (#6 OR #7)
#9 MeSH descriptor Atrial Fibrillation explode
all trees
#10 (heart NEAR/3 fibrillat*):ti,ab
#11 (atrial and fibrillat*):ti,ab
#12 atrial fibrillat*
#13 (#9 OR #10 OR #11 OR #12)
#14 (#5 AND #8), from 2004 to 2007
#15 (#13 AND #8), from 2004 to 2007
#16 (#14 OR #15)
#17 MeSH descriptor Sotalol explode all trees
#18 sotalol
#19 (#17 OR #18)
#20 (#5 OR #13)
#21 (#20 AND #19)
#22 (#8 AND #19)
#23 (#19 AND #5)
Number of hits (download file)
Cochrane Database of Systematic Reviews (CDSR)
magnesium: 1
CDSR sotalol: 8
CENTRAL magnesium: 8
CENTRAL magnesium + sotalol: 1
CENTRAL sotalol: 16
Ovid MEDLINE
1950 to May week 1 2007
Searched 15 May 2007
1 "Atrial Fibrillation"/ (19465)
2 Atrial Flutter/ (3991)
3 (atrial adj3 fibrillat$).mp. (25464)
4 (heart adj3 fibrillat$).mp. (950)
5 atrial  fibrillat$.mp.  (25294)
6 (atrium adj3 flutter$).mp. (23)
7 (atrium adj3 fibrillat$r).mp. (0)
8 (auricular$ adj3 fibrillat$).mp. (736)
9 (auricular$ adj3 flutter$).mp. (274)
10 Tachycardia Supraventricular/ (3781)
11 or/1-10 (30644)
12 "Coronary Artery Bypass"/ (31512)
13 (CABG or coronary artery bypass graft$).ti,ab.
(16229)
14 (coronary artery bypass adj3 surgery).ti,ab.
(7332)
15 (coronary adj3 revasculari$).ti,ab. (4439)
16 (myocardial adj3 revascular$).ti,ab. (4063)
17 (coronary adj6 graft).ti,ab. (6832)
18 (coronary adj6 bypass).ti,ab. (26085)
19 (coronary adj6 surgery).ti,ab. (15257)
20 (aortocoronary adj6 bypass).ti,ab. (2453)
21 (valve$ adj6 surgery).ti,ab. (4554)
22 Cardiac Surgical Procedures/ (23335)
23 or/12-22 (71271)
24 MgSO4.mp. (1029)
25 magnesium sulfate/ (3419)
26 magnesium sulfate$.ti,ab. (1735)
27 exp magnesium compounds/ (10471)
28 magnesium/ (56302)
29 (magnesium and (sulphate$ or sulfate$)).ti,ab.
(3192)
30 magnesium sulphate$.ti,ab. (729)
31 magnesium sulfate$.ti,ab. (1735)
32 7487-88-9.rn. (3419)
33 Magnesium Deficiency/ (3387)
34 or/24-33 (67330)
35 3930-20-9.rn. (1695)
36 Sotalol/ (1695)
37 sotalol.ti,ab. (1997)
38 or/35-37 (2418)
39 11 and 23 and 34 (48)
40 23 and 34 (242)
41 11 and 34 (151)
42 39 or 40 or 41 (345)
43 limit 42 to (humans and english language and
yr="2004 - 2007") (45)
44 RANDOMISED CONTROLLED TRIAL.pt.
(234701)
45 CONTROLLED CLINICAL TRIAL.pt. (74869)
46 RANDOMISED CONTROLLED TRIALS.sh.
(48464)
47 RANDOM ALLOCATION.sh. (57810)
48 DOUBLE BLIND METHOD.sh. (91140)
49 SINGLE BLIND METHOD.sh. (10900)
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Appendix 1
Search strategy for RCTs and systematic reviews50 or/44-49 (397972)
51 CLINICAL TRIAL.pt. (435563)
52 exp CLINICAL TRIALS/ (190865)
53 (clin$ adj25 trial$).ti,ab. (129659)
54 ((singl$ or doubl$ or trebl$ or tripl$) adj25
(blind$ or mask$)).ti,ab. (90466)
55 PLACEBOS.sh. (26144)
56 placebo$.ti,ab. (102017)
57 random$.ti,ab. (370373)
58 RESEARCH DESIGN.sh. (47354)
59 or/51-58 (843224)
60 COMPARATIVE STUDY.sh. (0)
61 exp Evaluation Studies/ (596080)
62 FOLLOW UP STUDIES.sh. (337594)
63 PROSPECTIVE STUDIES.sh. (220463)
64 (control$ or prospectiv$ or volunteer$).ti,ab.
(1775327)
65 or/60-64 (2564190)
66 or/50,59,65 (2918050)
67 43 and 66 (32)
68 from 67 keep 1-32 (32)
69 from 68 keep 1-32 (32)
70 (review or review-tutorial or review-
academic).pt. (1275632)
71 (Medline or medlars or embase).ti,ab,sh. (23800)
72 (scisearch or psychinfo or psycinfo).ti,ab,sh.
(1277)
73 (Psychlit or psyclit).ti,ab,sh. (709)
74 cinahl.ti,ab,sh. (2178)
75 ((hand adj59 search$) or (manual$ adj9
search$)).mp. [mp=title, original title,
abstract, name of substance word, subject
heading word] (3888)
76 (electronic database$ or bibliographic
database$ or computeri#ed database$ or
online database$).mp. [mp=title, original title,
abstract, name of substance word, subject
heading word] (4129)
77 (pooling or pooled or mantel haenszel).mp.
[mp=title, original title, abstract, name of
substance word, subject heading word] (25915)
78 (peto or dersimonian or der simonian or fixed
effect).mp. [mp=title, original title, abstract,
name of substance word, subject heading word]
(1092)
79 71 or 72 or 73 or 74 or 75 or 76 or 77 or 78
(52839)
80 70 and 79 (19955)
81 meta-analysis.pt. (15271)
82 meta-analysis.sh. (7414)
83 (meta-analys$ or meta analys$ or
metaanalys$).mp. [mp=title, original title,
abstract, name of substance word, subject
heading word] (27299)
84 (systematic$ adj9 review$).mp. [mp=title,
original title, abstract, name of substance
word, subject heading word] (13485)
85 (systematic$ adj9 overview$).mp. [mp=title,
original title, abstract, name of substance
word, subject heading word] (416)
86 (quantitativ$ adj9 review$).mp. (1754)
87 (quantitativ$ adj9 overview$).mp. [mp=title,
original title, abstract, name of substance
word, subject heading word] (142)
88 (quantitativ$ adj9 synthesis$).mp. (1376)
89 (methodologic$ adj9 review$).mp. (2493)
90 (methodologic$ adj9 overview$).mp. (153)
91 (integrative research review$ or research
integration).mp. (51)
92 or/81-91 (41150)
93 80 or 92 (53669)
94 43 and 93 (6)
95 from 94 keep 1-6 (6)
96 11 or 23 (99880)
97 34 and 38 and 96 (10)
98 from 97 keep 1-10 (10)
99 38 and 93 and 96 (27)
100 from 99 keep 1-27 (27)
101 100 (27)
102 38 and 66 and 96 (313)
103 limit 102 to (humans and english language)
(268)
104 103 not 99 (246)
105 23 and 104 (45)
106 104 not 105 (201)
107 23 and 38 and 66 (52)
108 limit 107 to (humans and english language)
(51)
109 23 and 38 and 92 (6)
110 108 not 109 (47)
Number of hits (download file)
Systematic reviews (SRs) magnesium: 5
SRs magnesium + sotalol: 2
SRs sotalol: 6
RCTs magnesium: 24
RCTs magnesium + sotalol: 10
RCTs sotalol: 47
EMBASE
1980 to 2007 week 19
Searched 16 May 2007
1 heart atrium fibrillation/ (21875)
2 heart atrium flutter/ (3362)
3 exp Heart Atrium Arrhythmia/ (35266)
4 (atrial adj3 fibrillat$).mp. (17803)
5 (heart adj3 fibrillat$).mp. (31983)
6 atrial fibrillat$.mp. (17577)
7 (atrium adj3 flutter$).mp. (3380)
8 (atrium adj3 fibrillat$r).mp. (0)
9 (auricular$ adj3 fibrillat$).mp. (108)
10 (auricular$ adj3 flutter$).mp. (29)
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5211 Supraventricular Tachycardia/ (5812)
12 or/1-11 (47152)
13 coronary artery bypass graft/ (22523)
14 Coronary Artery Bypass Surgery/ (6944)
15 exp coronary artery surgery/ (39530)
16 (CABG or coronary artery bypass graft$).ti,ab.
(14959)
17 (coronary artery bypass adj3 surgery).ti,ab.
(6804)
18 (coronary adj3 revasculari$).ti,ab. (4087)
19 (myocardial adj3 revascular$).ti,ab. (3015)
20 (coronary adj6 graft).ti,ab. (6026)
21 (coronary adj6 bypass).ti,ab. (23026)
22 (coronary adj6 surgery).ti,ab. (13234)
23 (aortocoronary adj6 bypass).ti,ab. (1469)
24 (valve$ adj6 surgery).ti,ab. (3618)
25 or/13-24 (50320)
26 MgSO4.mp. (1011)
27 magnesium sulfate/ (6009)
28 Magnesium Derivative/ (989)
29 magnesium/ (23019)
30 (magnesium and (sulphate$ or sulfate$)).ti,ab.
(2910)
31 magnesium sulphate$.ti,ab. (642)
32 magnesium sulfate$.ti,ab. (1548)
33 7487-88-9.rn. (6022)
34 Magnesium Deficiency/ (1203)
35 or/26-34 (30923)
36 3930-20-9.rn. (7170)
37 Sotalol/ (7144)
38 sotalol.ti,ab. (2048)
39 or/36-38 (7279)
40 12 and 25 and 35 (88)
41 25 and 35 (209)
42 12 and 35 (667)
43 41 or 42 (788)
44 limit 43 to (humans and english language and
yr="2004 - 2007") (229)
45 12 or 25 (95066)
46 35 and 39 and 45 (149)
47 exp Postoperative Complication/ (188542)
48 exp meta analysis/ (30150)
49 meta#analy$.ab,sh,ti. (30151)
50 methodologic$ review$.ab,sh,ti. (128)
51 methodologic$ overview$.ab,sh,ti. (31)
52 (integrative research adj5 review$).mp. or
research integration.ab,ti. [mp=title, abstract,
subject headings, heading word, drug trade
name, original title, device manufacturer, drug
manufacturer name] (28)
53 quantitat$ synthesis.ab,sh,ti. (91)
54 quantitat$ review$.ab,sh,ti. (260)
55 quantitat$ overview$.ab,sh,ti. (60)
56 systematic$ review$.ab,sh,ti. (23698)
57 systematic$ overview$.ab,sh,ti. (287)
58 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55
or 56 or 57 (43716)
59 44 and 58 (28)
60 from 59 keep 1-2,4-5,8-9,12-13,15,17-20,22-
25,28 (18)
61 randomisation/ (22296)
62 controlled study/ (2402316)
63 single blind procedure/ (6576)
64 placebo/ (98219)
65 double blind procedure/ (63899)
66 clinical trial/ (423526)
67 crossover procedure/ (18621)
68 placebo$.tw. (98196)
69 blind$ fashion.tw. (3585)
70 random$.tw. (335411)
71 clinical trial?.tw. (99670)
72 or/61-71 (2809080)
73 limit 72 to human (1793268)
74 44 and 73 (120)
75 74 not 59 (92)
76 from 75 keep 5,7,10,16,18,20,22-25,27,30-
31,33,39-40,43,45,48,50-51,58,60,65,68-
77,80,84,86,88,90-92 (41)
77 46 and 58 (18)
78 77 not (59 or 75) (4)
79 from 78 keep 1-4 (4)
80 46 and 73 (69)
81 limit 80 to english language (66)
82 81 not 74 (34)
83 from 82 keep 2-4,7,10-12,14-15,17,19-24,26-
27,31,34 (20)
84 12 and 25 and 39 and 58 (18)
85 from 84 keep 1,3 (2)
86 84 not (78 or 59 or 75 or 81) (12)
87 from 86 keep 1,3-5,7-8,10 (7)
88 12 and 25 and 39 and 73 (102)
89 limit 88 to (human and english language) (91)
90 89 not 84 (74)
91 from 90 keep 1-6,9,15,17-20,25-
27,30,36,38,41,43-46,49,52-53,55-63,65-74
(45)
Number of hits (download file)
SRs magnesium: 18
SRs magnesium + sotalol: 4
SRs sotalol: 20
RCTs magnesium: 41
RCTs magnesium + sotalol: 20
RCTs sotalol: 45
Ovid MEDLINE In-Process and
Other Non-Indexed Citations
14 May 2007
Searched 15 May 2007
1 (atrial adj3 fibrillat$).mp. (728)
2 (heart adj3 fibrillat$).mp. (32)
3 atrial fibrillat$.mp. (727)
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5 (atrium adj3 fibrillat$r).mp. (0)
6 (auricular$ adj3 fibrillat$).mp. (16)
7 (auricular$ adj3 flutter$).mp. (0)
8 or/1-7 (747)
9 (CABG or coronary artery bypass graft$).ti,ab.
(482)
10 (coronary artery bypass adj3 surgery).ti,ab.
(220)
11 (coronary adj3 revasculari$).ti,ab. (134)
12 (myocardial adj3 revascular$).ti,ab. (83)
13 (coronary adj6 graft).ti,ab. (173)
14 (coronary adj6 bypass).ti,ab. (638)
15 (coronary adj6 surgery).ti,ab. (353)
16 (aortocoronary adj6 bypass).ti,ab. (22)
17 (valve$ adj6 surgery).ti,ab. (117)
18 or/9-17 (968)
19 MgSO4.mp. (38)
20 (magnesium and (sulphate$ or sulfate$)).ti,ab.
(98)
21 magnesium sulphate$.ti,ab. (23)
22 magnesium sulfate$.ti,ab. (55)
23 19 or 20 or 21 or 22 (129)
24 sotalol.ti,ab. (30)
25 8 or 18 (1659)
26 23 and 25 (3)
27 from 26 keep 1-3 (3)
28 24 and 25 (14)
29 from 28 keep 5,8,10-13 (6)
Number of hits (download file)
RCTs magnesium: 3
RCTs sotalol: 6
DARE (on CRD databases)
magnesium and (atrial fibrillat* or coronary)
Sotalol and (atrial fibrillat* or coronary)
Number of hits (download file)
Magnesium: 7
Sotalol: 10
HTA Database (on CRD
databases)
Magnesium and (atrial fibrillat* or coronary)
Sotalol and (atrial fibrillat* or coronary)
Number of hits
0
National Research Register
#1. magnesium 197 
#2. (atrial next fibrillat*) 442 
#3. ((coronary or heart or atri*) and surgery) 1991 
#4. (#1 and (#2 or #3)) 10
Number of hits (download file)
Single-centre projects (ongoing): 2
Single-centre (completed): 7
Lead centre for multicentre projects (completed):
1 
Current Controlled Trials
including MRC Trials Database
http://controlled-trials.com/
Magnesium and (atrial fibrillat* or coronary)
Number of hits (download file)
Magnesium: 1 (UK)
Clinical Trials.gov
http://clinicaltrials.gov/
Magnesium and (atrial fibrillation or coronary)
Sotalol and (atrial fibrillation or coronary)
Number of hits (download file)
Magnesium: 1
Sotalol: 5
TOTAL KEYWORDED
SRs magnesium: 15
SRs magnesium + sotalol: 5
SRs sotalol: 26
RCTs magnesium: 45
RCTs magnesium + sotalol: 28
RCTs sotalol: 71
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Appendix 2
Decision tree for screening abstracts and full papers
Trial name or number:
Adult patients with AF after elective CABG  Yes Unclear No Type:
↓↓ →
Either on-pump or off-pump CABG techniques;  next question next question Exclude Exclude 1
any number of grafts; any conduit type  (not the correct 
(CABG must be specified; with or without valvular  patient group)
surgery)
Design: RCT or systematic review Yes Unclear No Exclude 2
↓↓ → (not the right 
next question next question Exclude study design)
Interventiona
IV magnesium sulphate as bolus or continuous  Yes Unclear No Exclude 3
infusion, or sotalol (oral or IV) or IV magnesium  ↓↓ → (not the right 
sulphate combined with sotalol, each of a specified  next question next question Exclude intervention)
dose and duration, as a prophylactic measure 
before onset of AF. (NB. Oral Mg, Mg chloride 
and Mg hydroxide are outside the scope of the 
review)
Report one or more of primary outcomes: Yes Unclear No Exclude  4
incidence of AF after CABG (include broader  ↓↓ → (not the right 
arrhythmia definitions only if proportion with  next question next question Exclude outcome 
AF reported), measured using a continuous  measures)
electrocardiogram (ECG) and confirmed by 
standard 12-lead ECG)
Final decision Include Unclear Exclude Results of 
(discuss) discussion:
IV, intravenous.
a Compared with placebo and/or sotalol.Health Technology Assessment 2008; Vol. 12: No. 28
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Appendix 3
Data extraction templates for the 15 RCTs 
included in this review
Reference and  Intervention Participants Outcome measures
design
Authors: 
Bert et al.15
Year: 2001
Country: USA
Study design: RCT
Number of centres:
One
Funding: NR
Interventions for which
data extracted:
1. IV magnesium
sulphate 
2. Control
Other groups (data not
extracted):
3. Digoxin 
4. MgSO4 + digoxin 
5. Propranolol 
6. MgSO4 +
propranolol
Intervention details:
1. 2 g magnesium
sulphate diluted in
50 ml of normal
saline infused i.v.
during 30 minutes
after termination of
CPB (after
protamine
neutralisation) and
again on arrival in
the ICU. A daily
dose of 2 g
magnesium sulphate
then infused each
morning for the first
4 days postoperation
for a total of 12 g in
96 h. No patients
received magnesium
pre-CPB
2. Received no
antiarrhythmic agent
(not stated whether
normal saline was
administered as in
group 1)
Number of participants: 
Intervention: 63
Control: 60
Sample attrition/dropout: 
Three patients were excluded after
randomisation, but it was not reported whether
these were from the magnesium and/or control
groups, nor whether any data from these
patients were analysed
Inclusion criteria for study entry: 
Patients scheduled for primary CABG surgery
were eligible for enrolment, including patients
with additional aortic valve replacement surgery
Exclusion criteria for study entry:
Patients with: a history of atrial or ventricular
arrhythmias, or any rhythm other than sinus
rhythm on the ECG obtained the evening before
surgery; LVEF  20% on angiography; airway
disease requiring bronchodilator therapy; renal
failure requiring haemodialysis; other surgical
procedures (mitral valve surgery aortic arch
replacement, or ventricular aneurysmectomy)
Baseline characteristics of subjects: 
Mean ± SD age (years):
Intervention: 62.7 ± 9.7b
Control: 63.6 ± 9.6b
(difference was tested only across six study
groups)
Gender (M/F):
Intervention: 56/7
Control: 50/10
(difference was tested only across six study
groups)
Magnesium/control group values appeared
similar for: LVEF, %  -blockers, Ca channel
blockers, digoxin, diuretics, number of bypass
grafts, % incomplete revascularisation, %
inotropic use, number of patients with CABG +
valve surgery (3/1) and mean cross-clamp time
(59.6/55.1 minutes) (differences were tested
only across six study groups)
AF outcome(s):
Incidence of POATa
(primary outcome)
Other outcomes
extracted:
Duration of hospital stay
Other outcomes (data not
extracted): 
Time to extubation, MI,
ventricular ectopic
activity, initial ventricular
rate
Adverse symptoms: 
No deaths occurred in
either the magnesium or
control group during the
study. The proportions
of patients with MI or
ventricular ectopic
activity appeared similar
in these groups
Length of follow-up: 
4 days after CABG
Recruitment dates: 
3-year period (dates not
specified)
a POAT (post-operative atrial tachyarrhythmia) includes AF, atrial flutter or an SVT that was sustained for >5 minutes and
warranted pharmacological therapy.
b Variance measure not stated.
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Results
AF outcome Intervention (n = 63) Control (n = 60) Difference
Incidence of POAT, n (%)c 24d (38%) 23d (38%) p = 0.98 
c Overall, across all six study groups, 90.4% of the POAT were AF (the proportion of AF in the magnesium and control
groups was not reported). 
d Calculated by reviewers.
Other outcomes Intervention (n = 63) Control (n = 60) Difference
Duration of hospital stay (days) 8.2 ± 3.1e 8.0 ± 2.9e Not reported for
this comparison; for
comparison across
six groups p = 0.69
(ns)
e Assumed by reviewers (not stated) to be the mean value; variance measure not stated.
Methodological comments 
Allocation to treatment groups: Stated that patients were randomised to the study groups based on a table of random
numbers (no other details provided). 
Blinding: Stated that all arrhythmia tracings were reviewed by a cardiologist unaware of the patient’s treatment group. No
other details of blinding were given.
Comparability of treatment groups: Baseline characteristics of the groups appear similar; differences were not significant if all
six study groups were tested together (no pairwise tests of baseline characteristics were reported).
Method of data analysis: 
● One-way analysis of variance and 2 × 6 contingency tables with  2 test were used to compare baseline characteristics,
intraoperative measures and POAT among the six treatment groups. 
● 2 × 2 contingency tables with  2 test were used to compare the incidence of POAT between each pair of treatment
groups.
● An independent samples t-test was used to compare age between POAT and non-POAT groups (data not extracted).
● Statistical tests were not supported by hypotheses; normality of data was not reported.
Sample size/power calculation: NR. 
Attrition/dropout: Three patients were excluded after randomisation, but it was not reported whether these were from the
magnesium and/or control groups, nor whether any data from these patients were analysed. Patients experiencing AF were
regarded as having completed the study protocol (the end-point and duration of study therefore varied among patients).
General comments
Generalisability: No details of ethnicity or social background; single-location study in USA.
Outcome measures: POAT mainly comprised AF (90.4% overall), but AF was not reported separately for individual
treatment comparisons.
Intercentre variability: NA.
Conflict of interests: None reported.
LVEF, left ventricular ejection fraction; MI, myocardial infarction; ns, not significant; POAT, postoperative atrial tachycardia;
SVT, supraventricular tachycardia.Health Technology Assessment 2008; Vol. 12: No. 28
59
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
Reference and  Intervention Participants Outcome measures
design 
Authors: Bhudia 
et al.16
Year: 2006
Country: USA
Study design: RCT
Number of centres:
One
Funding: NR
Interventions:
1. IV magnesium
sulphate 
2. Placebo control
Intervention details:
1. 780 mg (32 mmol)
magnesium sulphate
in 100 ml of normal
saline given i.v. over
15 minutes during
anaesthesia
induction, followed
by 3160 mg
(130 mmol) in
100 ml of normal
saline over 24 h; the
CPB circuit was
primed with
magnesium sulphate
to a concentration of
3.6 to 4.8 mg dl–1
2. Patients received
normal saline given
i.v. in the CPB circuit
and over 24 h in
bags and syringes
indistinguishable
from those used for
group 1
Number of participants: 
Intervention: 174
Control: 176
Sample attrition/dropout: NR
Inclusion criteria for study entry: Patients
undergoing elective on-pump CABG
[magnesium 71 (41%), placebo 57 (32%)],
valve surgery [magnesium 59 (34%), placebo
65 (37%)] or combined CABG + valve
surgery [magnesium 44 (25%), placebo 54
(31%)]
Exclusion criteria for study entry:
Patients with preoperative AF or renal
impairment (this may be an incomplete lista) 
Baseline characteristics of subjects:
Mean ± SD age (years):
Intervention: 64 ± 12
Control: 64 ± 13
Difference: p = 0.7 (ns)
Gender (M/F): 
Intervention: 133/41 (24% F)
Control: 137/39 (22% F)
Difference: p = 0.8 (ns)
Differences between groups were not
statistically significant (p > 0.5) for: BMI,
diabetes, hypertension, COPD, carotid
disease, smoking history, MI history,
preoperative AF, previous cardiac surgery,
NYHA class, moderate or greater aortic
regurgitation, mitral regurgitation and/or
mitral stenosis, number undergoing isolated
CABG or CABG + valve surgery, perfusion
time, ischaemic time, education duration and
standards
Differences between groups were
statistically significant for peripheral vascular
disease (intervention 77, control 59,
p = 0.04) and moderate or greater aortic
stenosis (intervention 36, control 57,
p = 0.01)
AF outcome(s):
Incidence of AF (safety
outcome) 
Other extracted outcomes:
Length of stay in ICU and
hospital
Other outcomes (data not
extracted): MI, stroke,
return to operating room
for treatment, blood
transfusion units,
neurological and
psychological assessments
(primary outcome), plasma
magnesium concentration,
renal insufficiency,
respiratory insufficiency,
septicaemia
Adverse symptoms: 
One death occurred in each
group in hospital. Within
3 months of enrolment
there was one death in the
magnesium group and there
were four deaths in the
placebo group (p = 0.2, ns);
these were not related to
stroke or neurological injury
Length of follow-up: 
Not stated for the
outcomes extracted here
(median length of
postoperative stay was
6 days)
Recruitment dates: 
February 2003 to
September 2003
a The authors refer to Figure E1 and Appendix E1 for exclusion criteria, but these sources were not included in the primary
article and no links for locating them elsewhere were provided
Results
AF outcome Intervention (n = 174) Control (n = 176) Difference
No. (%) of patients with AF  57 (33%) 64 (36%) p = 0.5 (ns)
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Other outcomes Intervention  Control  Difference
(n = 174) (n = 176)
Median length of stay (days) in ICU (15th, 85th percentiles) 2 (1, 3) 2 (1, 3) p > 0.9 (ns)
Median length of postoperative stay (days) (15th, 85th percentiles) 6 (5, 9) 6 (5, 9) p > 0.9 (ns)
Median length of hospital stay (days) (15th, 85th percentiles) 7 (5, 11) 7 (5, 10) p = 0.3 (ns)
Methodological comments 
Allocation to treatment groups: Patients were randomised 1:1 at operation, with a block size of 2 and 4, independently for
each of 11 operating rooms (no other details).
Blinding: The pharmacy department who prepared study medications and the anaesthetic team who administered the 24-h
infusions were blinded to the study. The perfusion teams who dosed the CPB circuits were not blinded; they were required
to monitor and maintain magnesium levels during CPB.
Comparability of treatment groups: Significantly more of the magnesium group had PVD, while significantly more of the
control group had aortic stenosis; other variables did not differ between the groups (p-values were provided for all
variables). 
Method of data analysis: 
● Continuous data with a skewed (unspecified) distribution were analysed with a Wilcoxon rank-sum test. 
● Categorical data were analysed using a  2 test, or Fisher’s exact test when the frequency was <5. 
● Presentation of results did not indicate which tests were actually used for each outcome; normality of outcomes was not
reported.
● Statistical tests were not supported by hypotheses.
Sample size/power calculation: Stated that the study was powered for 300 patients, based on neurological assessments as the
primary outcome, but no details given. 
Attrition/dropout: NR.
General comments
Generalisability: No details of ethnicity or social background; single-location study in USA.
Outcome measures: Appropriate.
Intercentre variability: NA.
Conflict of interests: None reported.
BMI, body mass index; COPD, chronic obstructive pulmonary diseases; NYHA, New York Heart Association; 
PVD, peripheral vascular disease.Health Technology Assessment 2008; Vol. 12: No. 28
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Reference and  Intervention Participants Outcome measures
design 
Authors: 
Caspi et al.13
Year: 1995
Country: Israel
Study design: RCT
Number of centres:
One
Funding: NR
Interventions:
1. Intravenous
magnesium sulphate 
2. Placebo control
Intervention details:
1. Two doses of
magnesium sulphate
continuously with a
syringe pump
(Graseby 3100;
Watford, Herts, UK): 
● 16 mmol from the
time of anaesthetic
induction to aortic
cross-clamping
● 32 mmol after the
release of aortic
cross-clamping until
24 h later 
2. 20 ml of saline
solution
Number of participants: 
Intervention: 50
Control: 48
Sample attrition/dropout: 
NR
Inclusion criteria for study entry: Patients with
unstable angina (grade IV) undergoing
CABG, the criteria for unstable angina: the
presence of chest pain at rest lasting for
more than 15 minutes, associated with
transient ST segment changes and with or
without haemodynamic instability
Exclusion criteria for study entry: 
NR
Baseline characteristics of subjects:
Mean age (range) (years):
Intervention: 60 (41–78)
Control: 62 (43–76)
Gender (M/F) (n):
Intervention: 34/16
Control: 38/10
Authors state that other baseline values 
(e.g. previous MI, use of  -blockers and
Ca2+ blockers, ejection fraction, left main
coronary artery disease) do not differ
significantly between groups. No statistical
tests reported. Two patients in intervention
group and one patient in control group
required intra-aortic balloon support before
operation because of low cardiac output
AF outcome(s) 
(1st = primary outcome):
The incidence of
postoperative AF defined as
AF at rates greater than
120 bpm
Other outcomes (data not
extracted):
Premature ventricular
contractions, ventricular
tachycardia, ventricular
fibrillation, plasma
magnesium ion
concentration,
haemodynamic variables
Adverse symptoms: There
was one operative death in
intervention group (low
cardiac output and multiple
organ failure). Postoperative
hypertension: one in
magnesium group, 14 in
placebo group (p < 0.05).
Postoperative ventricular
tachycardia, 0 in magnesium
group, one in placebo
group. Frequent premature
ventricular beats requiring
lidocaine: one in magnesium
group, 12 in placebo group
(p < 0.05). No other
differences between groups
reported by authors
Length of follow-up: 24 h
after operation
Recruitment dates:
NR
Results
AF outcome Intervention (n = 50) Control (n = 48) Difference
Incidence of postoperative AF 22 (44.0%) 18 (37.5%) NR
Authors reported only the numbers of patients with AF in intervention and placebo groups. Other outcomes are given with
p-value or standard deviation. 
Methodological comments 
Allocation to treatment groups: It is stated that patients were randomly assigned to receive treatment or placebo in coded
ampules. The means by which an allocation sequence was generated is not reported and the allocation concealment is
unclear.
Blinding: Patients were blinded (received treatment or placebo in coded ampules) and cardiologists (who interpreted the
ECG) were also blinded to whether the patient received the magnesium sulphate.
Comparability of treatment groups: No notable differences; authors report that the groups were similar in baseline
characteristics and other preoperative and operative characteristics. No statistical tests reported.
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Method of data analysis: Patients’ parameters were compared between two groups using an unpaired t-test and  2 test, as
required. However, no statistical method used in the analysis of the outcome concerning AF.
Sample size/power calculation: The power calculations and variance estimates are not provided.
Attrition/dropout: NR.
General comments
Generalisability: No details of ethnicity or social background; single location in Israel.
Outcome measures: Appropriate.
Intercentre variability: NA.
Conflict of interests: NR.
Reference and  Intervention Participants Outcome measures
design
Authors: 
Dagdelen et al.17,18a
Year: 2002 (2003a)
Country: Turkey
Study design: RCT
Number of centres:
NR (assumed one)
Funding: Not stated
Interventions:
1: Intravenous
magnesium sulphate 
2: Control (not
reported as placebo)
Intervention details:
1: 1.5 g day–1
magnesium sulphate
in 100 ml of 0.9%
sodium chloride
(25 ml h–1) 1 day
before CPB, just
after CPB surgery
and then once daily
for 4 days after CPB 
2: 100 ml of 0.9%
sodium chloride
(25 ml h–1) at the
same time-points as
in the magnesium
sulphate group
Number of participants: 
Intervention: 93
Control: 55
Sample attrition/dropout: 
NR
Inclusion criteria for study entry: Patients
scheduled for elective, first time, isolated CABG
(no other details)
Exclusion criteria for study entry:
Patients with AF, a past history of AF, heart valve
disease, diabetes, chronic renal disease, thyroid
disorders and/or COPD; cardiomyopathy,
congenital heart disease, congestive heart failure,
pericarditis, pulmonary embolism, pre-excitation
syndromes, sick sinus syndrome, complete
bundle branch block, atrioventricular block, and
patients receiving antiarrhythmic drugs, digoxin
and/or  -blocking agents
Baseline characteristics of subjects:
Mean ± SD age (years):
Intervention: 62.5 ± 7.0
Control: 61.3 ± 7.0; difference ns
Gender (M/F) (n): Intervention: 93/21
Control: 43/12; difference: ns
Preoperative heart rate, magnesium
concentration, QRS interval duration, PQ
interval duration, P wave maximum, P wave
minimum, and P wave dispersion did not differ
significantly between groups (data not extracted)
AF outcome(s): Incidence
of AF after CABG
Other outcomes (data not
extracted): Heart rate;
magnesium
concentration. Also ECG
characteristics of QRS,
PQ intervals and P wave
Adverse symptoms: NR
Length of follow-up: 
4 days after CABG
surgery
Recruitment dates: NR
a Dagdelen et al. (2003)18 is a brief summary of the same data.
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Results
AF outcome Intervention (n = 93) Control (n = 55) Difference
Frequency of AF occurrence (n) (%) 2 (2%) 20 (36%) p < 0.001
Other outcomes Outside scope of assessment: data not extracted
Methodological comments
Allocation to treatment groups: Stated that this was randomised, but no details provided.
Blinding: Control group patients received the same doses and times of saline solution administration as the intervention
group, but without magnesium; cardiologist reading ECGs was blinded.
Comparability of treatment groups: No notable differences.
Method of data analysis: 
• Stated that demographic and clinical variables as well as the incidence of AF were analysed using the  2-test or Fisher’s
exact test for categorical variables and paired or unpaired t-tests for continuous variables. However, the results presented
do not indicate in which cases each of these tests was applied, nor whether the data satisfied assumptions of normality.
• Overall, statistical tests were not supported by any hypotheses.
Sample size/power calculation: NR.
Attrition/dropout: NR.
General comments
Generalisability: No details of ethnicity; limited information on social background; single-location study in Turkey.
Outcome measures: Appropriate, but note that 12-lead Holter ECG was only used for reactive, not continuous, monitoring
(authors discuss whether this might have missed some cases of AF).
Intercentre variability: NA.
Conflict of interests: None reported.Appendix 3
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Reference and  Intervention Participants Outcome measures
design
Authors: 
Fanning et al.19
Year: 1991
Country: USA
Study design: RCT
Number of centres:
One
Funding: NR
Interventions:
1. Intravenous
magnesium sulphate 
2. Placebo
Intervention details:
1. Study group
maintenance fluids of
5% dextrose in
water with 20 mEq
of potassium
chloride l–1 plus
40 mEq magnesium
sulphate l–1, given as
a continuous infusion
at 100 ml h–1 over
the first 24 h
postoperatively,
followed by
25 ml h–1 over
postoperative hours
25–96. Magnesium
sulphate given was
96 mEq in first 24 h
(4 mEq h–1) followed
by 72 mEq over
hours 25–96
(1 mEq h–1) 
2. Placebo maintenance
fluids of 5%
dextrose in water
with 20 mEq of
potassium
chloride l–1, given as
a continuous infusion
according to the
same protocol as
group 1
Number of participants: 
Intervention: 49
Control: 50
Sample attrition/dropout: 
NR
Inclusion criteria for study entry: Patients
undergoing elective first time CABG
Exclusion criteria for study entry:
Serum creatinine >2.5 mg l–1; history of second
or third degree heart block; with a permanent
pacemaker; any documented or suspected
supraventricular or ventricular arrhythmias,
including isolated atrial or ventricular premature
depolarisations noted on preoperative surface
ECG; patients requiring additional procedures
such as valve replacement or left ventricular
aneurysmectomy; patients refusing to participate
Baseline characteristics of subjects:
Age (years) (range):b
Intervention: 59 (43–75)
Control: 62 (42–79)
Gender (M/F): 
Intervention: 35/14
Control: 39/11
The authors stated that the two groups were
well matched with regard to age, gender and
history of MI, and that there was no significant
difference in  -blocking or calcium channel-
blocking medication, although preoperative
digoxin use was more common in the control
group (digitalis 0 vs 7 in magnesium and control
groups; no p-value provided). Also stated that
left ventricular systolic function, ischaemic time,
number of grafts and the method of myocardial
protection were similar between the groups (no
p-values provided). LVEF, plasma magnesium
concentration, number of grafts and duration of
cross-clamp were also reported (no comments
or p-values provided)
AF outcome:
Incidence of AF (primary
outcome)a
Other outcomes (data not
extracted): 
Postoperative MI; serum
magnesium
concentration;
ventricular arrhythmias
Adverse symptoms: Stated
that no side-effects
could be attributed to
the magnesium therapy.
One death occurred in
the control group during
the study
Length of follow-up:
4 days post-CABG
Recruitment dates: 
NR
a The primary article does not clearly define whether AF includes atrial flutter and/or SVT.
b Not stated whether mean or median.
Results 
AF outcomes  Intervention  Control  Difference
(n = 49) (n = 50)
No. of patients with AF (no. of AF episodes) 7 (12)  14 (42) p < 0.02c
No. of patients with persistent and/or recurrent (>1 episode) AF 2 9 NR
c Unclear whether statistical test refers to the number of patients or the number of episodes.
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Other outcomes Outside scope of assessment: data not extracted
Methodological comments 
Allocation to treatment groups: Stated that patients were randomised, but no details were provided.
Blinding: Stated that: (1) all patients received the intervention or placebo in a double-blind fashion (no details); (2) the
patient’s physicians were not blinded to the results of serum magnesium testing but no patient received additional
magnesium therapy.
Comparability of treatment groups: Preoperative digoxin and diuretic use was more frequent in the control group; other
baseline variables were similar between the groups (reported narratively; no p-values provided).
Method of data analysis:
• The incidence of postoperative arrhythmias was analysed for group differences using a two-sided  2 analysis.
• Mean serum magnesium levels and the mean number of episodes of arrhythmias between groups were analysed using a
paired or two-sample t-test where appropriate. 
• Presentation of results did not indicate which tests were actually used for each outcome; normality of outcomes was not
reported.
Sample size/power calculation: NR.
Attrition/dropout: NR.
General comments
Generalisability: No details of ethnicity or social background; single-location study in USA.
Outcome measures: Appropriate, but note ambiguous definition of AF (see above).
Intercentre variability: NA.
Conflict of interests: None reported.
Reference and  Intervention Participants Outcome measures
design
Authors: 
Forlani et al.20,21a
Year: 2002 (2003a)
Country: Italy
Study design: RCT
Number of centres:
NR (assumed one) 
Funding: NR
Interventions:
1. Intravenous
magnesium sulphate
2. Control
3. Oral sotalol
4. Intravenous
magnesium sulphate
+ oral sotalol
Intervention details:
1. 1.5 g (12 mEq) i.v.
magnesium sulphate
daily, starting just
before CPB until
5 days postoperation
2. No drug
3. 80 mg sotalol given
orally twice daily
from 1 day to 5 days
postoperation, then
40 mg orally twice
daily for 4 weeks
4. A combination of
magnesium sulphate
and sotalol in the
same dosages as
groups 1 and 3
Number of participants: 
1. Mg: 54
2. Control: 50
3. Sotalol: 51
4. Mg + sotalol: 52
Sample attrition/dropout: 
Excluded from study: 
1. Magnesium: three patients: one due to
intraoperative MI with reduced cardiac index;
two due to AF on day of operation
2. Control: no withdrawals reported
3. Sotalol: one patient due to prolongation of
QTc
4. Magnesium + sotalol: two patients, one due
to intraoperative MI with reduced cardiac
index; one due to bradycardia
In addition, patients were excluded on the
morning of the first postoperative day (i.e. after
commencement of intervention) if heart rate
<60 bpm (beats per minute), systolic arterial
pressure <100 mmHg, wedge pulmonary
pressure >15 mmHg, cardiac index
<2.5 l minute–1 m–2 with inotropic support
(dopamine dose >3  gk g –1 minute–1).
However, the group(s) from which these
patients were excluded were not reported
AF outcomes:
Incidence, and time to
onset, of AF
Other outcomes
extracted: 
Postoperative length of
stay
Other outcomes (data not
extracted): 
Heart rate during AF;
serum magnesium
concentration
Adverse symptoms: 
One patient in the
magnesium group died
of a pulmonary
embolism 5 days after
operation. One patient
in the magnesium group
and one in the
magnesium + sotalol
group (both excluded)
had intraoperative MI
with reduced cardiac
index. Sotalol was
cautiously discontinued
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Reference and  Intervention Participants Outcome measures
design
Inclusion criteria for study entry: Patients
undergoing first time isolated CABG with CPB
Exclusion criteria for study entry:
Patients with preoperative ejection fraction
<0.40, sick sinus syndrome and atrioventral
node disease, a corrected QT interval >440 ms;
preoperative use of antiarrhythmic drugs, with
the exception of  -blockers; history of SVA,
severe COPD, serum creatinine levels
>2.0 mg dl–1
Baseline characteristics of subjects: 
Mean ± SD age (years):
1. Mg: 64 ± 7 
2. Control: 64 ± 9 
3. Sotalol: 64 ± 10 
4. Mg+sotalol: 62 ± 11 
Gender (% M):
1. Mg: 85%
2. Control: 88%
3. Sotalol: 82%
4. Mg+sotalol: 91%
With reference to 18 listed variables, the
authors stated that preoperative and
intraoperative variables did not differ significantly
among the four groups (SD provided for six of
these variables)
3 days postoperation in
two patients (both
excluded) due to
bradycardia (one patient
in magnesium + sotalol
group) and prolongation
of QTc (one patient in
sotalol group). The
authors reported that
there were no noted
proarrhythmic effects of
magnesium, sotalol or
magnesium + sotalol
Length of follow-up: 
End-point of study was
considered any AF
episode that required
treatment for symptoms
or haemodynamic
deterioration from 
1 day to 1 month
postoperation.
Interventions were
administered for 5 days
postoperation
Recruitment dates: 
January to July 2001
continued
a Forlani et al. (2003)21 is a brief summary of the same data.
Results
AF Outcomes  1. Mg 2. Control  3. Sotalol  4. Mg + sotalol  Difference 
(n = 54)  (n = 50) (n = 51)  (n = 52)
Incidence of AF, n (%) 8 (14.8%) 19 (38%) 6 (11.8%) 1 (1.9%) Versus control:
1. p = 0.007
3. p = 0.002
4. p < 0.0001
Versus Mg + sotalol:
1. p = 0.01
3. p = 0.04
Mg versus sotalol:
p > 0.05 (ns)a
Mean ± SD time (days  2.4 ± 1.4 2.3 ± 0.8 2.0 ± 1.6 2.0 ± 0.0 p > 0.05 (ns)a
postoperation) to onset of AF 
a Inferred by reviewers (not directly reported).Health Technology Assessment 2008; Vol. 12: No. 28
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Other outcomes  1. Mg  2. Control  3. Sotalol  4. Mg + sotalol  Difference
(n = 54)  (n = 50) (n = 51)  (n = 52)
Mean ± SD length of stay  5.7 ± 0.9 5.9 ± 1.7 5.6 ± 1.4 5.2 ± 1.3 Versus control:
(days postoperation)  4. p = 0.02
All other pairwise
comparisons:
p > 0.05 (ns)b
b Inferred by reviewers (not directly reported).
Methodological comments 
Allocation to treatment groups: Stated that patients were randomised to the study groups according to a computer-generated
random code. 
Blinding: NR.
Comparability of treatment groups: Authors stated that preoperative and intraoperative measurements did not differ
significantly among the four groups of patients.
Method of data analysis: 
● Comparisons of continuous or discrete variables between the four groups were performed using an unpaired Student’s 
t-test or a  2 test, respectively.
● Other analyses were also carried out for comparisons outside the scope of this assessment, including stepwise logistic
regression to investigate predictors of AF (data not extracted).
Sample size/power calculation: NR.
Attrition/dropout: Stated that all analyses were performed according to the ITT principle (ITT not defined). Patients excluded
owing to AF, MI or related arrhythmia were described, but it is unclear whether these patients were also excluded from the
analyses (if so, also unclear how the missing data were treated). Other patients were excluded after CABG if haemodynamic
criteria were not met, but the numbers and identities of these patients were not reported. Accordingly, there is
considerable doubt as to the final composition of the analysed populations. 
General comments
Generalisability: No details of ethnicity or social background; assumed single-location study in Italy. Following the oral
presentation of this paper at the 38th Annual Meeting of the Society of Thoracic Surgeons, limited generalisability of the
findings due to the highly-selected patient population was noted.
Outcome measures: Appropriate.
Intercentre variability: NA 
Conflict of interests: None reported.
SVA, supraventricular arrhythmia.Appendix 3
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Reference and  Intervention Participants Outcome measures
design
Authors: 
Hazelrigg et al.22
Year: 2004
Country: USA
Study design: RCT
Number of centres:
one (comprising
two hospitals)
Funding: 
Part-funded by
Southern Illinois
University School of
Medicine, Central
Research
Committee grant
Interventions:
1. Intravenous
magnesium sulphate 
2. Control
Intervention details:
1. 80 mg kg–1 (ideal
body weight) of
magnesium sulphate
administered in
100 ml D5W over a
30-minute period
before CPB.
Thereafter,
8m gk g –1 (ideal
body weight) per
hour magnesium
sulphate i.v. infusion
in 100 ml D5W
continued for 48 h
2. 100 ml of D5W 
pre-CPB and 100 ml
of D5W for 48 h
post-CPB according
to same schedule as
intervention group
Number of participants: 
Intervention: 105
Control: 97
Sample attrition/dropout: 
NR
Inclusion criteria for study entry: Patients
undergoing elective isolated CABG; age
 18 years; lack of chronic arrhythmia history;
ejection fraction >25%; normal renal function
(creatinine <1.5 mg dl–1)
Exclusion criteria for study entry:
Elevated liver functions [sic]; hypotension
(systolic BP < 90 mmHg); postoperative
creatinine > 1.8 (units not stated); patients who
required cardiac assist
Baseline characteristics of subjects
Mean ± SD age (years):
Intervention: 62.1 ± 9.5
Control: 63.7 ± 11.1
Difference: p   0.05 (ns)
Gender (M/F): 
Intervention: 78/27 (26% F)
Control: 66/31 (32% F)
Difference: p   0.05 (ns)
Differences for the mean ± SD duration of
cross-clamping (minutes) were significant
(p = 0.04):
Intervention: 61.11 ± 21.1
Control: 55 ± 21.89 
Differences between groups were not
statistically significant for 21 other preoperative
and perioperative variables listed
AF outcome:
Incidence of AF (primary
outcome)
Method of assessing AF
outcome: 
NR
Other extracted
outcomes:
Length of stay in ICU;
length of stay in hospital
Other outcomes (data not
extracted): Incidence of
atrial flutter; incidence of
frequent/multifocal
premature ventricular
contraction; ventricular
tachycardia; ventricular
fibrillation; mean arterial
pressure, BP and other
haemodynamic variables;
serum, urine and tissue
electrolyte
concentrations
Adverse symptoms:
Ventricular tachycardia
occurred in significantly
more control patients
(details below); urine
magnesium and calcium
excretion were
significantly higher in the
intervention group
(details below); death
occurred in one and 
two patients in
intervention and control
groups, respectively 
(p   0.05, ns)
Length of follow-up:
5 days after operation
Recruitment dates: 
Over a 5-year period
(dates not reported)
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Results
AF outcomes  Intervention  Control  Difference
(n = 105) (n = 97)
No. of patients with AF 
Operative 1 2 p   0.05 (ns)
0 days postoperative 1 1 p   0.05 (ns)
1 day postoperative 4 10 p < 0.05
2 days postoperative 12 15 p   0.05 (ns)
3 days postoperative 13 10 p   0.05 (ns)
4 days postoperative 1 3 p   0.05 (ns)
5 days postoperative 0 0 p   0.05 (ns)
Total 32 41 p   0.05 (ns)
Specific p-values were not provided.
Other outcomes Intervention  Control  Difference
(n = 105) (n = 97)
Mean ± SD length of ICU stay (days)  1.33 ± 0.72  1.36 ± 1.4  p   0.05 (ns)
Mean ± SD length of hospital stay (days)  6.65 ± 3.27  6.96 ± 4.98  p   0.05 (ns)
Specific p-values were not provided.
Methodological comments 
Allocation to treatment groups: Pharmacy staff randomised patients to the interventions using a randomisation table created
by a statistician (no other details).
Blinding: The patients and those caring for them were blinded to the randomisation arm [sic].
Comparability of treatment groups: No notable differences, except that mean cross-clamp time was significantly (~5 minutes)
longer in the magnesium sulphate group (p = 0.04).
Method of data analysis:
•A  2  × 2  2 test was used to compare incidence of AF between the groups.
• For other comparisons between the groups,  2 tests, a Fisher’s exact test for categorised variables, and an independent-
groups t-test for continuous variables were used. However, the results presented do not indicate in which cases each of
these tests was applied, nor whether the data satisfied assumptions of normality.
• Overall, statistical tests were not supported by any hypotheses.
Sample size/power calculation: Stated that, based on the incidence of arrhythmias after CABG (data source not reported),
100 patients per group would assure detecting an effect of supplemental magnesium that reduced arrhythmias by half, with
power 0.80 and α = 0.05 (two-sided).
Attrition/dropout: NR. 
General comments
Generalisability: No details of ethnicity or social background; single-location study in USA. 
Outcome measures: Appropriate.
Intercentre variability: NA.
Conflict of interests: None reported.
BP , blood pressure.Appendix 3
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Reference and  Intervention Participants Outcome measures
design
Authors: 
Kaplan et al.23
Year: 2003
Country: Turkey
Study design: RCT
Number of centres:
One
Funding: NR
Interventions:
1. Intravenous
magnesium sulphate 
2. Placebo control
Intervention details:
1. 24.34 mEq (3 g)
magnesium sulphate
in 100 ml saline
solution
administered over
2 h (50 ml h–1)
preoperatively
(–12 h),
perioperatively and
postoperatively (0,
1, 2, 3 days)
2. 100 ml saline
according to same
administration
schedule as group 1
Number of participants: 
Intervention: 100
Control: 100
Sample attrition/dropout:
NR
Inclusion criteria for study entry: 
Patients undergoing elective and initial CABG
(no other details)
Exclusion criteria for study entry:
History of AF (or paroxysmal AF with
subsequent sinus rhythm); preoperative heart
rate <50 bpm; concomitant valve surgery; redo
coronary artery surgery; BP < 100 mmHg;
history of renal failure (serum creatinine
>2.0 mg dl–1); severe respiratory function
disorder
Baseline characteristics of subjects:
Mean ± SD age (range) (years):
Intervention: 57.63 ± 9.68 (41–76)
Control: 59.56 ± 9.29 (44–80) 
Gender (M/F): 
Intervention: 76/24
Control: 74/26 
Difference: p = 0.183 (ns)
Differences between groups were not
statistically significant (p > 0.05) for previous MI,
hypertension or diabetes; preoperative
frequency of  -blockers, calcium channel
blockers, ACE inhibitors or digoxin; LVEF;
duration of CPB or aortic cross-clamping;
number of blood transfusion units
Groups appeared similar (statistical significance
not reported) for preoperative magnesium
sulphate concentrationa and number of bypass
grafts; preoperative risk (EuroSCORE %):
intervention 1.75, control 2.15
AF outcomes:
Postoperative
development time of AF
(primary outcome); day
of onset of AF; incidence
of AF
Other extracted
outcomes:
Duration in ICU;
duration in hospital
Other outcomes (data not
extracted): 
Perioperative and
postoperative
arrhythmias
(extrasystole and SVT
attacks); ventricular rate
(LVEF) at onset of AF;
duration of intubation;
plasma magnesium
sulphate concentration
Adverse symptoms:
One death in each
group. Stated that
magnesium sulphate did
not cause any cases of
severe bradycardia or
hypotension
Length of follow-up: 
2 days after operation
Recruitment dates: 
NR
a Units not stated.
Results
AF outcomes  Intervention  Control  Difference
No. of patients with AF  15 (n = 100) 16 (n = 100) p = 0.845
Mean ±SD time to onset of AF (h) 37.87 ± 12.76 (n = 15) 45.26 ± 15.27 (n = 16) p = 0.140
(primary outcome)
% of patients with AF whose age  62.5 (n = 15) 77.7 (n = 15) p = 0.174b
was >60 years
No. of patients with AF onset  1/2/12 (n = 15) 2/2/12 (n = 15) NR
~0 days/+1 day/+2 days after operation
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Other outcomes Intervention (n = 100) Control (n = 100) Difference
Mean ±SD length of ICU stay (h) 22.40 ± 4.79  23 ± 4.46  p = 0.650
Mean ±SD length of hospital stay (days)c 5.16 ± 1.18c 5.67 ± 1.31c p = 0.004c
Mean ±SD length of hospital stay (days)  6.0 ± 1.2 (n = 15d) 6.31 ± 0.87 (n = 16d) p = 0.410
in patients with AF
b This p-value is assumed by the reviewers to refer to the difference between interventions (meaning not stated in the
primary article).
c It is unclear whether these data refer to the total population (with AF + without AF) or the cohort without AF
(accordingly, the appropriate n-value is also unclear).
d n-Values were not reported here, but are assumed by the reviewers to include all patients with AF.
Methodological comments 
Allocation to treatment groups: stated random; no further details.
Blinding: Stated that only 100 ml of saline was administered to the control group for the placebo effect (no other details
reported).
Comparability of treatment groups: No notable significant differences.
Method of data analysis: 
● Independent samples t-test for comparing mean durations of hospitalisation.
● Fisher’s exact test for comparing ratios of atrial extrasystole and SVT in treatment and control groups (interpretation
ambiguous).
● Mann-Whitney U-test for comparing numbers of patients with/without AF (unequal n precluded t-test).
● Pearson  2 test for effects of interventions on time to onset of AF and for age differences in incidence of AF.
● Binary logistic regression used to evaluate the importance of baseline risk factors on incidence of AF (data not extracted;
all p-values ns).
● Multivariate linear regression to investigate correlation between heart rate and serum magnesium sulphate concentration
(data not extracted; p = 0.158).
Sample size/power calculation: NR.
Attrition/dropout: NR.
General comments
Generalisability: No details of ethnicity or social background; single-location study in USA.
Outcome measures: Appropriate.
Intercentre variability: NA.
Conflict of interests: None reported.
ACE, angiotensin-converting enzyme.Appendix 3
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Reference and  Intervention Participants Outcome measures
design
Authors: 
Karmy-Jones et al.24
Year: 1995
Country: Canada 
Study design: RCT
Number of centres:
One (assumed by
the reviewers)
Funding: NR
Interventions:
1. Intravenous
magnesium sulphate 
2. Placebo control
Intervention details:
1. Six doses of 2.4 g
(19.2 mEq)
magnesium sulphate
i.v. in the first
24 h after the
cardiac operation.
Total dosage: 14.4 g
(115 mEq). First
dose: magnesium
sulphate in 50 ml of
D5W over
20 minutes at the
termination of CPB;
further 5 doses: the
same dosage every
4h
2. 50 ml D5W at the
same time-points as
group 1
Number of participants: 
Intervention: 46
Control: 54
Sample attrition/dropout: 
NR
Inclusion criteria for study entry: 
Patients who were undergoing elective coronary
artery bypass, valve replacement/repair, or a
combination of these; enrolled after informed
consent was obtained. 39 patients (84.8%) in
intervention group and 47 patients in control
group (87.0%) were undergoing CABG. One
patient in intervention group and two patients in
control were undergoing combined procedure
Exclusion criteria for study entry: 
Abnormal renal function, reoperation,
emergency operation, evidence of ongoing
ischaemia (angina, ST changes), use of
medications to control dysrhythmias, and
inability to obtain informed consent
Baseline characteristics of subjects:
Mean ± SD age (years):
Intervention: 64.5 ± 7.9
Control: 60.2 ± 11.9
Gender (M/F) (n): 
Intervention: 28/18
Control: 38/16
Authors noted that the magnesium group was
significantly older (p = 0.036 reported) and that
there were no significant differences in other
baseline characteristics between groups (mean
± SD but not p-values reported): preoperative
calcium channel blocker,  -blocker, diuretics,
digoxin; COPD; diabetes; prior MI; history of
dysrhythmia: supraventricular or ventricular,
palpitations; NYHA class; Canadian
Cardiovascular Society class; ejection fraction;
number of vein grafts; cross-clamp time; CPB
time
AF outcome:
Not reported directly;
however, incidence of
AF inferred from the
incidence of SVAs (of
which 92% overall were
AF)
Other extracted
outcomes:
Length of hospital stay
(days); length of stay at
ICU (h)
Other outcomes (data
not extracted):
Ventilator hours (mean
± SD); number of
patients with ventilator
hours >24 h; cardiac
performance after
CABG (cardiac index,
left ventricular stroke
work index, stroke
volume index); patients
with inotropes, intra-
aortic balloon pump,
pacing and/or ischaemia;
ventricular and
supraventricular
arrhythmias (and Lown
grades); MB isoenzyme
of creatine kinase and
serum magnesium
concentrations
Adverse symptoms:
There were two deaths
in the placebo group,
one caused by multiple
organ failure and the
other caused by
ventricular fibrillation.
Over the whole hospital
stay, six types of
ventricular tachycardia
and two classes of
ischaemia were each
significantly more
frequent in placebo than
magnesium group
(various p-values).
Postoperative ST
segment elevation was
significantly less frequent
in the magnesium group.
Postoperative creatinine
kinase concentration
was significantly lower in
the magnesium group
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Reference and  Intervention Participants Outcome measures
design
Length of follow-up: 
Entire hospital stay (see
results on other
outcomes). Continuous
monitoring at bedside
 24 h, then
subsequently SVT
identified on clinical
signsa
Recruitment dates:
NR
a ECGs were obtained postoperatively and on the first two mornings after operation. After this period, when there was a
question of dysrhythmia either on clinical grounds or by telemetry, a 12-lead ECG was obtained. 
Results
AF outcomes  Intervention  Control  Difference
(n = 46) (n = 54)
Incidence of SVT episodes, n (%)b 12 (26%) 13 (24%) p = 0.83 (ns)
Mean ± SD SVTb episodes per patient 0.46 ± 0.98 0.51 ± 1.1 p = 0.80 (ns)
b 92% of all SVT episodes were AF (this implies that 23 out of the 25 patients with SVT had AF). 
Other outcomes Intervention  Control  Difference 
(n = 46) (n = 54)
Mean ± SD length of hospital stay (days) 6.0 ± 1.9 8.3 ± 11.5 p = 0.35 (ns)
Mean ± SD length of stay at ICU (h) 25.6 ± 16.6 38.0 ± 73.4 p = 0.68 (ns)
Methodological comments 
Allocation to treatment groups: It was only mentioned that patients were randomised into placebo and magnesium groups. 
Blinding: Patients received magnesium sulphate in solution or the solution without magnesium at the same time points (no
further details; blinding of patients was not stated explicitly). Individuals recording data and designating dysrhythmias were
not involved in patient management and were blinded to serum magnesium concentrations. Physicians directing therapy
were also blinded to all but the initial postoperative serum magnesium results.
Comparability of treatment groups: The magnesium group was significantly older (p = 0.036 reported); stated by authors that
there were no significant differences between groups in other baseline characteristics (p-values not reported). 
Method of data analysis:
Discrete variables were analysed using  2 test. Continuous variables were studied using two-tailed t-test. Kruskal-Wallace
[sic] one-way analysis of variance was used to perform rank analysis. 
Sample size/power calculation: Assuming a 30% incidence of ventricular tachyarrhythmia and hoping to demonstrate a 50%
reduction, the authors calculated that a sample size of 154 would be required, using an   error of 0.05 and a   error of 0.1.
They mentioned that a review of the literature had suggested that significant differences could be identified with a sample of
100 patients.
Attrition/dropout: NR.
General comments
Generalisability: No details of ethnicity or social background; single location in Canada.
Outcome measures: Authors noted only the numbers of patients with SVT episodes. The incidence of AF in the intervention
and the control groups was not reported, but is inferred here from the SVT data (of which 92% overall comprised AF).
Data on the length of hospital stay and stay at ICU appropriate. 
Intercentre variability: NA.
Conflict of interests: Not reported.Appendix 3
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Reference and  Intervention Participants Outcome measures
design
Authors: 
Nurözler et al.25
Year: 1996
Country: Turkey
Study design: RCT
Number of centres:
One (assumed by
reviewers)
Funding: NR
Interventions:
1. Intravenous
magnesium sulphate 
2. Placebo
Intervention details:
1. 16 mmol l–1
magnesium in the
cardioplegia solution.
Then 100 mEq
magnesium sulphate
i.v. infusion over the
1st postoperative
day, followed by
25 mEq day–1 from
the 2nd to 5th days
as i.v. continuous
infusion (in 1000 ml
of D5W over 24 h)
2. Received a
cardioplegia solution
without any
magnesium. No
other details of the
placebo were
reported
Number of participants: 
Intervention: 25
Control: 25
Sample attrition/dropout: 
NR
Inclusion criteria for study entry: 
Consenting patients undergoing CABG with
good left ventricular function and no history of
arrhythmias
Exclusion criteria for study entry:
Other surgical procedures in addition to CABG,
documented history of preoperative
supraventricular or ventricular arrhythmias,
second or third degree heart block, ejection
fraction <40%, postoperative low cardiac
output requiring inotropic drugs or intra-aortic
balloon support, COPD (FEV1 < 60%
predicted) and/or serum creatinine
concentration > 2.5 mg dl–1
Baseline characteristics of subjects:
Mean ± SD age (years):
Intervention: 56.3 ± 1.3a
Control: 53.6 ± 2.0a
Difference: p = 0.23 (ns)
Gender (M/F):
Intervention: 23/2
Control: 23/2
Differences between groups were not significant
(p > 0.05) for: left ventricular function, ejection
fraction, left ventricular end-diastolic pressure,
number of diseased vessels, number of bypass
grafts, CPB time, ischaemic time or haemoglobin
on day 3
Group values appeared similar (no statistics
presented) for: previous infarction, diabetes,
hypertension, smoking and postoperative
pericarditis
AF outcome:
Incidence of AF 
Other outcomes (data not
extracted): 
Serum magnesium and
potassium
concentrations
Adverse symptoms: 
Authors stated that no
adverse effect of
magnesium replacement
was noticed
Length of follow-up: 
5 days after CABG
Recruitment dates: 
2-month period (dates
not specified)
a Variance measure not stated.
Results 
AF outcomes  Intervention  Control  Difference
(n = 25) (n = 25)
Incidence of AF, n (%)b 1 (4%) 5 (20%) p = 0.02 
b Excludes transient AF that converted to sinus rhythm in <1 minute or AF that was not confirmed by ECG.
Other outcomes Outside scope of assessment: data not extracted
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Methodological comments 
Allocation to treatment groups: Stated that patients were randomised, but no details of the procedure were given. 
Blinding: Stated that the design was double-blind, but no details were given. 
Comparability of treatment groups: Stated that there were no differences in clinical, angiographic and surgical characteristics
between the two groups; where p-values were provided (for six continuous variables) they were not significant (p > 0.05). 
Method of data analysis: 
●  2 test was used to analyse differences in proportions.
● Multiple logistic regression and analysis of variance were also used, but address questions outside the scope of this
assessment (data not extracted).
● Statistical tests were not supported by hypotheses; normality of data was not reported.
Sample size/power calculation: NR.
Attrition/dropout: NR.
General comments
Generalisability: No details of ethnicity or social background; single-location study in Turkey.
Outcome measures: Appropriate.
Intercentre variability: NA.
Conflict of interests: None reported.
FEV1, forced expiratory volume in 1 second.
Reference and  Intervention Participants Outcome measures
design
Authors: 
Parikka et al.26
Year: 1993
Country: Finland
Study design: RCT 
Number of centres:
One (assumed by
reviewers) 
Funding: Finnish
Heart Foundation,
Helsinki
Interventions:
1. Intravenous
magnesium sulphate 
2. Placebo control
Intervention details:
1. Two doses of
magnesium sulphate: 
• 40 mmol l–1 of 5%
glucose-in-water
solution during the
first 24 h after the
infusion (the
infusion was
started within 2 h
of the operation)
• 30 mmol 500 ml–1
of the solution
during the next
24 h
2. The same as in the
intervention: 5%
glucose–water
solution without
magnesium
Number of participants: 
Intervention: 69
Control: 71
Sample attrition/dropout: 
In the final postoperative analysis the number of
patients in the control group was 70. One
patient died on the first postoperative day
because of graft occlusion and consequent
perioperative infarction
Inclusion criteria for study entry: Consecutive
patients, who had had their first CABG
Exclusion criteria for study entry: Patients with
chronic AF, concomitant valve replacement and
antiarrhythmic medication 
Baseline characteristics of subjects:
Mean age (mean + SD) (years):
Intervention: 57 ± 8
Control: 54 ± 8
Authors noted that the magnesium group was
older, p = 0.032 (ns)
Gender (proportion of males, %)
Intervention: 84% 
Control: 82% 
Difference: ns
Authors stated that prior AF episodes were
more common in the magnesium group (9% vs
1%; p = 0.061; ns), and (probably) owing to
AF outcomes:
Clinically determined:
• incidence of AF;
• time of first AF (days)
• incidence of AF
relapsed
Holter ECGa determined
2 days postsurgery: 
• incidence of AF
• AF episodes per
patient
• duration of AF (h)
• rate of AF (bpm)
Other outcomes (data not
extracted):
Ventricular ectopic beat;
ventricular tachycardia;
supraventricular ectopic
beat; SVT other than AF
or atrial flutter; serum
total calcium,
magnesium, sodium and
potassium
concentrations;
haematology (creatinine,
creatine kinase
isoenzyme and 
C-reactive protein
measurements);
perioperative MI; sinus
rate (bpm)
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Reference and  Intervention Participants Outcome measures
design
this, digoxin therapy was more frequent in this
group (12% vs 3%; p = 0.054; ns). Groups
were not statistically different considering other
baseline characteristics, e.g. NYHA class, left
ventricular and diastolic BP , ejection fraction,
incidence of three-vessel disease, prior 
 -blockers, diuretics (p-values not provided) or
left atrial transverse diameter in
echocardiography (p = 0.071; ns)
Adverse symptoms: 
One patient had
postoperative cerebral
thrombosis and died of
massive pulmonary
embolism 4 weeks after
CABG. It is not stated in
which group the death
occurred
Length of follow-up: 
1. Cardiac rhythm was
monitored
continuously the first
2 postoperative days.
Thereafter, for up to
10 days every
symptomatic
palpitation was
recorded by 12-lead
ECG (monitoring in
total 12 days after
operation)
2. A 48-h two-channel
Holter recording was
started on the second
postoperative day
Recruitment dates: 
NR
continued
a Technically acceptable recording was achieved in 108 patients.
Results
Clinical AF outcomes  Intervention (n = 69) Control (n = 70) Difference
Incidence of AF, n (%) 20 (29%) 18 (26%) ns
Mean ± SD time of first AF (days) 3.5 ± 1.9 3.8 ± 2.7 ns
Incidence of AF relapsed, n (% of AF patients) 9 (45% of AF patients) 11 (61% of AF patients) ns
Holter AF outcomes  Intervention (n = 52) Control (n = 56) Difference
Incidence of AF, n (%) 7 (14%) 7 (13%) ns
Mean ± SD episodes of AF  1.4 ± 0.8 1.2 ± 0.4 ns
Mean ± SD duration of AF (h) 5.1 ± 4.3 5.0 ± 6.3 ns
Mean ± SD rate of AF (bpm) 115 ± 26 123 ±15 NS (p = 0.538)
Methodological comments
Allocation to treatment groups: It was only mentioned that patients were randomised.
Blinding: Patients were blinded (received magnesium sulphate in solution or the same volume of solution without
magnesium). Authors did not provide any information concerning the blinding of doctors or assessors. 
Comparability of treatment groups: In the magnesium group patients were older (p = 0.032), prior AF episodes were more
common (9% vs 1%; p = 0.061, ns) and digoxin therapy was more frequent (12% vs 3%; p = 0.054, ns). The groups were
not statistically different in terms of other prognostic factors (either p-values were reported or ns stated if the difference was
not significant).Health Technology Assessment 2008; Vol. 12: No. 28
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Method of data analysis: 
• Continuous variables were analysed by two-tailed Student’s t-test and for non-normal distributions by the Mann–Whitney
rank sum test.
• Predictors of AF were investigated (data not extracted). 
• However, it was not stated whether data sets conformed to normality.
Sample size/power calculation: NR.
Attrition/dropout: One patient in the control group died on the first postoperative day because of graft occlusion and
consequent perioperative infarction.
General comments
Generalisability: No details of ethnicity or social background; single location in Finland.
Outcome measures: Appropriate.
Intercentre variability: NA.
Conflict of interests: Not reported.
Reference and  Intervention Participants Outcome measures
design
Authors: 
Toraman et al.27
Year: 2001
Country: Turkey
Study design: RCT
Number of centres:
One
Funding: NR
Interventions:
1. Intravenous
magnesium sulphate 
2. Control (not
reported as placebo)
Intervention details:
1. 6 mmol magnesium
sulphate in 100 ml of
0.9% sodium
chloride (25 ml h–1)
1 day before CBP ,
just after CBP
surgery and then
once daily for 4 days
after CBP
2. 100 ml of 0.9%
sodium chloride
(25 ml h–1) at the
same time-points as
in the magnesium
sulphate group
Number of participants: 
Intervention: 100
Control: 100
Sample attrition/dropout: 
NR
Inclusion criteria for study entry: Patients
scheduled for elective, first time, isolated CABG
(no other details)
Exclusion criteria for study entry:
Patients with AF, a past history of AF, heart valve
disease, diabetes, chronic renal disease, thyroid
disorders and/or COPD; patients receiving
antiarrhythmic drugs, digoxin and/or  -blocking
agents
Baseline characteristics of subjects:
Mean ± SD age (years):
Intervention: 62 ± 6.7
Control: 61.4 ± 8.7
Difference: p = 0.56 (ns)
Gender (M/F) (n): 
Intervention: 78/22
Control: 83/17
Difference: p = 0.48 (ns)
There were no significant differences between
the groups in 14 other preoperative and 
12 perioperative variables reported (p-values
were provided; all p > 0.05)
AF outcome: 
Incidence of AF after
CABG
Other outcomes
extracted: 
Duration in ICU, ICU
readmission, length of
postoperative hospital
stay
Other outcomes (data not
extracted)
Stroke incidence,
duration of extubation,
postoperative cardiac
output, total chest
drainage, serum
magnesium
concentration
Adverse symptoms: Stated
that all patients in the
magnesium group
received their scheduled
doses of magnesium
without any adverse
effects such as
bradycardia or
hypotension (no other
details)
Length of follow-up: 
4 days after CABG
surgery
Recruitment dates: 
February 1999 to March
2000
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Results
AF outcome Intervention (n = 100) Control (n = 100) Difference
Frequency of AF occurrence, n (%) 2 (2%) 21 (21%) p < 0.001
Other outcomes Intervention (n = 100) Control (n = 100) Difference
Mean ± SD length of stay in ICU (h) 21.6 ± 5.6 22.6 ± 6.9 p = 0.58
ICU readmission, n 13 p = 0.62
Mean ± SD length of postoperative hospital stay (days) 5.4 ± 0.9 5.8 ± 4.1 p = 0.36
Methodological comments 
Allocation to treatment groups: Stated that this was randomised, but no details provided.
Blinding: Stated that all ECGs were analysed by a cardiologist who was blinded to the study (no further details provided).
Comparability of treatment groups: No notable differences.
Method of data analysis: 
• Stated that demographic and clinical variables as well as the incidence of AF were analysed using the  2 test or Fisher’s
exact test for categorical variables and t-tests for continuous variables. Kruskal–Wallis one-way analysis of variance was
used to perform rank analysis. However, the results presented do not indicate in which cases each of these tests was
applied, nor whether the data satisfied assumptions of normality.
• Overall, statistical tests were not supported by any hypotheses.
Sample size/power calculation: NR.
Attrition/dropout: NR.
General comments
Generalisability: No details of ethnicity; limited information on social background; single-location study in Turkey.
Outcome measures: Appropriate, but note that 12-lead Holter ECG was only used for reactive, not continuous, monitoring
(authors discuss whether this might have missed some cases of AF).
Intercentre variability: NA.
Conflict of interests: None reported.Health Technology Assessment 2008; Vol. 12: No. 28
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Reference and  Intervention Participants Outcome measures
design
Authors: Treggiari-
Venzi et al.28
Year: 2000
Country:
Switzerland 
Study design: RCT
Number of centres:
One
Funding: 
Swiss Society of
Cardiology
Interventions:
1. Intravenous
magnesium sulphate 
2. Placebo control
3. Amiodarone (data
not extracted)
Intervention details:
1. 16 mmol (32 mEq)
(4 g) magnesium
sulphate per 24 h
(Bichsel, Interlaken,
Switzerland), over
72 h, starting within
1 h of arrival in ICU
2. 0.9% sodium
chloride, over 72 h,
starting within 1 h of
arrival in ICU
Number of participants: 
Intervention: 47 (49 randomised)
Control: 51 (53 randomised)
Sample attrition/dropout: 
Magnesium sulphate and placebo each had two
dropouts (magnesium sulphate: one due to
cardiac arrest and one incomplete ECG data;
placebo: one due to pacemaker dependence and
one incomplete data)
Inclusion criteria for study entry: 
Patients scheduled for elective CABG (no other
details) 
Exclusion criteria for study entry:
Refusal of consent; chronic AF, second or third
degree atrioventricular block, pacemaker
dependence, amiodarone treatment <1 year
before operation; thyroid disease, other
associated heart surgery, valvular disease,
chronic renal failure (creatinine clearance rate
<30 ml minute–1) and liver dysfunction
(prothrombin time <50% and/or bilirubin
>35  mol l–1 and/or presence of ascites)
Baseline characteristics of subjects:
Mean age (range) (years):
Intervention: 65 (46–81)
Control: 65 (37–88)
Gender (M/F) (n):
Intervention: 42/5
Control: 43/8
Other baseline values (e.g. previous MI, history
of SVA) appear similar between groups. No
statistical tests reported
AF outcomes (1st =
primary outcome):
Prevention of AF first;a
time to onset of AF;
frequency of AF >30s;
heart rate during AF
Other extracted
outcomes: 
Duration in ICU
Other outcomes (data not
extracted):
Duration of intubation;
period of required
catecholamine infusion;
plasma magnesium
sulphate concentration
Adverse symptoms: 
Stated that incidences of
MI, cardiac arrest, need
for surgical haemostasis
and prolonged tracheal
intubation (>72 h) were
similar in the two groups
Length of follow-up: 
3 days (72 h) after start
of intervention
Recruitment dates: 
NR
a Primary end-point (outcome) definition does not precisely correspond with the reported data.
Results
AF outcomes  Intervention (n = 47) Control (n = 51) Difference
Frequency of AF occurrence >30s n (%) 11 (23%) 14 (27%) p = 0.82
Time to onset of AF (h) after start of  Given in chart, but  Given in chart, but  p = 0.5
intervention from log-rank test not clearly extractable not clearly extractable
Mean ± SD delay in AF onset (h)  45 ± 14 42 ± 12 p = 0.37
after start of interventionb
No. of AF episodes (maximum) per patientc 17 (3) 14 (1) p = 0.88
Mean ± SD heart rate (bpm) during AF 146 ± 9 153 ± 18 p = 0.26
b It is not clear which statistical analysis was used here; this could have been an unpaired t-test or a Mann–Whitney test
depending upon normality of the variable (not stated).
c Assumed by reviewers (not stated) to be the number per patient.
Other outcomes Intervention (n = 47) Control (n = 51) Difference 
Median (range) length of stay in ICU (days) 3 (2–21) 3 (2–7) NR
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Adverse events: One patient in the placebo group died 5 days after surgery
Methodological comments 
Allocation to treatment groups: Random assignment of patients to interventions was based on colour-coded spheres drawn
from an opaque container (no other details). Additional patients were added to compensate for ‘technical’ dropouts, but no
indication is given of whether this procedure was also randomised. Precise timing of the start of interventions not reported;
assumed to be immediately post-CABG operation in ICU.
Blinding: Study drugs were prepared in an opaque syringe with opaque tubing by an independent observer; study described
as ‘double blind’ (no other details given).
Comparability of treatment groups: No notable differences; authors report that the groups were similar in baseline
characteristics and surgical procedure.
Method of data analysis: 
• For continuous data, either an unpaired t-test (normally distributed data) or a Mann–Whitney test (non-normal data) was
used. However, it is not stated which data sets conformed to normality, hence it is unclear which tests were used for
each comparison.
• For categorical variables a  2 test was used. However, no  2 results were presented, only p-values were given, so it is
unclear where this test was applied.
• Kaplan–Meier analysis was used to analyse the delay in onset and the duration of AF (no other details provided).
• Overall, statistical tests were not supported by any hypotheses.
Sample size/power calculation: Reported for detecting a 50% reduction of frequency of AF using Holter ECG (80% power
with   = 0.5), but the power calculation is unclear (no variance estimate provided). 
Attrition/dropout: Reported, but not stated whether accounted for in analysis. Probably not analysed according to ITT (the
authors remarked for the magnesium group that “the final number of patients in the interim analysis was 47”).
General comments
Generalisability: No details of ethnicity or social background; single-location study in Switzerland.
Outcome measures: Appropriate.
Inter-centre variability: NA.
Conflict of interests: None reported.
Reference and  Intervention Participants Outcome measures
design
Authors: 
Yilmaz et al.14
Year: 2000
Country: Turkey
Study design: RCT
Number of centres:
One (assumed by
reviewers)
Funding: NR
Interventions:
1. Magnesium sulphate
bolusa
2. Control
Intervention details:
1. 17 mmol l–1
magnesium sulphate
in cardioplegia
infusion and
0.4 mmol kg–1 bolus
of magnesium
sulphate
administered at the
start of CPB
2. 17 mmol l–1
magnesium sulphate
in cardioplegia
infusion only
Number of participants: 
Intervention: 15
Control: 15
Sample attrition/dropout: 
NR
Inclusion criteria for study entry: Patients
undergoing elective CABG, with ejection
fraction of >50% and no arrhythmias before
surgery
Exclusion criteria for study entry:
NR
Baseline characteristics of subjects: 
NR
AF outcome:
Incidence of AF
Other outcomes (data not
extracted): 
Defibrillation, total
postoperative
arrhythmias, undefined
arrhythmia subgroup
(‘VES’), total lidocaine
Adverse symptoms: 
NR
Length of follow-up: 
Stated that an ECG was
analysed for each patient
24 h postoperation (no
other details reported)
Recruitment dates: 
NR
a It was not stated whether the bolus was administered intravenously; the composition and dilution of the infusion were not
reported.
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Results
AF outcome Intervention (n = 15) Control (n = 15) Difference
Incidence of AF, n 13 n s b
b Lack of statistical significance inferred by reviewers (the difference was not marked as significant); threshold p-value not
stated. Note that the incidence of all arrhythmias differed significantly between the groups (p < 0.01).
Other outcomes Outside scope of assessment: data not extracted
Methodological comments 
Allocation to treatment groups: Stated that patients were randomised, but no details were provided. 
Blinding: NR. 
Comparability of treatment groups: Unclear, as few baseline characteristics were reported.
Method of data analysis: 
• An unpaired t-test was used for data analysis.
• Statistical testing was not supported by hypotheses; normality of data was not reported.
Sample size/power calculation: NR. 
Attrition/dropout: NR.
General comments
Generalisability: No details of ethnicity or social background; single-location study in Turkey.
Outcome measures: Appropriate but described only briefly.
Intercentre variability: NA.
Conflict of interests: None reported.
Reference and  Intervention Participants Outcome measures
design
Authors: 
Zangrillo et al.29
Year: 2005
Country: Italy
Study design: RCT
Number of centres:
One
Funding: NR
Interventions:
1. Intravenous
magnesium sulphate 
2. Placebo
Intervention details:
1. 2.5g (20 mEq)
magnesium sulphate
diluted in 100 ml
normal saline
solution over a 
30-minute period,
immediately after
central venous
cannulation
2. Placebo of 100 ml
normal saline
solution
Number of participants: 
Intervention: 80
Control: 80
Sample attrition/dropout:
The analysis focused on patients receiving off-
pump CABG; patients who required conversion
to on-pump CABG were discontinued from the
intervention (eight in magnesium group, nine in
placebo group) but were included in the analysis
on an ITT basis (all randomised patients were
analysed in their allocated groups)
Inclusion criteria for study entry: 
Patients referred for isolated elective coronary
artery surgery; age  18 years; in sinus rhythm
and for whom off-pump CBP was deemed
technically feasible
Exclusion criteria for study entry:
History of AF; any other surgical procedure
during the current admission; Q-wave MI in the
preceding 6 weeks; ongoing treatment with
amiodarone, digoxin or warfarin; permanent
pacemaker implanted; or valvular regurgitation
AF outcomes:
Incidence of AF (primary
outcome); AF at hospital
discharge
Other outcomes
extracted: 
Length of stay in ICU;
length of stay in hospital
Other outcomes (data not
extracted): 
Ventricular tachycardia;
low cardiac output;
mechanical ventilation;
biochemical data; oral
amiodarone at hospital
discharge; pacemaker,
inotropes and
transfusion frequency
Adverse symptoms: Stated
that there were no
serious adverse drug
events and no patients
died in the hospital
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Reference and  Intervention Participants Outcome measures
design
Baseline characteristics of subjects
Mean ± SD age (years):
Intervention: 65 ± 9.8
Control: 66 ± 9.7
Gender (M/F): 
Intervention: 74/6 (7.5% F)
Control: 69/11 (13.8% F)
Preoperative data were presented for 21 other
variables; mean ± SD were reported for nine of
these, but only n and % were reported for the
remaining 12. The authors stated that baseline
clinical characteristics and demographic details
of the two groups were similar, but statistical
significance was not mentioned and no p-values
were provided
There were no significant intraoperative
differences (p > 0.05) between the groups in:
number of grafts, pacemakers, ischaemia
(>2 minutes), perioperative AFa or patients with
conversion from off-pump to on-pump CABG
Length of follow-up: Not
reported but mean
length of hospital stay
was ~1 week
Recruitment dates: 
May 2002 to March
2003
a Perioperative AF was restored to sinus rhythm in all cases by direct synchronised electric shock (20 J). Patients (n, %) with
perioperative AF were: magnesium 7 (8.8%), placebo 4 (5.0%), p = 0.5.
Resultsb
AF outcomes  Intervention (n = 80) Control (n = 80) Difference
Postoperative AF, n (%)c 16 (20%)c 18 (22.5%) p = 0.8 (ns)
AF at hospital discharge, n (%) 2 (2.5%) 2 (2.5%) p = 0.7 (ns)
Other outcomes Intervention (n = 80) Control (n = 80) Difference
Mean ± SD length of ICU stay (h)  26 ± 20.9  31 ± 24.4  p = 0.2 (ns)
Mean ± SD length of hospital stay (days)d 7 ± 3.8d 6 ± 2.8d p = 0.004d
b No indication was given about the timing of the results relative to patient admission, surgery or intervention.
c Four patients who had perioperative AF went on to also develop postoperative AF; these four were all in the magnesium
group and their data are included here.
d The data given here are credited to two different comparisons in the primary article: (1) a comparison between magnesium
and placebo groups (reported in Table 4), and (2) a comparison between AF and non-AF groups (reported in the text). 
The reviewers have assumed that the tabulated data (as extracted here) are correct (those data reported in the text
appear inconsistent, suggesting a misprint).
Methodological comments 
Allocation to treatment groups: Randomisation was stratified in blocks of 40 patients; independent nurses dispensed either
magnesium or placebo in the operating room according to a computer-generated list (no other details).
Blinding: Stated that all study personnel and participants were blinded to treatment assignment for the duration of the study
(no details provided).
Comparability of treatment groups: Some slight preoperative differences in numbers in magnesium/placebo groups for diabetes
(30/24), COPD (3/6), MI (44/49),  -blocker use (54/42), calcium channel blockers (24/37) and ACE inhibitors (31/36), but no
variance measures or p-values were provided for these variables. The authors considered that the baseline characteristics
were similar between the groups, but did not robustly test for differences.
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Method of data analysis: 
• The study tested the hypothesis that prophylactic magnesium supplementation as compared with placebo would reduce
the occurrence of postoperative AF. Perioperative AF was noted, but not included in the analysis. All significance tests
were two-sided.
• Analysis focused on patients receiving off-pump CABG; patients who required conversion to on-pump CABG were
discontinued from the intervention (eight in magnesium group, nine in placebo group), but were included in the analysis
on an ITT basis (no definition of ITT given).
• Dichotomous data were compared using a two-tailed  2 test with Yates’ correction, or a Fisher’s exact test when
appropriate.
• Continuous measures were compared with analysis of variance or the Mann–Whitney U-test when appropriate.
• Presentation of results did not indicate which tests were actually used for each outcome; normality of outcomes was not
reported.
• Stepwise multivariate logistic regression was used to investigate predictors of AF (analysis outside the scope of this
assessment; data not extracted).
Sample size/power calculation: With two-sided   = 0.05 and 80% power, based on previous publications, frequency of
arrhythmia in intervention and placebo groups was assumed to be 30% and 50%, respectively, which would require 120
patients per group to detect. The actual number of patients recruited was 80 per group, suggesting that statistical power
would have been <80%. However, the actual statistical power is unclear (interim analyses were included in the protocol for
analyses with 40 patients per group or 80 patients per group, but the statistical power of the interim analyses was not
stated; the study was terminated after interim analysis with 80 patients per group, as recruitment of a further 80 per group
was considered unlikely to detect a benefit in either treatment group, but no explanation was given). 
Attrition/dropout: All randomised patients were analysed; there were no losses to follow-up. Patients who withdrew from
intervention (due to conversion to on-pump CABG) were included according to the ITT principle (ITT not defined). 
General comments
Generalisability: No details of ethnicity or social background; single-location study in Italy.
Outcome measures: Appropriate.
Intercentre variability: NA.
Conflict of interests: None reported.Health Technology Assessment 2008; Vol. 12: No. 28
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Appendix 4
Studies screened and included in the current review
Potentially relevant papers identified from Alghamdi et al. (2005)10
systematic review and systematic database searches:
  204 abstracts screened  
158 abstracts excluded:
  29 on population
  69 on study design
  51 on intervention
    9 on outcome
2 additional relevant papers
identified in reference lists
48 full papers retrieved and screened
26 papers excluded:
    6 on population
  10 on study design
    7 on intervention
    3 on outcome
22 papers included
17 papers describing 
15 RCTs
5 systematic reviewsHealth Technology Assessment 2008; Vol. 12: No. 28
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Appendix 5
Detection and definitions of atrial fibrillation 
given in the included RCTs
Study Method of detecting AF Definition of AF
Bert, 200115 Continuous bedside ECG monitoring with automated alarmed
arrhythmia detection and recall (Hewlett-Packard) in the ICU. On
hospital wards, monitoring was performed by telemetry to a central
nursing station to  4 days postoperation. Thereafter, clinical
observation and a daily ECG study were performed. If a suspected
arrhythmia occurred after discontinuation of continuous ECG
monitoring, a 12-lead ECG study was obtained to confirm arrhythmia
classification
AF was not defined separately
from atrial flutter and SVT.
These arrhythmias together
were referred to as
postoperative atrial
tachycardias (POAT). All
episodes of POAT had an
initial ventricular rate
>110 bpm, were sustained for
>5 minutes and warranted
pharmacological therapy.
POAT classification excluded
premature atrial contractions
Bhudia, 200616 NR NR (AF was not a primary
outcome)
Caspi, 199513 12-Lead ECG was performed before operation and at 6, 12 and 24 h
after operation. All patients underwent ECG monitoring to 3 days
postoperation using a bedside arrhythmia detection system (Mennen
Horizon 2000)
Reported only that AF was at
rates greater than 120 bpm
Dagdelen, 200217 Standard 12-lead surface ECG was obtained on the day before
operation, just after operation, and once daily for 4 days
postoperation. After ICU discharge, trained nurses performed clinical
observation every hour. Patients were monitored routinely with an
alarm-triggered seven-lead telemetry system (Siemens Infinity) until
4 days postoperation under the close attention of a monitor technician.
When there was a question of AF on clinical grounds or by telemetry, a
12-lead ECG was obtained
AF was defined as the absence
of consistent P waves before
each QRS complex, irregular
QRS complexes and
appearance of F waves
Fanning, 199119 Continuous ECG monitoring to 4 days postoperation using a bedside
arrhythmia detection system (Mennen Horizon 2000)
AF was not defined separately
from atrial flutter and SVT
with rates >110 bpm and
duration >30 s
Forlani, 200321 Cardiac rhythm was continuously monitored in the ICU until the
morning of the second postoperative day. For the remaining days until
discharge, 12-lead ECG was recorded every 8 h
NR
Hazelrigg, 200422 NR NR
Kaplan, 200323 Rhythm was monitored continuously during the operation and first
2 days postoperation (Datascope, Datascope 2001A). In the wards
patients were monitored with a 12-lead ECG and telemetry system
(Fukuda Denshi DynaScope) if physical examination revealed a
tachycardia attack or the development of an arrhythmia or if a patient
had a palpitation or any rhythm-related complaint
NR
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Study Method of detecting AF Definition of AF
Karmy-Jones,
199524
Continuous monitoring for minimum 24 h using alarm-triggered
bedside monitors (Hewlett-Packard) capable of automated recall,
observed constantly by monitor nurses. ECG were obtained
postoperatively and on the first 2 mornings postoperation.
Thereafter, a 12-lead ECG was obtained if there was a question
of dysrhythmia either on clinical grounds or by telemetry
NR
Nurözler,
199625
Continuous ECG over 5 days postoperation with 12-h memorised
arrhythmia detection monitor (Drager U-M 3). AF identified on
the monitor confirmed by a reading of a rhythm strip. AF
excluded if not confirmed by ECG or if <1 minute duration
NR (except for duration
  1 minute)
Parikka, 199326 Continuous monitoring of cardiac rhythm with bedside monitors
on the first 2 days postoperation in the ICU. Thereafter, for up to
10 days, every symptomatic palpitation was recorded by 12-lead
ECG. A 48-h two-channel Holter recording was started 2 days
postoperation. The recording was analysed by one of the
investigators using a Marquette electrocardioscanner
Clinical AF was defined as irregular
QRS complexes without detectable
regular atrial activity continuing for
1 h, or less if treatment was
necessary because of intolerable
symptoms or haemodynamic
deterioration. Episodes of this type
of arrhythmia seen at Holter were
defined as AF episodes if they
lasted for 15 s and were at least
1 minute apart. Holter recording
did not reveal any AF patient who
had not been identified by clinical
symptoms
Toraman,
200127
ECGs were obtained preoperatively and 0–5 days
postoperatively. Patients were continuously monitored while in
the ICU using alarm-triggered bedside monitors (Siemens). After
discharge from the ICU, trained nurses performed clinical
observations every 4 h and all patients were monitored with an
alarm-triggered seven-lead telemetry system (Siemens Infinity),
under close attention of a monitor technician, until the morning
of day 5 postoperation. When AF was suspected clinically or by
telemetry a 12-lead ECG was obtained
AF was defined as the absence of
consistent P waves before each
QRS complex and an irregular rate
lasting for >10 minutes or
requiring therapy as a result of
haemodynamic compromise
Treggiari-Venzi,
200028
A Holter ECG (Delmar Avionics three-channel Cardiocorder)
recording was obtained throughout the 72-h infusion period.
Additional 12-lead ECGs were recorded every 12 h. The Holter
recording was analysed on completion of the 72-h study period
or earlier if the study was terminated because of arrhythmia. SVA
episodes were detected visually and printed for accurate
diagnosis by two investigators
SVT was defined as an arrhythmia
of more than three narrow QRS
complexes at a rate greater than
100 bpm and lasting for more than
30 s. AF was defined as a totally
irregular atrial rhythm leading to
irregular ventricular rhythm.
Unclear whether AF definition was
independent of the definition of
SVT; note that the authors mention
both SVA and SVT as extracted
here
Yilmaz, 200014 A 12-lead standard ECG was analysed for each patient during
30 minutes and 24 h postoperation
NR
Zangrillo,
200529
Continuous monitoring until hospital discharge through telemetry
with continuous display of the ECGs on multiple oscilloscopes
simultaneously in the ICU, high-dependency unit (HDU) or main
ward. 12-Lead ECGs were obtained routinely every 6 h in ICU
and daily in HDU, at hospital discharge, and when AF was
detected on telemetry. In addition, ECG was performed
whenever AF was suspected clinically
Any documented episode of AF
(12-lead ECG) defined as an
irregular rhythm with an irregular
fluctuating baseline, without well-
defined P waves and irregular RR
intervals. AF excluded if
 10 minutes or requiring medical
attention owing to patient
instabilityHealth Technology Assessment 2008; Vol. 12: No. 28
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Appendix 6
Exclusion criteria reported for the selection of 
patients in RCTs
Study
Exclusion criterion
Previous AF ✕✕ ✕ ✕ ✕✕
Atrial arrhythmias ✕
Atrioventricular block ✕✕
Angina ✕
Atrioventricular node disorder ✕
Bradycardia ✕
Bronchospastic ✕
Bundle branch block ✕
COPD (defined or undefined) ✕✕ ✕✕
Diabetes ✕
Heart block, heart disease ✕✕ ✕
Liver dysfunction  ✕✕
Hypotension ✕✕
Inotropic drugs required ✕
Intra-aortic balloon required ✕
Ischaemia ongoing ✕
LV function or LVEF abnormal ✕✕ ✕
Non-sinus rhythm ✕
Pacemaker/cardiac assistance ✕✕ ✕✕
Pericarditis ✕
Pre-excitation syndrome ✕
Pulmonary embolism ✕
QT interval increased ✕
Q wave MI  6 weeks presurgery ✕
Creatinine elevated ✕✕✕✕ ✕
Creatinine clearance decreased ✕
Reoperation ✕✕
Severe respiratory disorder ✕
Sick sinus syndrome ✕✕
Surgery, cardiac ✕✕ ✕
Surgery, concomitant ✕✕
Surgery, emergency ✕
SVA or SVT ✕✕ ✕
Valve disease or valve surgery ✕ ✕ ✕✕✕ ✕
Ventricular arrhythmias ✕✕ ✕
Non-consent or unavailable consent ✕✕✕
Renal disease, impairment or failure ✕✕ ✕ ✕✕ ✕✕
Thyroid disorders ✕✕ ✕
Antiarrhythmics ✕✕ ✕✕ ✕
Digoxin ✕✕
 -blockers ✕✕
Amiodarone  1 year presurgery ✕
Amiodarone ongoing ✕
Digoxin ongoing ✕
Warfarin ongoing ✕
No exclusion criteria reported ✕✕ ✕
LV, left ventricular; ✕; exclusion criterion reported. 
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5Ovid MEDLINE
1950 to May week 1 2007
Searched 15 May 2007
1 "Atrial Fibrillation"/ (19465)
2 Atrial Flutter/ (3991)
3 (atrial adj3 fibrillat$).mp. (25464)
4 (heart adj3 fibrillat$).mp. (950)
5 atrial fibrillat$.mp. (25294)
6 (atrium adj3 flutter$).mp. (23)
7 (atrium adj3 fibrillat$r).mp. (0)
8 (auricular$ adj3 fibrillat$).mp. (736)
9 (auricular$ adj3 flutter$).mp. (274)
10 Tachycardia Supraventricular/ (3781)
11 or/1-10 (30644)
12 "Coronary Artery Bypass"/ (31512)
13 (CABG or coronary artery bypass graft$).ti,ab.
(16229)
14 (coronary artery bypass adj3 surgery).ti,ab.
(7332)
15 (coronary adj3 revasculari$).ti,ab. (4439)
16 (myocardial adj3 revascular$).ti,ab. (4063)
17 (coronary adj6 graft).ti,ab. (6832)
18 (coronary adj6 bypass).ti,ab. (26085)
19 (coronary adj6 surgery).ti,ab. (15257)
20 (aortocoronary adj6 bypass).ti,ab. (2453)
21 (valve$ adj6 surgery).ti,ab. (4554)
22 Cardiac Surgical Procedures/ (23335)
23 or/12-22 (71271)
24 MgSO4.mp. (1029)
25 magnesium sulfate/ (3419)
26 magnesium sulfate$.ti,ab. (1735)
27 exp magnesium compounds/ (10471)
28 magnesium/ (56302)
29 (magnesium and (sulphate$ or sulfate$)).ti,ab.
(3192)
30 magnesium sulphate$.ti,ab. (729)
31 magnesium sulfate$.ti,ab. (1735)
32 7487-88-9.rn. (3419)
33 Magnesium Deficiency/ (3387)
34 or/24-33 (67330)
35 3930-20-9.rn. (1695)
36 Sotalol/ (1695)
37 sotalol.ti,ab. (1997)
38 or/35-37 (2418)
39 11 and 23 and 34 (48)
40 23 and 34 (242)
41 11 and 34 (151)
42 39 or 40 or 41 (345)
43 limit 42 to (humans and english language and
yr="2004 - 2007") (45)
113 exp ECONOMICS/ (374970)
114 exp ECONOMICS, HOSPITAL/ (14701)
115 exp ECONOMICS, PHARMACEUTICAL/
(1761)
116 exp ECONOMICS, NURSING/ (3739)
117 exp ECONOMICS, DENTAL/ (3555)
118 exp ECONOMICS, MEDICAL/ (11345)
119 exp "Costs and Cost Analysis"/ (129053)
120 Cost-Benefit Analysis/ (39951)
121 VALUE OF LIFE/ (4844)
122 exp MODELS, ECONOMIC/ (5178)
123 exp FEES/ and CHARGES/ (7124)
124 exp BUDGETS/ (9947)
125 (economic$ or price$ or pricing or financ$ or
fee$ or pharmacoeconomic$ or pharma
economic$).tw. (325412)
126 (cost$ or costly or costing$ or costed).tw.
(189830)
127 (cost$ adj2 (benefit$ or utilit$ or minim$ or
effective$)).tw. (48757)
128 (expenditure$ not energy).tw. (10369)
129 (value adj2 (money or monetary)).tw. (595)
130 budget$.tw. (10852)
131 (economic adj2 burden).tw. (1410)
132 "resource use".ti,ab. (2055)
133 or/113-131 (754771)
134 news.pt. (118759)
135 letter.pt. (589482)
136 editorial.pt. (202717)
137 comment.pt. (329262)
138 or/134-137 (951676)
139 133 not 138 (695184)
140 42 and 139 (8)
141 from 140 keep 4-6,8 (4)
142 23 and 38 and 139 (13)
143 from 142 keep 4-5,8-9,12-13 (6)
144 11 and 38 and 139 (27)
145 limit 144 to english language (25)
146 from 145 keep 1,9,11-15,17,19-20,24 (11)
147 34 and 38 and 139 (2)
Number of hits (download file)
Costs magnesium: 4
Costs sotalol: 17
Costs magnesium + sotalol: 2
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Appendix 7
Search strategy for economic evaluationsEMBASE
1980 to 2007 week 19
Searched 16 May 2007
1 heart atrium fibrillation/ (21875)
2 heart atrium flutter/ (3362)
3 exp Heart Atrium Arrhythmia/ (35266)
4 (atrial adj3 fibrillat$).mp. (17803)
5 (heart adj3 fibrillat$).mp. (31983)
6 atrial fibrillat$.mp. (17577)
7 (atrium adj3 flutter$).mp. (3380)
8 (atrium adj3 fibrillat$r).mp. (0)
9 (auricular$ adj3 fibrillat$).mp. (108)
10 (auricular$ adj3 flutter$).mp. (29)
11 Supraventricular Tachycardia/ (5812)
12 or/1-11 (47152)
13 coronary artery bypass graft/ (22523)
14 Coronary Artery Bypass Surgery/ (6944)
15 exp coronary artery surgery/ (39530)
16 (CABG or coronary artery bypass graft$).ti,ab.
(14959)
17 (coronary artery bypass adj3 surgery).ti,ab.
(6804)
18 (coronary adj3 revasculari$).ti,ab. (4087)
19 (myocardial adj3 revascular$).ti,ab. (3015)
20 (coronary adj6 graft).ti,ab. (6026)
21 (coronary adj6 bypass).ti,ab. (23026)
22 (coronary adj6 surgery).ti,ab. (13234)
23 (aortocoronary adj6 bypass).ti,ab. (1469)
24 (valve$ adj6 surgery).ti,ab. (3618)
25 or/13-24 (50320)
26 MgSO4.mp. (1011)
27 magnesium sulfate/ (6009)
28 Magnesium Derivative/ (989)
29 magnesium/ (23019)
30 (magnesium and (sulphate$ or sulfate$)).ti,ab.
(2910)
31 magnesium sulphate$.ti,ab. (642)
32 magnesium sulfate$.ti,ab. (1548)
33 7487-88-9.rn. (6022)
34 Magnesium Deficiency/ (1203)
35 or/26-34 (30923)
36 3930-20-9.rn. (7170)
37 Sotalol/ (7144)
38 sotalol.ti,ab. (2048)
39 or/36-38 (7279)
40 12 and 25 and 35 (88)
41 25 and 35 (209)
42 12 and 35 (667)
43 41 or 42 (788)
44 limit 43 to (humans and english language and
yr="2004 - 2007") (229)
45 12 or 25 (95066)
46 35 and 39 and 45 (149)
92 (cost$ adj2 effective$).ti,ab. (37066)
93 (cost$ adj2 benefit$).ti,ab. (7616)
94 cost effectiveness analysis/ (48505)
95 cost benefit analysis/ (26055)
96 budget$.ti,ab. (7837)
97 cost$.ti. (34748)
98 (cost$ adj2 (effective$ or utilit$ or benefit$ or
minimi$)).ab. (40355)
99 (economic$ or pharmacoeconomic$ or
pharmaco economic$).ti. (13532)
100 (price$ or pricing$).ti,ab. (10064)
101 (financial or finance or finances or
financed).ti,ab. (20781)
102 (fee or fees).ti,ab. (4745)
103 cost/ (19051)
104 cost minimization analysis/ (1127)
105 cost of illness/ (3798)
106 cost utility analysis/ (1908)
107 drug cost/ (29425)
108 health care cost/ (52431)
109 health economics/ (9184)
110 economic evaluation/ (3590)
111 economics/ (5146)
112 pharmacoeconomics/ (884)
113 budget/ (6946)
114 economic burden.ti,ab. (1415)
115 "resource use".ti,ab. (1899)
116 or/92-115 (214586)
117 (editorial or letter).pt. (525894)
118 116 not 117 (191116)
119 118 and 35 and (12 or 25) (43)
120 from 119 keep 7,15,22,32,34,39 (6)
121 118 and 39 and (12 or 25) (137)
122 121 not 119 (123)
123 limit 122 to english language (118)
124 from 123 keep 3,10,18,25-27,31-32,42,47,
49-50,52-56,61,63-64,66,68-69,71,73,77,
79-80,86,88-89,92,94-97,99-100,102-104,
106,111-113,115-118 (49)
Number of hits (download file)
Costs magnesium: 6
Costs sotalol: 49
Ovid MEDLINE In-Process and
Other Non-Indexed Citations
14 May 2007
Searched 15 May 2007
1 (atrial adj3 fibrillat$).mp. (728)
2 (heart adj3 fibrillat$).mp. (32)
3 atrial fibrillat$.mp. (727)
4 (atrium adj3 flutter$).mp. (1)
5 (atrium adj3 fibrillat$r).mp. (0)
6 (auricular$ adj3 fibrillat$).mp. (16)
7 (auricular$ adj3 flutter$).mp. (0)
8 or/1-7 (747)
9 (CABG or coronary artery bypass graft$).ti,ab.
(482)
Appendix 7
9210 (coronary artery bypass adj3 surgery).ti,ab.
(220)
11 (coronary adj3 revasculari$).ti,ab. (134)
12 (myocardial adj3 revascular$).ti,ab. (83)
13 (coronary adj6 graft).ti,ab. (173)
14 (coronary adj6 bypass).ti,ab. (638)
15 (coronary adj6 surgery).ti,ab. (353)
16 (aortocoronary adj6 bypass).ti,ab. (22)
17 (valve$ adj6 surgery).ti,ab. (117)
18 or/9-17 (968)
19 MgSO4.mp. (38)
20 (magnesium and (sulphate$ or sulfate$)).ti,ab.
(98)
21 magnesium sulphate$.ti,ab. (23)
22 magnesium sulfate$.ti,ab. (55)
23 19 or 20 or 21 or 22 (129)
24 sotalol.ti,ab. (30)
25 8 or 18 (1659)
26 23 and 25 (3)
27 from 26 keep 1-3 (3)
28 24 and 25 (14)
29 from 28 keep 5,8,10-13 (6)
30 (economic$ or price$ or pricing or
pharmacoeconomic$ or pharma
economic$).tw. (3394)
31 (cost$ or budget$).tw. (7334)
32 (cost$ adj2 (benefit$ or utilit$ or minim$)).tw.
(373)
33 (value adj2 (money or monetary)).tw. (31)
34 30 or 31 or 32 or 33 (9858)
35 23 and 34 (2)
Number of hits (download file)
Costs magnesium: 3
Costs sotalol: 2
NHS EED (CRD database)
Magnesium and (atrial fibrillate* or coronary)
Sotalol and atrial fibrillat*
Number of hits (download file)
Costs magnesium: 1
Costs sotalol: 6
Econlit
Magnesium 0
Sotalol 0
Number of hits (download file)
0
Total keyworded
Costs magnesium: 8
Costs sotalol: 25
Number of hits (download file)
8
55
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Appendix 8
Inclusion criteria for economic review
Q1. Economic evaluation  Q2. Prophylaxis for  Q3. Comparators Q4. Include
or costing study AF following CABG
1 = Full economic evaluation  1 = Y 1 = Mg 1 = Y (primary)
(CBA, CUA, CEA or  2 = N 2 = Sotalol 2 = Y (secondary)
CMA) 4 = Unclear 3 = Other 3 = N
2 = Costing study (no  4 = Unclear
assessment of 
effectiveness). Reports 
costings or resource use
3 = No
4 = Unclear
If Q1 = (1 or 2) AND Q2 = 1 AND Q3 = (1 and 2) – then include = 1
If Q1 = (1 or 2) AND Q2 = 1 AND Q3 = (1 or 2 or 3) – then include = 2
If 4 – then include = 4
Otherwise include = 3
CBA, cost–benefit analysis; CEA, cost-effectiveness analysis; CMA, cost-minimisation analysis; CUA, cost–utility analysis. Volume 1, 1997
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